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MD Proposal  
Edinburgh University 
Student: Doctor Alex J. Graveling 
Supervisor:  Professor Brian M. Frier 
The proposed thesis will examine three areas of research: (1) the effects of 
hypoglycaemia on cognitive function in adults with and without T1DM, (2) the 
symptoms and awareness of hypoglycaemia in children and adolescents with 
T1DM and (3) hypoglycaemia and driving in people with insulin-treated 
diabetes: self-treatment and adherence to recommendations for avoidance. 
(1) Executive cognitive function governs organisation of thoughts, 
prioritisation of tasks, and time management. This study examined the effect of 
acute hypoglycaemia on executive function in adults with and without diabetes.  
Thirty-two adults with and without type 1 diabetes were studied. Two 
hyperinsulinaemic glucose clamps were performed at least 2 weeks apart in a 
single-blind, counterbalanced order. Executive functions were assessed with a 
validated test suite (Delis-Kaplan Executive Function). A general linear model 
(repeated-measures ANOVA) was used. Compared with euglycaemia, 
executive functions (with one exception) were significantly impaired during 
hypoglycaemia; lower test scores were recorded with more time required for 
completion. Large Cohen d values (>0.8) suggest that hypoglycaemia induces 
decrements in aspects of executive function with large effect sizes. In some 
tests, the performance of participants with diabetes was more impaired than 
those without diabetes.  Executive cognitive function, which is necessary to 
carry out many everyday activities, is impaired during hypoglycaemia in adults 
with and without type 1 diabetes.  
(2) In children with type 1 diabetes mellitus (T1DM) the prevalence of 
impaired awareness of hypoglycaemia (IAH) is uncertain.  Questionnaires were 
completed by 98 children with T1DM (mean age 10.6 years) and their 
parent(s); hospital admission data for the previous year were collected. 
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Awareness of hypoglycaemia was assessed using two questionnaire-based 
methods that have been validated in adults. For 4 weeks, participants 
performed routine blood glucose measurements and completed questionnaires 
after each episode of hypoglycaemia.  The ‘Gold’ questionnaire classified a 
greater proportion of the participants as having IAH than the ‘Clarke’ 
questionnaire (68.4 vs. 22.4%).  Using the ‘Clarke’ method, but not the ‘Gold’ 
method, children with IAH were younger and more likely to require external 
assistance or hospital admission. In contrast to adults, behavioural symptoms 
were the best predictors of awareness status.  IAH affects a substantial minority 
of children and impending hypoglycaemia may be heralded by behavioural 
symptoms. The ‘Clarke’ method was more effective at identifying those at 
increased risk. 
(3) A clinical survey of an outpatient clinic population to ascertain current 
knowledge and practice among drivers with insulin-treated diabetes. A 
representative sample of 202 current drivers with insulin-treated diabetes 
completed a structured questionnaire. A minimum blood glucose level of 4.0 
mmol/L or higher was considered necessary for driving by 74.8%, and 87.1% 
reported always keeping carbohydrate in their vehicle. However, 38.1% 
reported never carrying a glucose meter when driving, and 59.9% that they 
never test blood glucose before driving, or test only if symptomatic of 
hypoglycaemia. Most participants 89% would stop driving to treat 
hypoglycaemia although only 13.9% would wait longer than 30 min. 
Compliance with statutory requirements to inform the licensing authority and 
motor insurer is good. 
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Search strategy 
Articles were sourced from Google Scholar and Medline searches (English 
language and human) using relevant keywords.  Articles were also sourced 
from the author’s personal collection. 
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Chapter 1 
1.1 Introduction to hypoglycaemia 
Hypoglycaemia is derived from the classical Greek words “hypo” (under), 
“glykys” (sweet) and “haima” (blood) and is used to describe lower than 
normal blood glucose concentrations.  Despite advances in the delivery and 
type of insulin, along with improved education and support available for people 
with type 1 diabetes mellitus (T1DM), hypoglycaemia remains a common and 
feared intermittent side effect of the insulin therapy used in the treatment of 
T1DM.  Hypoglycaemia results in profound physical, cognitive and 
psychological effects and is therefore an important and clinically relevant area 
of study.  
The Diabetes Control and Complications Trial (DCCT) demonstrated the 
benefits of intensified insulin therapy in T1DM.  Strict glycaemic control was 
shown to limit the risk of predominantly microvascular but also macrovascular 
complications and this benefit was shown to be sustained for ten years 
following the period of tighter glycaemic control (DCCT Research Group, 
1993, Nathan et al., 2005, DCCT/EDIC Group et al., 2009).  The downside to 
striving for blood glucose levels closer to those achieved by people without 
diabetes is the increased incidence of hypoglycaemia; the intensively treated 
arm of the DCCT experienced a threefold increase in severe hypoglycaemia. 
The huge increase in numbers of people with diabetes both in the developed 
and developing worlds will provide additional strain on many countries 
healthcare systems (Wild et al., 2004, Shaw et al., 2010, Yang et al., 2010).  
Scotland is in the unique position of having a national register of people 
diagnosed with diabetes.  The 2012 Scottish Diabetes Survey reported that over 
250,000 people in Scotland had a diagnosis of diabetes which represents 4.9% 
of the total population; 11.2% of these had a diagnosis of T1DM (Scottish 
Diabetes Survey Monitoring Group, 2014).  This compares with around 3% of 
the population in 2002; 18.2% of these had a diagnosis of T1DM (Scottish 
Diabetes Survey Monitoring Group, 2003).  Other countries are experiencing 
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an even greater increase; particularly in people diagnosed with type 2 diabetes 
mellitus (T2DM).  A recent study (2008) of over 46,000 participants reported 
that 9.7% of the Chinese population is now affected with diabetes in 2008 
compared with 2.5% in 1994 (Pan et al., 1997, Yang et al., 2010).  The 
increasing prevalence of diabetes, albeit predominantly T2DM, will result in 
more people prescribed being prescribed sulfonylurea or insulin therapy with a 
consequent increased risk of hypoglycaemia. 
This thesis is mainly confined to a discussion of hypoglycaemia occurring in 
humans with T1DM, other causes of hypoglycaemia will not be discussed.  To 
highlight key differences, reference will be made to hypoglycaemia occurring 
in adults with T2DM.   
1.2 Historical aspects of hypoglycaemia 
Prior to the discovery of insulin, careful dietetic regulation in people with 
T1DM helped prolong the inevitable descent into a fatal hyperglycaemic, 
ketotic coma.  In 1889 von Mering and Minkowski reported that a total 
pancreatectomy would induce diabetes in dogs (Luft, 1989).  Subsequent 
investigators endeavoured to discover the pancreatic extract responsible for 
moderating blood glucose levels in animals or humans.  The pancreatic extract 
which became known as insulin was first developed by a team based in 
Toronto in the early 1920s comprising of Frederick Banting, Charles Best, 
James Collip and John Macleod.  In 1921, Banting and Best under the 
stewardship of Macleod managed to extract insulin from bovine pancreases and 
successfully treated their first patient Leonard Thompson who had a two year 
history of T1DM (Banting et al., 1922).  Their successful refinement and 
administration of their pancreatic extract resulted in the award of the Nobel 
Prize to Banting and Macleod.  This is described in the “Discovery of Insulin” 
by the Canadian historian, Michael Bliss (Bliss, 2000). 
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Prior to the first human trials of insulin, Collip had observed that on injecting 
the pancreatic extract into normal rabbits they became very hungry and would 
start eating anything put in front of them, further injections of the extract 
resulted in seizure, coma and then death.  If he took a blood sample from the 
rabbits, mixed it with glucose and then re-injected one of the comatose rabbits 
they would recover.  This is one of the first descriptions of hypoglycaemia and 
its subsequent treatment (Bliss, 2000); Collip may have been alerted to the idea 
by a paper demonstrating hypoglycaemia after hepatectomy and the restorative 
effect of administering glucose (Mann and Magath, 1921).  The Toronto team 
would therefore have been aware of this potentially fatal side effect of insulin 
therapy prior to commencing human trials. 
Shortly after the first people with T1DM were successfully treated with insulin 
it was recognised that the if insulin was administered in sufficient quantities it 
could result in a lowering of blood glucose to below normal (Maddock and 
Trimble, 1928).  These hypoglycaemic reactions or “insulin shocks” were 
noted to induce particular symptoms such as tremor and sweating followed by 
impaired cognitive performance.  Williams in Rochester gave this memorable 
account after treating his second patient with insulin in June 1922; “we threw 
him into profound insulin shock.  He was so lifeless that the chief of our 
surgical staff pronounced him dead. We immediately restored him by the 
injection of some glucose, and it was looked upon as a miracle in the hospital.” 
(Bliss, 2000).  The importance of people with T1DM always carrying a supply 
of carbohydrate for treatment of “insulin shocks” was emphasised the 
following year (Hinds-Howell, 1923).   
The observation that repeated exposure could result in a diminution of these 
symptoms was first reported a few years later (Maddock and Trimble, 1928).  
Lawrence noted that as duration of insulin treatment progressed, that the 
symptoms experienced changed and often diminished in intensity leading to 
people being unaware of the impending onset of hypoglycaemia (Lawrence, 
1941).  Many different research teams noted the variable blood glucose 
threshold at which people experienced symptoms with some experiencing 
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hypoglycaemic symptoms at “normal” levels of blood glucose (Maddock and 
Krall, 1953).   
1.3 Definition of hypoglycaemia 
In adults with diabetes, hypoglycaemia is defined by ability to self-treat when 
exposed to low blood glucose.  If self-treatment is possible, the episode is 
termed “mild”, irrespective of the nature or intensity of symptoms experienced. 
“Severe” hypoglycaemia is defined as any episode that requires external 
assistance for recovery, and is not confined to the development of coma or a 
reduced consciousness level (DCCT, 1991, Graveling and Frier, 2009).  
Whipples’ triad (i.e. presence of typical symptoms, a low blood glucose and 
amelioration of the symptoms with the ingestion of glucose) was created in the 
context of pathological spontaneous hypoglycaemia (Whipple, 1938).  The 
American Diabetes Association proposed five classifications of a 
hypoglycaemic episode (Workgroup on Hypoglycemia, 2005, Seaquist et al., 
2013): 
1. Severe hypoglycaemia: An event requiring third party assistance to 
administer carbohydrate. 
2. Documented symptomatic hypoglycaemia: an event with typical 
symptoms of hypoglycaemia and a measured plasma glucose 
≤3.9mmol/L. 
3. Asymptomatic hypoglycaemia: an event not accompanied by typical 
symptoms of hypoglycaemia but with a measured plasma glucose 
≤3.9mmol/L. 
4. Probable symptomatic hypoglycaemia: an event with typical symptoms 
of hypoglycaemia but no measurement of plasma glucose was 
performed. 
5. Relative hypoglycaemia: an event during which the person experiences 
typical symptoms of hypoglycaemia but the measured plasma glucose 
is ≥4.0mmol/L. 
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The usual definition of severe hypoglycaemia (SH) used in adults (i.e. 
requiring external help for recovery), cannot be used in young children, as most 
require assistance to treat hypoglycaemia regardless of severity.  Because of 
this limitation, SH in children has been defined as hypoglycaemia resulting in 
coma or seizure activity with moderate hypoglycaemia defined as requiring 
third party assistance (Clarke et al., 2009).  
The blood glucose level that defines hypoglycaemia is the subject of topical 
debate and is a complex issue (Frier, 2009, Cryer, 2009, Amiel, 2013).  As a 
result, there is no single level of plasma glucose concentration that defines 
hypoglycaemia.  If the blood glucose level that defines hypoglycaemia is set 
too high, then some of the hypoglycaemic episodes captured will have no 
clinical relevance (Swinnen et al., 2009).  The plasma glucose thresholds that 
result in symptom generation, counter-regulation and cognitive dysfunction are 
dynamic and show substantial intra- and inter-individual variation.  There is the 
additional complication that the inherent inaccuracy of many capillary blood 
glucose meters in the hypoglycaemic range means that a “buffer” zone may be 
appropriate (Graveling, 2010).  Falsely high blood glucose readings can lead to 
a delay in the diagnosis and subsequent treatment of hypoglycaemia (see 
section 1.5) (Korsatko et al., 2009). 
For clinical purposes having different thresholds for different patient groups is 
awkward and Diabetes UK, the principal British diabetes charity, adopts the 
pragmatic policy of “make four the floor”. This is also reflected in the UK 
guidelines for the treatment of hypoglycaemia occurring in hospitalised adults 
(Walden et al., 2013).  This should be regarded as the alert level that may 
herald the onset of hypoglycaemia, not the biochemical definition.   
1.4 Frequency of hypoglycaemia 
1.41  Frequency of hypoglycaemia in T1DM 
People with T1DM experience around two episodes of mild hypoglycaemia per 
week (Pramming et al., 1991, Pedersen-Bjergaard et al., 2004).  This number 
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has not changed over 20 years despite developments in insulin therapy.  
Differences in the reported frequencies of mild hypoglycaemia between 
clinical studies may be related to the heterogeneity of the populations studied 
and differing hypoglycaemia definitions.  Changing the glucose cut-off used to 
define hypoglycaemia has a substantial effect on the reported frequency of 
hypoglycaemia as can be seen in Figure 1.1 (Swinnen et al., 2009).  Raising the 
biochemical cut-off increases the proportion of asymptomatic evidence as well 
as increasing the overall number of reported hypoglycaemic episodes.  Thirty 
percent experienced only asymptomatic hypoglycaemia during the 12-week 
monitoring period when using <2.9mmol/L as the biochemical cut off 
compared with around 60% when using <3.9mmol/L (Swinnen et al., 2009). 
The clinical significance of an asymptomatic episode of hypoglycaemia 
measured at 3.8mmol/L is debateable.  Many research groups examining rates 
of hypoglycaemia find it difficult to find a biochemical cut-off that captures 
clinically significant events without including too many events that are not 
significant.  
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SMBG <3.9 mmol/l. Thus, to identify 28 more patients with
severe hypoglycaemia, the number of patients experiencing
only non-severe hypoglycaemia more than doubled. Similarly,
82.2% (199/242) of the severe hypoglycaemic episodes
occurred in patients who had had a SMBG <3.1 mmol/l at
some other time during the 12 weeks, and 97.5% (236/242) in
patients who had had a SMBG <3.7 mmol/l.
Discussion
Our main finding was that, in a large cohort of type 2 diabetic
patients starting insulin therapy, higher cut-off points for the
definition of hypoglycaemia considerably increased the
reported frequency of hypoglycaemia, and particularly that
of asymptomatic hypoglycaemia. Higher cut-offs identified
more patients having severe hypoglycaemia, but this was at
the expense of the specificity, i.e. a very large number of
patients that did not experience severe hypoglycaemic
episodes were also labelled as ‘at risk’.
Because we combined the data of two large clinical trials,
our analysis was based on a substantial number of hypogly-
caemic episodes that had been systematically recorded.
Nevertheless, hypoglycaemia may have been under-reported
as in both trials investigators depended on the patients
bringing their diaries to the site visits. Moreover, hypoglycae-
mia had been defined as an event confirmed by an SMBG
value <3.9 mmol/l, so we did not include episodes with
symptoms typical of hypoglycaemia but without glucose
determinations. Third, as the study population had only just
started insulin and thus many were hypoglycaemia-naive,
some hypoglycaemic episodes may not have been recognised
as such. However, this under-recognition was minimised by
repeated discussion of hypoglycaemia symptomatology dur-
ing the clinic visits. Finally, the presence of hypoglycaemia
unawareness, which was not formally assessed, could have
confounded our results because this is associated with an
increased frequency of (severe) hypoglycaemia but fewer self-
reported events [4, 5]. However, hypoglycaemia unawareness
is rare in patients with type 2 diabetes recently initiated on
basal insulin therapy.
The proportions of affected patients and hypoglycaemia
event rates we found were higher than those reported for
newly diagnosed participants in the UK Prospective Diabetes
Study [6], but equal to those reported for type 2 diabetic
patients newly started on insulin (<2 years) in a recent
observational study [7]. With regard to severe hypoglycae-
mia, population-based and retrospective studies of insulin-
treated individuals with type 2 diabetes reported higher event
rates [8–10]. However, our study population had just started
insulin, and the frequency of hypoglycaemia and the
prevalence of hypoglycaemia unawareness are much greater
in people with type 1 diabetes and type 2 diabetic patients
with a longer duration of insulin treatment. It might be useful
to perform an analysis such as ours for these patient groups
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Figure 1.1: Proportion of participants experiencing at least one non-severe 
hypoglycaemic episode over 12 weeks according to pre-defined glucose cut-off 
po nts for the definition of hypoglycaemia plotted against endpoint HbA1c 
categories (Swinnen et al., 2009). 
The annual prevalence of severe hypoglycaemia in unselected populations (i.e. 
those including anyone, irrespective f ri k factors) has been reported 
consistently at 30-40% in several large studies, with an incidence varying from 
1.0 – 1.7 episodes per person per year (Strachan, 2014).  This rises to more 
than 3 episodes per person per year in those with T1DM of > 15 years duration 
(UK Hypoglycaemia Study Group, 2007).  Figure 1.2 shows the proportion of 
each group experi ncing severe h poglycaemia ov r the 9-12 month 
monitoring period; 22% of those with short duration T1DM (<5 years) 
increasing to 45% of those of longer duration T1DM (>15 years) (UK 
Hypoglycaemia Study Group, 2007) (Figure 1.2).   
People with a history of severe hypoglycaemia are at higher risk of 
experiencing further events, with a median of 2-3 events per year (Lammert et 
al., 2009).  The distribution of severe hypoglycaemia is therefore skewed in 
that most people do not experience any episodes while a small number of 
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individuals experience multiple events (Pedersen-Bjergaard et al., 2004). 
Recall of severe hypoglycaemia is robust with almost 90% correctly recalling 
whether than had experienced severe hypoglycaemia in the preceding year 
(Pedersen-Bjergaard et al., 2003b).  For a variety of reasons, many episodes of 
severe hypoglycaemia are not coded (e.g. using ICD-9) and so do not appear in 
health service statistics; in one survey 5% of participants reported an episode of 
severe hypoglycaemia in the preceding month but only 1% had a compatible 
ICD-9 diagnosis (Libby et al., 2010).   
 
Figure 1.2: Proportion of each group experiencing at least one severe 
hypoglycaemia episode during 9-12 months of follow up (UK Hypoglycaemia 
Study Group, 2007). 
1.42 Frequency of hypoglycaemia in the paediatric population with 
T1DM 
Varying definitions of hypoglycaemia make it difficult to compare observed 
frequencies in the paediatric population.  However, large, well-conducted 
studies show similar rates of severe hypoglycaemia.  Severe hypoglycaemia in 
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the paediatric population is usually defined as hypoglycaemia leading to altered 
consciousness or seizure resulting in hospital attendance or admissions.  An 
Australian study of 1335 children with T1DM reported an incidence of 16.6 
severe events per 100 patient-years (Bulsara et al., 2004).  A follow up paper 
reported that the incidence of severe hypoglycaemia had fallen over time from 
around 17 per 100 patient-years in 2001 to 6 per 100 patient years in 2009 
(O'Connell et al., 2011).  A large American study of 1243 children with T1DM 
reported an overall incidence of severe hypoglycaemia of 19 per 100 patient-
years (Rewers et al., 2002).  Given the skewed distribution of severe 
hypoglycaemia within the patient population, patient selection is crucial and 
may account for some of the variance in the reported incidence. 
Nocturnal hypoglycaemia is more frequently associated with improved 
glycaemic control and younger age, with one third of those under five years 
experiencing nocturnal hypoglycaemia once every three nights (Porter et al., 
1997).   Hypoglycaemia can mimic a number of other conditions.  In children, 
non-disclosure of the hypoglycaemic event led to elevated suspicion of drug or 
alcohol misuse (Berlin et al., 2005).   
1.43 Frequency of hypoglycaemia in T2DM 
Many trials of insulin-treated T2DM have documented very low rates of severe 
hypoglycaemia, partly because of patient selection (excluding those at high 
risk) and short periods of study.  Severe hypoglycaemia is less common in 
people with insulin-treated T2DM, but still represents a substantial clinical 
problem, with between 7% and 25% of people experiencing at least one severe 
episode annually; the frequency increases with longer duration of insulin 
therapy (Henderson et al., 2003b, Leiter et al., 2005, UK Hypoglycaemia Study 
Group, 2007).  As with people with T1DM, the distribution of severe 
hypoglycaemia is very skewed, in one study 5% of participants accounted for 
57% of events (Akram et al., 2009).  People with insulin-treated T2DM are 
more likely to require assistance from the medical services for severe 
hypoglycaemia than those with T1DM (30% vs. 10% of episodes) (Donnelly et 
al., 2005).  Dementia and an inability to self-manage medications are strong 
Chapter 1 
 36 
risk factors for severe hypoglycaemia requiring the assistance of the healthcare 
services (hazard ratios of 3.0 and 4.2 respectively) (Bruce et al., 2009).  
Because of the much larger number of people with insulin-treated T2DM 
compared with T1DM, the overall number of hypoglycaemic events is greater 
for the population with T2DM.   
 
Sulfonylureas cause much more hypoglycaemia than is generally recognised, 
with the annual prevalence of severe episodes in people with well-controlled 
diabetes being 7% (UK Hypoglycaemia Study Group, 2007). Long-acting 
agents such as glibenclamide are associated with a higher risk of 
hypoglycaemia and are particularly dangerous in the elderly (Lassmann-Vague, 
2005, Campbell, 2009).  
1.5 Biochemical detection of hypoglycaemia 
Self-monitoring of capillary blood glucose using a glucose meter is an integral 
part of diabetes management for people treated with insulin (Hirsch et al., 
2008).  Whether used at home or hospital, the performance of most glucose 
meters is compared against an International Organization for Standardization 
(ISO) standard.  Below 4.2 mmol/L, glucose meters are considered accurate if 
95% of measurements obtained are within 0.8 mmol/L of the actual 
concentration (International Organization for Standardization, 2003).  A 
glucose meter is therefore considered to be accurate provided it measures an 
actual glucose concentration of 3.6 mmol/L as any value between 2.8 mmol/L 
and 4.4 mmol/L) on 95% of occasions.  Above 4.2 mmol/L a glucose meter is 
considered accurate if its readings are within 20% of the actual concentration 
on 95% of occasions.  In an evaluation of glucose meter accuracy four different 
glucose meter systems were tested with glucose samples <4.2 mmol/L.  None 
of these meters met the relatively lax ISO criteria as they were out of range on 
more than 95% of occasions, with the worst performing meter within range on 
only 62.5% of occasions (Kost et al., 2008).  Perhaps in recognition of the need 
for stricter standards in 2013 the ISO standards were updated (International 
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Organization for Standardization, 2013).  Below 4.2mmol/L the standards 
remain unchanged; above 4.2 mmol/L the readings must be within 15% (rather 
than 20%) of the actual glucose concentration on 95% of occasions. 
Two types of erroneous readings of clinical importance have been identified 
(Kost et al., 2008).  The first occurs when the reference measurement is <4.2 
mmol/L but the glucose meter reads >6.1 mmol/L; this may lead to clinical 
decisions that could worsen hypoglycaemia.  The second type occurs when the 
reference measurement is >6.1 mmol/L but the glucose meter reads <4.2 
mmol/L, encouraging clinical decisions that could aggravate hyperglycaemia.  
Other sources of diagnostic inaccuracy include hypotension, body temperature, 
and abnormalities of haematocrit, oxygenation or acid-base balance (Dungan et 
al., 2007).  Test strips using glucose dehydrogenase pyrroloquinolinequinone 
(GDH-PDQ) are susceptible to cross-contamination from other forms of 
carbohydrate.  The resultant inaccurate readings have been associated with 
fatal hypoglycaemia in people receiving peritoneal dialysis using icodextrin 
(Olansky and Kennedy, 2010).  User-related errors include inadequate 
cleansing of the skin or meter, failure to obtain an adequate blood sample or to 
use a quality control solution, and improper storage of test strips (Montagnana 
et al., 2009). 
1.51  Continuous Glucose Monitoring 
Continuous Glucose Monitoring (CGM), which measures interstitial tissue 
glucose, has been investigated as a potential tool to detect hypoglycaemia.  
Interstitial glucose is known to lag behind plasma glucose during euglycaemia 
by approximately 15-17 minutes (Wei et al., 2010, Kulcu et al., 2003).  
Interstitial glucose lags even further behind capillary glucose during the 
descent into hypoglycaemia, in one study by an average of 26 minutes (Boyne 
et al., 2003, Melki et al., 2006).  There was also a delay in return to 
euglycaemia following hypoglycaemia in interstitial glucose compared with 
plasma glucose (Aussedat et al., 2000).  A more recent study, using 
microdialysis catheters rather than CGM to measure interstitial glucose, found 
a shorter lag period of 5-6 minutes suggesting a processing delay when using 
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CGM (Basu et al., 2013).  This delay means that calibration of CGM devices 
should be avoided when blood glucose levels are changing rapidly.  
In a group of people with T1DM and mean HbA1c of 6.6%, CGM gave lower 
readings than paired whole blood samples analysed using a (Beckman) glucose 
analyser on 74% of occasions.  The lowest nocturnal reading was 38%±15% 
lower using CGM compared with the glucose analyser (McGowan et al., 2002).   
Placement of glucose sensor may have an impact with lower values obtained 
from the abdomen compared with forearm (von Dobeln et al., 2005).   
When CGM meters are evaluated using ISO standards (i.e. below 4.2 mmol/L, 
glucose meters are considered accurate if 95% of measurements obtained are 
within 0.8 mmol/L of the actual concentration (International Organization for 
Standardization, 2003)) only 32-48% readings meet this standard (Klonoff, 
2005, Guerci et al., 2003).  CGM has been proposed as a tool to alert people 
with T1DM to the presence of hypoglycaemia (glucose <3.9mmol/L), however 
CGM only detected 38% of measurements in the hypoglycaemic range.  CGM 
falsely alerted people that their blood glucose was low on 72 out of 135 of 
occasions, meaning that CGM was only predicting true hypoglycaemia on 47% 
of occasions (Zijlstra et al., 2013).  
Taking these issues into account, CGM has shown that asymptomatic mild 
hypoglycaemia occurs more frequently than is apparent using conventional 
intermittent measurements of capillary blood glucose (De Keulenaer et al., 
2012).  Despite reservations concerning the accuracy of CGM in the 
hypoglycaemic range, it is reasonably reliable (Caplin et al., 2003).  CGM 
detected asymptomatic episodes of hypoglycaemia in 63% of T1DM and 47% 
of insulin-treated T2DM over a three-day period (Chico et al., 2003).  Over six 
days, 90% of people with TIDM had at least one episode of biochemical 
hypoglycaemia, but only 15% experienced symptoms, even in those with 
normal hypoglycaemia awareness (Hoi-Hansen et al., 2005).  The clinical 
significance of these asymptomatic episodes is unclear but they may induce 
counter-regulatory hormonal deficiencies and impaired awareness of 
hypoglycaemia (IAH).  
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1.52  Detection of nocturnal hypoglycaemia 
Approximately 55% of severe hypoglycaemic events occurred at night in the 
Diabetes Control and Compilations Trials (DCCT) (DCCT, 1991).  Even in 
people with poorly controlled T1DM, nocturnal hypoglycaemia has been 
shown to be common and often prolonged (Gale and Tattersall, 1979).  
Conventional laboratory blood glucose analysis showed that nocturnal 
hypoglycaemia (laboratory glucose <3.5mmol/L) occurred in 47% of children 
with T1DM admitted for observation with hourly blood glucose measurements 
(without wakening the children); almost half (49%) of these episodes were 
asymptomatic (Beregszaszi et al., 1997).  The prevalence of nocturnal 
hypoglycaemia differs according to biochemical cut-off; when hypoglycaemia 
was defined as blood glucose <3.9mmol/L one third of participants 
experienced nocturnal hypoglycaemia, this reduced to about a quarter with 
hypoglycaemia defined as <3.0mmol/L (Wentholt et al., 2007).   
A high prevalence of nocturnal hypoglycaemia has been demonstrated using 
CGM; 67% of participants with T1DM experienced an episode of nocturnal 
hypoglycaemia (blood glucose <4.0mmol/L) during a 3 night experimental 
period (around 22% per night); morning hyperglycaemia was negatively 
associated with nocturnal hypoglycaemia (odds ratio 0.7, p<0.001) (Guillod et 
al., 2007).  This would suggest that the Somogyi phenomenon (i.e. morning 
hyperglycaemia following nocturnal hypoglycaemia through counter-
regulatory hormone release) does not occur; this will be discussed further in 
section 1.7.  The largest CGM study was the JDRF (Juvenile Diabetes 
Research Foundation) study that included 42 participants aged 15-24 years and 
70 aged over 25 years.  The prevalence of nocturnal hypoglycaemia (blood 
glucose <3.3mmol/L) was lower at 8.5% of nights; there was no difference 
between those with CSII or basal bolus insulin regimens (Juvenile Diabetes 
Research Foundation Continuous Glucose Monitoring Study, 2010).   
Asymptomatic hypoglycaemia is common with only 20-33% of nocturnal 
episodes of hypoglycaemia detected by CGM also being detected by the person 
with diabetes (Guillod et al., 2007, Woodward et al., 2009). A study of T1DM 
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and insulin-treated T2DM showed that 74% of episodes of undetected 
hypoglycaemia occurred during sleep when symptoms are undetected.  People 
with T1DM were exposed to proportionately more nocturnal episodes than 
people with insulin-treated T2DM (Chico et al., 2003).  The risk of nocturnal 
hypoglycaemia is greatest when bedtime blood glucose is below 7.0mmol/L; 
more than one third develop nocturnal hypoglycaemia if their bedtime blood 
glucose is below 4.0mmol/L (Guillod et al., 2007).  
Using CGM in the paediatric population, 10.1% of all values recorded were in 
the hypoglycaemic range at <3.5mmol/L.  The majority of hypoglycaemic 
episodes were nocturnal with 18.8% of values recorded at night compared with 
4.4% of values recorded during the day.  Only 9% of nocturnal episodes were 
symptomatic compared with 56% during the day (Amin et al., 2003).  
Nocturnal hypoglycaemia was most strongly predicted by a pre-bedtime blood 
glucose of <5.6 mmol/L (Shalwitz et al., 1990). 
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1.6 Clinical features of hypoglycaemia 
Fletcher and Campbell documented the clinical features during hypoglycaemia 
following the administration of insulin shortly after the discovery of insulin 
(Fletcher and Campbell, 1922).  One of the earliest hypoglycaemia symptom 
questionnaires was administered to 179 consecutive patients attending a 
diabetes clinic in London. Two-thirds had experienced hypoglycaemia and the 
most common clinical features were sweating (82%), weakness (74%), tremor 
(73%), visual disturbance (71%) and dizziness (67%) (Cooke, 1934).   
“While it must be admitted that hypoglycaemia symptoms are often unpleasant 
to the sufferer … and a clear understanding of the early symptomatology by 
patient and doctor gives at once a sense of confidence and a means of 
anticipating the more serious manifestations.” (Cooke, 1934) 
In adults, hypoglycaemia symptoms show substantial inter-individual variation 
and can be categorised into autonomic, neuroglycopenic and non-specific 
groups; children are unable to distinguish autonomic from neuroglycopenic 
symptoms (McCrimmon et al., 1995, Ross et al., 1998, Tupola and Rajantie, 
1998, Deary et al., 1993).  The blood glucose levels at which these symptoms 
are generated are associated with inter- and intra-individual variation according 
to factors such as prevailing glycaemic control and exposure to antecedent 
hypoglycaemia (McAulay et al., 2001).  Symptoms differ in children compared 
to adults, particularly with respect to age and pubertal status (Ross et al., 2005, 
McCrimmon et al., 1995).  Behavioural changes, such as becoming naughty or 
irritable, often alert parents to the presence of hypoglycaemia (Ross et al., 
1998, McCrimmon et al., 1995).  Increasing duration of diabetes showed a 
reduction in autonomic symptoms with neuroglycopenic symptoms becoming 
more prominent although it is unclear whether age was controlled for 
(Dammacco et al., 1998). 
1.61  Clinical assessment of hypoglycaemic symptoms 
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A simple 7-point Likert scale has been developed to assess the symptom 
intensity experienced during hypoglycaemia (Deary et al., 1993).   
1.62  Physiological methods of symptom classification 
Symptoms are generated by activation of the sympatho-adrenal system 
(autonomic) and the direct effects of glucose deprivation on the brain 
(neuroglycopenic) (Deary et al., 1993).  Maddock observed two symptom 
subgroups of autonomic or “adrenaline like” and neuroglycopenic or “central-
nervous system like” in the 1950s (Maddock and Krall, 1953).  In addition to 
observations in people with diabetes, studies were performed in people with 
impaired autonomic nervous systems.  People who have cervical cord 
transections have a preganglionic sympathectomy and exhibit tetraplegia.  
During acute hypoglycaemia they experience neuroglycopenic, but not 
autonomic symptoms (Corrall et al., 1979).  People who have undergone 
bilateral adrenalectomy or splanchnicectomy do not secrete adrenaline in 
response to hypoglycaemia but retain autonomic symptoms (Ginsburg and 
Paton, 1956, Altorfer et al., 1981, French and Kilpatrick, 1955).  Their 
autonomic neural pathways remain intact allowing normal end-organ 
stimulation that demonstrates that secretion of adrenaline is not essential in the 
generation of autonomic symptoms.  A pharmacological pan-autonomic 
blockade with phentolamine, propranolol and atropine) has been shown to 
affect the awareness of hypoglycaemia and to decrease autonomic but not 
neuroglycopenic symptom scores (Towler et al., 1993). 
1.63  Statistical methods of symptom classification 
The 11 most common symptoms have been utilised to form the basis of a 
scoring system for hypoglycaemic symptoms, the Edinburgh Hypoglycaemia 
Scale (Deary et al., 1993, McAulay et al., 2001).  Principal components 
analysis (PCA) was used to partition the symptoms into the 3 main groups, 
namely autonomic, neuroglycopenic and general malaise (Table 1.1).  A 
further sub-classification of neuroglycopenic symptoms has also been proposed 
into cognitive dysfunction (inability to concentrate, blurred vision, anxiety, 
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confusion, difficulty speaking, diplopia) and neuroglycopenia (drowsiness, 
tiredness, hunger, weakness) categories (McCrimmon et al., 2003).  Symptom 
scores (i.e. intensity) declined with age (Henderson et al., 2003a).  PCA has 
also been used to reveal similar underlying subgroups in T2DM, although a 
general malaise category did not clearly emerge and neuroglycopenic 
symptoms were more prominent than with younger people (Jaap et al., 1998).   
Table 1.1: Edinburgh Hypoglycaemia Scale (Deary et al., 1993)  
Autonomic Neuroglycopenic General malaise 
• Sweating 
• Palpitations 
• Shaking 
• Hunger 
• Confusion 
• Drowsiness 
• Odd behaviour 
• Speech difficulty 
• Incoordination 
• Headache 
• Nausea 
 
1.64  Do autonomic or neuroglycopenic symptoms herald the onset of 
hypoglycaemia? 
Studies of hypoglycaemia in subjects without diabetes using a stepped glucose 
clamp found that autonomic symptoms commenced before neuroglycopenic 
symptoms; the mean difference between the onset of autonomic symptoms and 
neuroglycopenic symptoms was 0.5mmol/L (Schwartz et al., 1987, Mitrakou et 
al., 1991).  A study using a non-stepped approach (insulin intravenous infusion 
technique) found no difference in symptom intensity between autonomic and 
neuroglycopenic symptoms at the onset of hypoglycaemia (Hepburn et al., 
1991).  Outside of the experimental setting when people in the community 
were asked about their initial warning symptoms of hypoglycaemia they 
reported autonomic and neuroglycopenic symptoms with equal frequency (Cox 
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et al., 1993b).  Similarly, when asked to report which symptoms appear in the 
early stages of hypoglycaemia both autonomic and neuroglycopenic symptoms 
are commonly reported (e.g. trembling, sweating, tiredness, difficulty 
concentrating and hunger) (Hepburn, 1993). 
1.65  Variability of symptoms 
There is considerable variation between individuals of symptoms experienced 
during hypoglycaemia.  The symptom profile provoked by hypoglycaemia is 
idiosyncratic and thus varies in character, pattern and intensity between 
individuals (Pennebaker et al., 1981, Cox et al., 1983).  A more recent study 
that included participants with both T1DM and T2DM demonstrated 
substantial intra-individual variation in symptom reporting between different 
episodes of hypoglycaemia (Zammitt et al., 2011).  Some participants were 
more consistent then others with men being more consistent than women.  
Consistency is clinically relevant because subjects with 4 or more reliable 
symptoms detect 75% of episodes; this drops to 50% if they only have 1 
reliable symptom (Cox et al., 1993a).  Although no single symptom is present 
consistently during hypoglycaemia in all people with diabetes, some symptoms 
are more common than others (Cox et al., 1983).   
The release of counter-regulatory hormones, the generation of symptoms and 
the development of cognitive dysfunction are triggered at specific levels of 
blood glucose, indicating that glycaemic thresholds exist for responses to 
hypoglycaemia.  These differ between individuals, and while reproducible in 
non-diabetic volunteers, in people with diabetes these thresholds can be 
modified by various factors.  These factors include the duration of diabetes, the 
prevailing degree of glycaemic control (as estimated by HbA1c) and recent 
exposure to hypoglycaemia (antecedent hypoglycaemia) (McAulay et al., 
2001).   
Improved glycaemic control is associated with a reduction in autonomic 
symptom intensity and reduction in tense arousal during hypoglycaemia 
compared with those with poorer glycaemic control (Weinger et al., 1995). 
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Individuals with poorer glycaemic control (HBA1c >10%) experience 
symptoms of hypoglycaemia at higher blood glucose levels than people 
without diabetes (4.3±0.3mmol/L compared with 2.9±0.1mmol/L) (Boyle et 
al., 1988).  Symptoms of hypoglycaemia also change in nature and diminish in 
intensity with advancing age (Pramming et al., 1991).    Although a difference 
in counter-regulatory responses has been observed between genders (discussed 
later) there was no difference in hypoglycaemia symptom scores between 160 
male and female participants (Geddes et al., 2006).   
1.66 Alteration of physical symptoms 
The emergence and perception of symptoms is referred to as interoception.  
Preconceptions affect the symptoms experienced during hypoglycaemia (Pohl 
et al., 1997).  Healthy volunteers with no experience of hypoglycaemia were 
given one of four possible treatments: 
1. Informed that they would be given insulin & given insulin  
2. Informed that they would be given saline & given insulin 
3. Informed that they would be given saline & given saline 
4. Informed that they would be given insulin & given saline 
Both autonomic and neuroglycopenic symptom scores were higher in those 
expecting to receive insulin and getting insulin.  Even those expecting to 
receive insulin and getting saline instead had higher symptom scores than those 
expecting saline and receiving saline.  Figure 1.3 summarises these results.  
Higher levels of anxiety at baseline have also been shown to increase symptom 
intensity scores and increase the accuracy of blood glucose estimation (Ryan et 
al., 2002).  Conversely acute stress (e.g. being asked to prepare and then give a 
speech) has been shown to reduce the increment in symptom scores (perhaps as 
a result of starting from a higher baseline symptom intensity) and therefore 
attenuates awareness of hypoglycaemia (Pohl et al., 1998). 
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Figure 1.3: Mean±SE baseline (B) and peak (P) sum scores of autonomic and 
neuroglycopenic symptoms (Pohl et al., 1997) 
1.67 Altered ability to detect symptoms 
Inability to detect prevailing hypo (or hyperglycaemia) can obviously be 
potentially dangerous.  Sixteen percent of participants estimated their blood 
glucose as 4.4mmol/L or higher when hypoglycaemic (2.1 mmol/L) during a 
glucose clamp study; conversely 32% estimated their blood glucose at 
4.4mmol/L or less when it was 21.1mmol/L (Weinger et al., 1995).  Cox et al 
(1985) categorised the errors that may occur and the likelihood of clinical harm 
(e.g. treatment of presumed hyperglycaemia with extra insulin when in fact the 
person with diabetes is in the hypoglycaemic range).  Figure 1.4 displays these 
errors in an error grid analysis graph which categorises estimates of blood 
glucose into 1 of 5 categories which describe the clinical implications of any 
estimation error (Cox et al., 1985).  This chart has been further refined to avoid 
small changes resulting in sudden transitions from a blood glucose that is 
considered safe to one that is considered harmful (Parkes et al., 2000).  
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Inability to detect episodes of hypoglycaemia will be discussed further in 
chapter 4. 
 
Figure 1.4:  Error Grid Analysis graph. Zone A represents accurate estimates; 
Zone B, clinically neutral or benign errors; Zone C, unnecessary correction of 
acceptable glucose; Zone D, dangerous failure to treat and Zone E, erroneous 
treatment (Cox et al., 1985). 
1.7 Causes and risk factors for hypoglycaemia 
The causes of hypoglycaemia are usually multifactorial and should be 
distinguished from risk factors; both are listed in table 1.2.  Severe 
hypoglycaemia (ascertained prospectively) in people with T1DM is associated 
with age, duration of diabetes, awareness of hypoglycaemia and history of 
severe hypoglycaemia (i.e. hypoglycaemia begets hypoglycaemia) (Gold et al., 
1997).  A German group found that severe hypoglycaemia was more likely in 
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those with a previous history of severe hypoglycaemia, a lower HbA1c, a 
larger insulin dose per kilogram, lower emotional coping ability scores and a 
longer duration of diabetes (Bott et al., 1997).   Using the DCCT data set, 
lower mean blood glucose and increased glucose variability were predictors of 
severe hypoglycaemia (Kilpatrick et al., 2007, Kovatchev et al., 2006).   
Pregnancy is associated with an increased risk of severe hypoglycaemia, 
especially during the first trimester; pre-pregnancy planning does not reduce 
this risk (Evers et al., 2002, Nielsen et al., 2008, Robertson et al., 2009). 
Alcohol consumption is a risk factor for severe hypoglycaemia (ter Braak et al., 
2000).  An early study found that alcohol was a factor in 31% of people 
admitted with hypoglycaemia (Seltzer, 1972).  Moderate alcohol consumption 
has been shown in both “real world” and experimental studies to increase the 
risk of hypoglycaemia the following morning in people with insulin treated 
diabetes; as well as those on sulfonylurea therapy (Burge et al., 1999, Turner et 
al., 2001, Richardson et al., 2005).  A practical and frequently encountered 
clinical correlate to this would be an evening spent drinking alcohol followed 
by fasting overnight.  Eating a meal before and after alcohol consumption has 
been suggested to reduce the risk of alcohol related hypoglycaemia; advice that 
is often given by diabetes teams in clinical practice (Ismail et al., 2006).   
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Table 1.2: Causes and risk factors for hypoglycaemia in people with T1DM 
(Graveling and Frier, 2009, Cryer, 2008, Muhlhauser et al., 1998, Pedersen-
Bjergaard et al., 2004, Stephenson et al., 1996) 
Risk factors Causes 
Previous exposure to 
severe hypoglycaemia 
Insulin doses are excessive, ill-timed or of the wrong 
type of insulin 
Impaired awareness of 
hypoglycaemia 
Inadequate exogenous carbohydrate (e.g. missed 
meal or snack, overnight fast) 
Increasing age Endogenous glucose production is decreased (e.g. 
following alcohol ingestion) 
Increasing duration of 
diabetes 
Glucose utilisation is increased (e.g. during and 
shortly after exercise) 
Strict glycaemic control Sensitivity to insulin is increased (e.g. in the middle 
of the night and following weight loss, improved 
fitness or improved glycaemic control)  
C-peptide negativity Insulin doses are excessive, ill-timed or of the wrong 
type of insulin 
Lower social status  
Peripheral or autonomic 
neuropathy 
 
Exercise  
Pregnancy  
Alcohol  
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Increased insulin sensitivity in glucose clamp studies has been shown in 
participants taking Angiotensin Converting Enzyme (ACE) inhibitors 
suggesting an increased risk of hypoglycaemia (Pollare et al., 1989, Vuorinen-
Markkola and Yki-Jarvinen, 1995, Santoro et al., 1992).  A nested case control 
study conducted in Tayside showed an increased risk of severe hypoglycaemia 
with ACE inhibitor use (Morris et al., 1997).   Various other medications (not 
used for glycaemic control) have been associated with small increased risks of 
hypoglycaemia; this will not be discussed further.  
An association has been described between elevated serum ACE levels and an 
increased risk of severe hypoglycaemia (Pedersen-Bjergaard et al., 2001, 
Pedersen-Bjergaard et al., 2003a).  In a large cohort of Danish children, 
increased serum ACE levels were found to increase the risk of hypoglycaemia 
in girls only (Johannesen et al., 2011).  It has been postulated that lower 
symptom scores during hypoglycaemia observed in a group with higher ACE 
levels may be responsible for the increased risk of hypoglycaemia (Hoi-Hansen 
et al., 2009).  Later studies performed in different countries have only shown a 
weak or no relationship between serum ACE and severe hypoglycaemia 
meaning that the association remains unproven (Bulsara et al., 2007, Zammitt 
et al., 2007). 
1.71  Disproving the “Somogyi” effect 
Michael Somogyi postulated that nocturnal hypoglycaemia may result in 
fasting hyperglycaemia as a result of excessive counter-regulatory hormone 
release, this became known as the “Somogyi” effect (Somogyi, 1959); the 
study was performed using glycosuria as a surrogate for plasma glucose levels.  
The phenomenon of rebound hyperglycaemia continues to be discussed and 
promoted by diabetes professionals to people with diabetes (Dose Adjustment 
for Normal Eating (DAFNE), 2012).   
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Using CGM data from more than 250 people with T1DM, a Danish group 
found that fasting blood glucose levels were lower after nocturnal 
hypoglycaemia compared with nights containing no hypoglycaemic episodes 
(6.1±0.3 versus 11.5±0.2 mmol/L (mean±SEM)) (Hoi-Hansen et al., 2005).  A 
follow on analysis confirmed that there was no association between nocturnal 
hypoglycaemia and hyperglycaemia the following morning taking into account 
the other potential determinants of late morning blood glucose levels (Hoi-
Hansen et al., 2006).  A similar picture was noted in a study analysing CGM 
data from the UK Hypoglycaemia Group Study showing again that fasting 
glucose was lower after nights with hypoglycaemia than without (5.5 versus 
14.5 mmol/L) (table 1.3) (Choudhary et al., 2013); when the fasting capillary 
blood glucose was <5 mmol/L there was evidence of hypoglycaemia in 94% of 
nights. 
Table 1.3: Number of nights with different nadir sensor glucose (lowest sensor 
glucose for at least 20 min) based on fasting capillary blood glucose (total 
nights = 89) (Choudhary et al., 2013) 
Lowest sensor 
glucose 
Fasting capillary glucose (following morning) 
< 5 mmol/L 5-10 mmol/L > 10 mmol/L 
< 3.5 mmol/L 16 14 2 
3.5-5.0 mmol/L 1 14 4 
5.1-10 mmol/L 0 18 13 
>10.1 mmol/L 0 1 6 
 
1.72 Risk factors for hypoglycaemia in the paediatric population 
The impact of different variables on the risk of severe hypoglycaemia is 
unclear, studies have often reported apparently conflicting results (table 1.4).  
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Many of these studies are not directly comparable looking at differing age 
groups or duration of diabetes.  Severe hypoglycaemia in children is often 
associated with improved glycaemic control and sometimes with increasing 
age (Allen et al., 2001).  A large Australian study reported that risk factors for 
severe hypoglycaemia altered with increasing age.  In children aged 0-6 years 
there were no significant associations with severe hypoglycaemia.  In children 
aged 6-12 years increasing disease duration was a risk factor for severe 
hypoglycaemia but not HBA1c, gender or treatment regimen.  In children aged 
>12 years duration of diabetes was again noted to be a strong risk factor with a 
10 fold risk of severe hypoglycaemia in those with >6 years of diabetes 
compared to those in their first year of diagnosis. (Cooper et al., 2013).  An 
inappropriate response to hypoglycaemia (i.e. by checking for ketones or 
taking no corrective action) was noted in 38% of hypoglycaemic episodes 
reported by adolescents (Johnson et al., 2000). 
Table 1.4: Risk factors for severe hypoglycaemia in the paediatric population 
Risk factor Positive (significant) association No (significant) association 
Diabetes 
duration 
Increased with duration (Rewers et 
al., 2002, O'Connell et al., 2011, 
Blasetti et al., 2011, Wagner et al., 
2005) 
(Bognetti et al., 1997). No 
significant difference after 
1 years duration (Davis et 
al., 1997). 
Age Decreased rate with younger age 
in girls (Rewers et al., 2002). 
Increased rate with younger age 
(Wagner et al., 2005, Bulsara et 
al., 2004). Increased with age 
(Bognetti et al., 1997) 
 
Glycaemic 
control 
Increased rate with lower HbA1c 
(Davis et al., 1998) 
No relationship (O'Connell 
et al., 2011, Blasetti et al., 
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2011) 
Gender Increased in males (Bulsara et al., 
2004) 
 
Insulin 
regimen 
Pump therapy associated with 
reduced rate (O'Connell et al., 
2011, Cooper et al., 2013) 
No relationship (Blasetti et 
al., 2011). No difference 
with analogue insulin 
compared with human 
insulin (Wagner et al., 
2008). 
  
1.72 Risk factors for hypoglycaemia in T2DM 
Hypoglycaemia in people with T2DM results from similar causes and risk 
factors to people with T1DM; a Scottish study identified previous 
hypoglycaemia and duration of insulin therapy as independent predictors 
(Donnelly et al., 2005).  A large study of people in North America with T2DM 
has shown that limited health literacy (i.e. problems learning, help reading, not 
confident with forms) increased the likelihood of severe hypoglycaemia over 
the preceding 12 months (Sarkar et al., 2010). 
1.73  Risk factor case study: Exercise 
Exercise and hypoglycaemia has recently been extensively reviewed (Gallen, 
2014).  Exercise has been shown to increase the risk of hypoglycaemia, both 
during the event itself and for up to 18 hours following the event (MacDonald, 
1987).  Late onset hypoglycaemia has been demonstrated in the paediatric 
population with children more likely to develop nocturnal hypoglycaemia on 
nights following exercise than following sedentary days (Tsalikian et al., 
2005).  Hypoglycaemia is common during endurance exercise such as 
marathon running, and is multifactorial in aetiology (Lumb and Gallen, 2009).  
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The warning symptoms of hypoglycaemia may be confused with those induced 
by exercise per se, and may delay its recognition and treatment.   
At rest and during low intensity exercise free fatty acids are used as the 
principal source of energy.  With exercise of at least moderate intensity, 
carbohydrate metabolism becomes an increasingly important source of fuel 
(Perry and Gallen, 2009).  Working groups of skeletal muscle initially obtain 
glucose for energy from muscle glycogen stores, but once depleted, a balance 
develops between glucose production (primarily via hepatic glycogenolysis) 
and glucose uptake by exercising muscle (Petersen et al., 2004).  Energy 
consumption and production during endurance exercise differs from that during 
intermittent high intensity exercise.  The increase in catecholamines is 
considerably greater with intermittent high intensity exercise (Sigal et al., 
1996), which increases glucose production and protects against hypoglycaemia. 
Extreme sporting events such as marathons can result in severe hypoglycaemia, 
especially in the setting of preceding nocturnal hypoglycaemia with associated 
seizure activity (Graveling and Frier, 2010).   In this case report, glycogen 
stores would have been severely depleted during the preceding nocturnal 
seizure and their replenishment would have been delayed due to post-
hypoglycaemia insulin resistance associated with the secretion of counter-
regulatory hormones (Orskov et al., 1996).  At rest, blood flow to skeletal 
muscle increases during hypoglycaemia (Hoffman et al., 1999), but during 
exercise, the blood flow to skeletal muscle is already maximal, so no further 
protective increase in blood flow can occur to maximise delivery of circulating 
glucose.  The reduced hepatic glycogen stores would have compounded the 
severity of the subsequent exercise-induced hypoglycaemia.  Storage of 
glycogen is reduced during hypoglycaemia (Orskov et al., 1996), but with 
adequate ingestion of oral carbohydrate it can be replenished within 12-14 
hours (Steppel and Horton, 2003). 
Because insulin is administered exogenously to treat diabetes, plasma levels do 
not fall when commencing endurance exercise as in a non-diabetic person.  
Indeed, exercise per se can accelerate insulin absorption by increasing blood 
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flow to contracting muscles (Hopkins, 2004).  Heat produced by working 
muscle groups is dissipated via an increase in subcutaneous blood flow; this 
increases insulin absorption from adjacent injection sites.  The increased ratio 
of insulin to glucagon results in less hepatic glucose production (Lumb and 
Gallen, 2009).  The exogenous administration of insulin also reverses the usual 
portal: systemic ratio of insulin levels.  The relatively higher peripheral 
concentrations promote peripheral muscle glucose uptake and predispose to 
hypoglycaemia. 
Delayed hypoglycaemia can occur for up to 15 hours after exercise, and is 
associated with increased uptake and storage of glucose by skeletal muscle, 
inadequate repletion of hepatic glycogen and increased insulin sensitivity 
(MacDonald, 1987).  Antecedent exercise blunts the counter-regulatory 
hormonal response and warning symptoms of impending hypoglycaemia 
(Sandoval et al., 2004). The fall in blood glucose after exercise is bimodal, 
decreasing for around 90 minutes immediately after exercise with a further 
decrement after 7 to 11 hours (McMahon et al., 2007).  More than 30 minutes 
of moderate to vigorous activity during the afternoon increased the risk of 
hypoglycaemia by 31% the following day in adolescents with T1DM (Metcalf 
et al., 2014).  
1.8  Chapter summary 
Hypoglycaemia is a common and feared complication of insulin therapy and 
the main obstacle to achieving good glycaemic control.  The frequency and 
symptoms vary widely between individuals.  The detection of hypoglycaemia 
may be made easier with new technologies such as CGM although it does have 
some limitations.  The main risk factor for hypoglycaemia is antecedent 
hypoglycaemia.  It is important to identify any contributing risk factors (e.g. 
exercise) that can result in hypoglycaemia after each episode.
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Chapter 2  Hypoglycaemia: Mechanisms, morbidity and 
mortality 
2.1 Pathophysiology of hypoglycaemia 
2.11 Introduction 
Acute hypoglycaemia provokes pronounced physiological responses, the 
important consequences of which are to maintain the supply of glucose to the 
brain and promote the hepatic production of glucose.  Blood flow is reduced to 
organs that are not important for counterregulation, such as the spleen and the 
skin.  By contrast blood flow is increased to the myocardium, splanchnic 
circulation (carrying 3-carbon precursors to the liver) and the brain.  
Autonomic activation, principally of the sympatho-adrenal system, results in 
end-organ stimulation and a profuse release of adrenaline, which provokes the 
haemodynamic changes listed in Table 2.1 (Cryer, 2013).  
Table 2.1: Haemodynamic changes during hypoglycaemia (Laing et al., 1999b, 
Hilsted et al., 1984, Fisher et al., 1990) 
• Increased heart rate  
• Increased peripheral systolic blood pressure  
• Decreased central blood pressure  
• Increased myocardial contractility with an increased ejection fraction  
• Decreased peripheral resistance (resulting in a widened pulse pressure) 
 
2.12 Defences against hypoglycaemia 
The normal defence against falling blood glucose levels is the ingestion of oral 
carbohydrate.  As blood glucose levels fall in healthy individuals insulin 
secretion from pancreatic beta-cells is inhibited (at around 4.4mmol/L); this 
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fall in insulin levels results in stimulation of pancreatic alpha-cells thus 
increasing glucagon secretion (Cooperberg and Cryer, 2010, McCrimmon, 
2008).  If glucose levels continue to fall then adrenaline and noradrenaline are 
released (at around 3.6-3.8mmol/L) (Fanelli et al., 1994).  Additional and less 
immediate responses include increased growth hormone and cortisol secretion 
(Beall et al., 2012).  
2.13 Unregulated hyperinsulinaemia 
Humans have evolved to deal with hypoglycaemia in the situation of low 
insulin and low glucose levels (i.e. periods of prolonged starvation).  People 
with T1DM have high insulin levels from exogenous insulin administration and 
low glucose levels.  This results in conflicting signals and compromises the 
defence systems against hypoglycaemia in people with T1DM.  The elevated 
insulin concentrations increase glucose uptake into muscle, fat and liver and 
limit gluconeogenesis.  Insulin also inhibits lipolysis, prevents the release of 
alternative energy stores and suppresses glucagon secretion through direct 
action on pancreatic alpha-cells (Beall et al., 2012, Garber et al., 1976).  
2.14 Counterregulatory deficiencies 
Glucagon increases glucose production by the liver through hepatic 
glycogenolysis, increased gluconeogenesis, increased amino acid transport and 
increased fatty acid metabolism (ketogenesis) (Fanelli et al., 2006).  Blood 
glucose was previously thought to be the dominant stimulus of glucagon 
secretion, displaying an inverse relationship with hypoglycaemia resulting in 
increased glucagon secretion.  However, it is the reduced beta-cell secretion of 
insulin, resulting in decreased inhibition of alpha-cells, which leads to an 
increase in glucagon secretion (Raju and Cryer, 2005, Taborsky and 
Mundinger, 2012).  Glucagon secretion is therefore inversely related to the 
prevailing intra-islet insulin concentration.  Artificially maintaining intra-islet 
insulin concentrations with a sulfonylurea markedly attenuates the glucagon 
response (Peacey et al., 1997, Banarer et al., 2002).  The glucagon response is 
therefore not dependent on innervation and people with pancreas transplants or 
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spinal cord transections have normal glucagon secretion (Diem et al., 1990, 
Palmer et al., 1976). 
Glucagon secretion in response to hypoglycaemia becomes attenuated and then 
eventually fails altogether in T1DM and advanced T2DM (Gerich et al., 1973, 
Bolli et al., 1983, Segel et al., 2002).  Glucagon responses to other stimuli are 
preserved, indicating that the alpha-cells remain functional (Cryer, 2005, 
Siafarikas et al., 2012).   Residual beta-cell function has been shown, in 
children, to be associated with a lower risk of severe hypoglycaemia (Sorensen 
et al., 2013). 
The next counter-regulatory deficiency to be acquired is a failure of adrenaline 
and noradrenaline secretion during hypoglycaemia.  This defect is not because 
of classical autonomic neuropathy but is primarily mediated by reduced 
sympathetic drive.  Secretion of adrenaline in response to hypoglycaemia is 
reduced in magnitude and occurs at a lower glucose concentration in T1DM 
and advanced T2DM but not those with T2DM of shorter duration (Levy et al., 
1998).  
2.15 Counter-regulatory deficiencies in children 
As in adults, the initial response to a decline in blood glucose in children is 
suppression of endogenous insulin production, followed by the release of 
counter-regulatory hormones including glucagon.  This is followed by 
sympatho-adrenal activation, which generates autonomic symptoms (such as 
pounding heart and trembling) while the cognitive dysfunction associated with 
neuroglycopenia underlies the development of cognitive symptoms (Matyka, 
2014).   There is a relative paucity of experimental studies in children, perhaps 
reflecting concerns from ethical committees about subjecting the developing 
brain to hypoglycaemia (Ryan, 2009).  Glucagon secretion in adolescents, as in 
adults, is lost early in the disease course (median of 8 months from diagnosis) 
(Siafarikas et al., 2012).  In children, the blood glucose levels at which counter-
regulatory hormone secretion occurs will differ according to pubertal stage and 
level of glycaemic control (Ross et al., 2005, Jones et al., 1991). 
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Compared to children without diabetes, adrenaline, cortisol and glucagon 
incremented to a lesser extent in children with T1DM (mean HbA1c 9.8%) 
(Bjorgaas et al., 1997).  A more recent study of children with T1DM and better 
glycaemic control (mean HbA1c 7.7%) found blunted counter-regulatory 
responses to a modest hypoglycaemic nadir (Diabetes Research in Children 
Network Study et al., 2009).  The mean glucose nadir was 3.3mmol/L and only 
one third mounted a response at >3.3mmol/L with one third mounting a 
response with blood glucose <3.3 mmol/L and one third exhibited no counter-
regulatory response.  The authors attributed this finding to hypoglycaemia 
associated autonomic failure (HAAF) although the hypoglycaemic stimulus 
may have simply have been insufficient to trigger a counter-regulatory 
response (Graveling et al., 2010).  In children with poorly controlled T1DM 
(mean HbA1c 10.8%) and moderate disease duration (mean 6 years) the 
adrenaline increase in response to hypoglycaemia was greater than in adults 
with T1DM and a similar level of glycaemic control but longer duration of 
diabetes (mean 11.8 years); the increased duration of diabetes may have been 
responsible for the attenuated response seen in adults rather than the older age 
of the participants (Amiel et al., 1987).   
During nocturnal hypoglycaemia the counter-regulatory responses are blunted.  
Pre-pubertal children experiencing nocturnal hypoglycaemia were shown to 
have significant increases in adrenaline (but not noradrenaline, cortisol or 
growth hormone) compared to nights when no nocturnal hypoglycaemia was 
observed (Matyka et al., 1999). 
2.2 Detection of hypoglycaemia and utilisation of glucose by the central 
nervous system 
2.21 Central versus peripheral glucose sensing during hypoglycaemia 
Glucose sensing cells regulate glucose concentrations throughout the body.  
Peripherally these cells are present in the portal vein, carotid body, pancreas 
and gut (McCrimmon, 2008).  Centrally they are mostly found in the 
hypothalamus and brainstem (Jensen et al., 2014, McCrimmon, 2011).   
Chapter 2 
 83 
 
In animal studies, portal vein glucose sensing is necessary for the attenuation 
of counter-regulatory responses following antecedent hypoglycaemia 
(Matveyenko et al., 2007).  However, it appears to be less important in humans 
in whom hormonal and symptomatic responses are unaffected by prevention of 
portal hypoglycaemia (Rossetti et al., 2009) and peripheral glucose sensors do 
not appear to be important in stimulating the counter-regulatory response to 
acute hypoglycaemia.   
A core network of brain regions, including the hypothalamus, is recruited 
during hypoglycaemia (Musen et al., 2008).  Sites of glucose sensing during 
hypoglycaemia is an area of on going debate; while the brain is known to play 
a key role more recently peripheral glucose sensing has been shown to be 
important (Cherrington, 2008).  The hypothalamus and more specifically the 
ventromedial hypothalamus (VMH) plays a key role in glucose sensing with a 
two-fold increase in blood flow to the hypothalamus during hypoglycaemia 
(Page et al., 2009, McCrimmon, 2009).  Glucose sensing neurones use glucose 
not as a fuel but as a signalling molecule to regulate their metabolic activity; 
there are two main types of glucose sensing neurones, inhibitory and excitatory 
(McCrimmon, 2008, McCrimmon, 2009).  Glucose excited neurones increase 
their activity as glucose levels increase and glucose-inhibited neurones increase 
their activity as glucose levels fall (Levin et al., 2004).  Glucose sensing 
neurones in the ventromedial hypothalamus (VMH) use ATP sensitive 
potassium (KATP) channels (similar to those found in the pancreatic beta-cell); 
closing these channels (using a sulfonylurea) results in supressed counter-
regulatory responses to systemic hypoglycaemia (Evans et al., 2004).  Mice 
with knockout mutations for neuronal insulin receptors displayed less 
hypothalamic activation and impaired counter-regulatory response (Diggs-
Andrews et al., 2010).   
The dominance of a particular area in glucose sensing may change with the rate 
of fall of blood glucose; the brain takes a more dominant role with rapid 
decrements in blood glucose (Saberi et al., 2008).  Nitric oxide is necessary to 
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detect hypoglycaemia in the VMH and to generate the counter-regulatory 
response (Fioramonti et al., 2010). 
A canine study illustrated the influence of the brain on counter-regulatory 
hormone secretion.  Dogs were rendered peripherally hypoglycaemic with 
glucose infusions into the carotid and vertebral arteries to prevent cerebral 
hypoglycaemia and compared with dogs rendered hypoglycaemic both 
centrally and peripherally.  When the cerebral perfusion was kept euglycaemic, 
the magnitude of hormonal responses were only 14% for adrenaline, 12% 
noradrenaline, 17% cortisol and 21% glucagon compared with whole body 
hypoglycaemia (Biggers et al., 1989).  A similar study in rats found a similar 
magnitude of reduction by perfusing the ventromedial hypothalamic nucleus 
with glucose on a background of peripheral hypoglycaemia (Borg et al., 1997). 
2.22 Cerebral energy metabolism during hypoglycaemia 
During hypoglycaemia, brain glucose uptake falls by 22-24% in all but those 
with tightly controlled T1DM (Boyle et al., 1995).  Human studies have shown 
that brain glucose uptake initially falls with hypoglycaemia but with antecedent 
hypoglycaemia brain glucose uptake is preserved at euglycaemic levels (Boyle 
et al., 1994).  The process of adaptation to hypoglycaemia depends on the 
degree and duration of previous hypoglycaemia.   
2.23 Glucose transporters 
The rate-limiting step in cerebral cellular glucose metabolism is glucose 
transport into cells.  Glucose does not freely permeate through the plasma cell 
membranes and therefore requires transport proteins.  Glucose is transported 
down a concentration gradient by energy-independent facilitative glucose 
transporters (GLUTs) and up a concentration gradient by energy-dependent 
sodium-dependent glucose transporters (SGLTs).  GLUT1 and GLUT3 are the 
main glucose transporters in the brain; GLUT1 transports glucose from the 
peripheral circulation into the brain (i.e. through the blood-brain barrier) and 
GLUT3 facilitates transport into neurones (Jensen et al., 2014, Reno et al., 
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2013).  The expression of glucose transporters is to some extent determined by 
previous glycaemic experience with a probable increase after hypoglycaemia 
(Amiel, 1995, McCall et al., 1986).   
2.24 Glucose concentrations in the brain during hypoglycaemia 
compared with euglycaemia 
As the brain is unable to store to store or synthesise glucose in any significant 
quantity, a continuous supply of glucose is required from the peripheral 
circulation (Cryer, 2007).  Glucose is the obligate fuel for cerebral metabolism 
under physiological conditions and the brain accounts for about 20%-25% of 
the total glucose utilised by the body in the resting state despite comprising 
only 2% of the body’s mass (Berg et al., 2002, Bryant et al., 2002, Belanger et 
al., 2011).  In children the relative proportion required by the brain is even 
higher, suggesting a increased vulnerability to any hypoglycaemic episodes 
(McCall, 2004).  
Microdialysis catheters placed in the cerebral circulation allow direct 
measurement of cerebral extracellular fluid concentrations of glucose and 
lactate.  Determination of ECF glucose is important as this indicates the 
prevailing glucose concentration that neurones will be exposed to.  Table 2.2 
displays this data; concentrations of cerebral ECF glucose were approximately 
17% of the systemic circulation during euglycaemia with the percentage 
remaining unchanged during hypoglycaemia.  Changes in ECF cerebral 
glucose lagged about 30 minutes behind that of plasma glucose; this may help 
protect the brain against severe hypoglycaemia (Abi-Saab et al., 2002).  During 
euglycaemia, the cerebrospinal fluid concentration is about 50-80% that of the 
systemic circulation (Owen et al., 1974, Leen et al., 2012).  
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Table 2.2: Concentrations of plasma and cerebral glucose of conscious human 
subjects during sequential hyperglycaemic-hypoglycaemic clamps (Abi-Saab et 
al., 2002). 
 Baseline Hyperglycaemia Hypoglycaemia 
Plasma glucose 
(mmol/L) 
5.50±0.46 11.5±1.27 3.00±0.78 
Cerebral ECF 
glucose (mmol/L) 
0.82±0.27 1.56±0.73 0.27±0.10 
 
2.25 Cerebral blood flow during hypoglycaemia 
Early studies reported variable effects of acute hypoglycaemia on cerebral 
blood flow with Porta et al (1964) reporting an increased flow (Porta et al., 
1964) but two others reporting a decreased flow (Kety and Woodford, 1948, 
Eisenberg and Seltzer, 1962).  In rat studies it has been suggested that the 
increase in cerebral blood flow occurs when glucose level fall below 
2.0mmol/L (Choi et al., 2001).  After ten minutes of hypoglycaemia 
(2.0mmol/L), cerebral blood flow increased by 25% in adults both with and 
without T1DM (Tallroth et al., 1992, Tallroth et al., 1993).  This increased 
cerebral flow was observed in children at a higher blood glucose level than in 
adults (Jarjour et al., 1995).  A stepped hypoglycaemic clamp was utilised to 
achieve the more modest hypoglycaemic stimuli of 2.8 mmol/L and 3.3 
mmol/L, rather than 2.0 mmol/L used during the studies of Tallroth et al (1992 
& 1993) (Powers et al., 1996).  No change in regional cerebral blood flow was 
observed.  Using more sophisticated measuring techniques more recent work 
has suggested that overall cerebral blood flow decreases slightly during 
hypoglycaemia (by ~7%) although the median prefrontal cortex showed 
increased neuronal activation (Teves et al., 2004).  The more complicated 
picture of regional variation in cerebral blood flow has emerged with more 
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sophisticated imaging techniques.  Cerebral blood flow increases to the motor 
cortices and thalamus during hypoglycaemia (Kennan et al., 2005, Mangia et 
al., 2012, Bie-Olsen et al., 2009).  
People with diabetes were shown to have a relatively greater uptake to the 
frontal cortex, especially in those with a history of severe hypoglycaemia 
(MacLeod et al., 1994).  A subsequent study failed to show any difference in 
regional blood flow in those with impaired awareness of hypoglycaemia 
compared to normal awareness; again flow was increased to the frontal cortices 
and thalamus with reduced flow elsewhere (MacLeod et al., 1996). 
2.26 Alternative cerebral energy sources 
During euglycaemia, glucose is the obligate metabolic substrate required to 
maintain cerebral function, although this may not be the case during 
hypoglycaemia (Wahren J et al., 1999).  While glucose remains the primary 
energy source of the brain, alternative substrates can be used (i.e. ketone bodies 
during fasting) (Butterworth, 1999).  
The likely contribution of other energy sources (e.g. lactate) remains small 
although there is some evidence that people with T1DM may be better able to 
utilise these alternative fuel sources (Lubow et al., 2006, Mason et al., 2006). 
In rodent models, lactate transport during hypoglycaemia is increased by 
antecedent hypoglycaemia.  However the concentrations achieved are 
insufficient to meet the metabolic demands of the brain, glucose transport is 
also unregulated however and this may help protect the brain against 
subsequent hypoglycaemia (Herzog et al., 2013). 
Studies using catheters placed in the jugular artery and vein failed to show an 
increased uptake of lactate or pyruvate (Wahren et al., 1999).  Using 
intracerebral microdialysis catheters, lactate concentrations in the human brain 
are three times that of the systemic circulation but remain unchanged during 
hypoglycaemia despite an increase in the systemic circulation (Abi-Saab et al., 
2002).  In contrast to earlier studies, using functional MRI during 
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hypoglycaemia, cerebral lactate concentrations increased five-fold in people 
with T1DM and impaired awareness of hypoglycaemia (IAH) compared to 
people without diabetes (De Feyter et al., 2013). 
Using magnetic resonance spectroscopy to detect metabolic changes, people 
with T1DM demonstrate a two-fold increase in monocarboxylic acid transport 
compared with healthy volunteers during acute hypoglycaemia; this up-
regulation in people with previous experience of hypoglycaemia would allow 
better utilisation of alternative energy sources (Mason et al., 2006).  The 
increased uptake of various free fatty acids (i.e. lactate, alanine and leucine) 
would not be enough to offset the energy deficit incurred by the reduction in 
circulating glucose experienced during cerebral hypoglycaemia (Lubow et al., 
2006).   
Human brain glycogen is primarily localised to the astrocytes (Wiesinger et al., 
1997, McCall, 2004).  The main storage sites for glycogen are liver and 
skeletal muscle with the accepted ratio of glycogen storage in liver/skeletal 
muscle/brain is 100:10:1 (Nelson et al., 1968).  Because of the low glycogen 
content, the central nervous system has very little endogenous fuel.   
More recently the role of cerebral glycogen has been re-examined.   An 
intravenous infusion of radiolabelled with nuclear magnetic resonance 
spectroscopy (13C NMR) allows visualisation of cerebral glycogen metabolism 
(Oz et al., 2007).  Human cerebral glycogen content was estimated at 
3.5µmol/g with a very slow turnover requiring 3-5 days for complete turnover.  
The very slow turnover and lack of increase with intense stimulation prompted 
the conclusion that cerebral glycogen is not extensively utilised under normal 
physiological condition, however it has subsequently been shown to act as a 
buffer during hypoglycaemia (Choi et al., 2003, Oz et al., 2009).   
2.27 Recovery from hypoglycaemia 
A reduced glucose recovery rate in people with T1DM has been shown 
compared to people without diabetes.  This was postulated to be as a result of 
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counter-regulatory deficiencies; infusion of glucagon improves the recovery 
rate but does not return it to normal (Lager et al., 1984).   Post hypoglycaemia 
insulin resistance occurs up to 7-8 hours following acute hypoglycaemia; it is 
mediated by noradrenaline in the early phase and later by growth hormone and 
cortisol (Fowelin et al., 1989, Lucidi et al., 2010).  
2.28 Factors which modify the counter-regulatory response 
The effect of antecedent hypoglycaemia and cerebral adaptation will be 
discussed in chapter 4 (Sherwin, 2008).  
2.3 Hypoglycaemia and cardiovascular function 
2.31 Introduction 
Wright and Frier (2008) have suggested that while a young healthy individual 
can tolerate the profound physiological effects of acute hypoglycaemia on the 
cardiovascular system, when these acute changes are superimposed on a 
diseased coronary vasculature, they may provoke myocardial ischaemia or an 
arrhythmia (Wright and Frier, 2008).  It would now be considered potentially 
dangerous and unethical to subject people with established coronary heart 
disease to experimental hypoglycaemia, but anecdotal case reports have 
demonstrated a relationship between hypoglycaemia and acute vascular events 
and sudden death (Miura et al., 1998, Frier et al., 1995, Burke and Kearney, 
1999). 
2.32  Effect of hypoglycaemia on endothelial and platelet function, 
coagulation and fibrinolysis 
During euglycaemia, insulin has been shown to reduce several key mediators 
of oxidative and inflammatory stress (Dandona et al., 2010b).  However, 
during hypoglycaemia the increased activity of the sympathetic nervous system 
and secretion of other hormones and peptides such as the potent 
vasoconstrictor, endothelin, have pronounced effects on intravascular 
haemorrheology, coagulability and viscosity (Wright and Frier, 2008).  
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Inflammatory markers such as interleukin-6, interleukin-8, tumour necrosis 
factor and endothelin-1 are increased during hypoglycaemia (Razavi 
Nematollahi et al., 2009, Wright et al., 2007).  Hypoglycaemia results in 
platelet activation and inflammation with increased CD40 expression and high 
sensitivity C-reactive protein (Wright et al., 2010, Galloway et al., 2000).  
Increased plasma viscosity occurs during hypoglycaemia because of an 
increase in erythrocyte concentration, while coagulation is promoted by platelet 
activation and an increment in factor VIII and Von Willebrand factor.  
Endothelial function may be compromised during hypoglycaemia because of 
an increase in C-reactive protein, mobilisation and activation of neutrophils 
and platelet activation (Dandona et al., 2010a, Galloway et al., 2000).   
Figure 2.1 indicates how these changes could promote vascular occlusion and 
localised tissue ischaemia leading to vascular complications.  Endothelial 
dysfunction is an early pathological feature in the development of 
atherosclerosis but the degree of impairment does not always correlate with the 
extent of coronary arterial disease (Vita and Keaney, 2002, Wykretowicz et al., 
2005).  Severe endothelial dysfunction, even in the absence of obstructive 
coronary heart disease, is associated with an increase in cardiac events 
(Suwaidi et al., 2000).   
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Figure 2.1: Haematological and inflammatory processes induced by 
hypoglycaemia that may lead to vascular complications (Wright and Frier, 
2008) 
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2.33 Hypoglycaemia and arterial wall stiffness 
People with diabetes develop arterial stiffness prematurely, with a significant 
increase being observed in young adults with T1DM of long duration (> 15 
years), as compared with age-matched non-diabetic volunteers and those with a 
shorter duration of T1DM (<5 years) (Sommerfield et al., 2007).  This arterial 
stiffness has important implications for coronary vascular flow as coronary 
artery filling mostly occurs during diastole.  Normal elasticity of the arterial 
wall ensures that the reflected pressure wave from the high-pressure arterioles, 
generated during each myocardial contraction, returns to the heart during early 
diastole so increasing diastolic pressure and thereby enhancing coronary 
arterial perfusion (Nicols and O'Rourke, 2005).  Progressive stiffening of the 
arterial wall results in the earlier arrival of the reflected wave during late 
systole, which may interfere with coronary arterial perfusion (Saito et al., 
2008).  The increased vascular stiffness that occurs in people with T2DM has 
been shown to predict cardiovascular mortality (Djaberi et al., 2008).   
2.34 Hypoglycaemia and cardiac function 
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Figure 2.2: Mechanisms that can adversely affect cardiovascular function 
during hypoglycaemia (Chow and Heller, 2012) 
Mechanisms that can adversely affect cardiovascular function during 
hypoglycaemia are shown in Figure 2.2.  Hypoglycaemia has profound effects 
on cardiac function but these can be difficult to distinguish from the effects of 
insulin per se.  Insulin is a coronary vasodilator and has pro-inflammatory 
actions (Sundell et al., 2002, Dandona et al., 2007).  The administration of 
intravenous insulin has a small, immediate effect to promote sympathetic 
neural activation and to increase left ventricular ejection fraction, before any 
fall in blood glucose occurs (Fisher et al., 1990).  These changes become more 
pronounced with a progressive decline in blood glucose; the maximal 
responses coincide with the glucose nadir.  Significant increments in stroke 
volume and cardiac output also occur during hypoglycaemia (Hilsted et al., 
1984).   
In an effort to separate the effects of insulin from that of hypoglycaemia, 
cardiac performance during a hyperinsulinaemic euglycaemic clamp was 
compared with performance during a hyperinsulinaemic hypoglycaemic clamp.  
The infusion of insulin resulted in increased left ventricular ejection fraction 
(LVEF) whereas hypoglycaemia resulted in a further increase in LVEF and 
also an increase in peak filling rate (PFR) in participants without diabetes.  
Participants with diabetes demonstrated an increase in LVEF and PFR with 
insulin but a blunted response to hypoglycaemia (Russell et al., 2001).   
Myocardial blood flow (MBF) reserve is calculated as the ratio of peak MBF to 
resting MBF.  MBF reserve is reduced during acute hypoglycaemia in adults 
with and without T1DM (Rana et al., 2011).  The haemodynamic changes 
during hypoglycaemia observed in non-diabetic adults are attenuated in some 
people with T1DM, particularly those with strict glycaemic control (Russell et 
al., 2001).   Hypoglycaemia has been shown using CGM and ambulatory blood 
pressure monitoring to increase blood pressure in “real world” studies in 
people with T1DM and T2DM (Feldman-Billard et al., 2010).   
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2.35 Can hypoglycaemia cause myocardial ischaemia? 
An early case report described a 58-year-old person with diabetes who 
experienced angina in association with “insulin shock” (hypoglycaemia) 
(Turner, 1930), while in a more contemporary case, typical ECG and enzyme 
changes were associated with an acute coronary syndrome (ACS) that followed 
a massive insulin overdose and subsequent severe hypoglycaemia (Kamijo et 
al., 2000).  Angiography demonstrated normal coronary vasculature; therefore 
dynamic changes in the coronary blood vessels may have caused the 
myocardial ischaemia.  
Anecdotal case studies such as these have prompted researchers to examine the 
association between hypoglycaemia and cardiovascular events.  
Hypoglycaemia was induced in 7 people with known coronary artery disease, 
this precipitated angina attacks in 2 out of 7 of the participants with typical 
electrocardiographic changes (Strouse et al., 1932).  The effect of insulin and 
hypoglycaemia on electrocardiographic (ECG) changes can be seen in Figure 
2.3 (Egeli and Berkmen, 1960).  Participants with diabetes were rendered 
hypoglycaemic with insulin (the lowest blood glucose was around 2.5 mmol/L) 
and ECG changes involving the ST segments and T waves were noted.  These 
changes could be partly ameliorated with beta-blockade or administration of 
serum potassium (Robinson et al., 2003). 
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Figure 2.3: ECG alterations under the influence of insulin, maximal ST 
depression corresponds with the glucose nadir at 45 minutes (Egeli and 
Berkmen, 1960) 
Ischaemic changes were noted in the ECGs of five out of six people with 
T2DM when they were rendered hypoglycaemic; a bradyarrhythmia occurring 
in one participant resulted in loss of consciousness (Lindstrom et al., 1992). 
Continuous blood glucose monitoring and Holter ECG monitoring were 
performed simultaneously in people with T2DM and known ischaemic heart 
disease; 54 episodes of hypoglycaemia (blood glucose <3.9mmol/L) were 
identified, 10 of which were accompanied by chest pain (Desouza et al., 2003).  
ST segment abnormalities were observed in four of the symptomatic episodes 
and in two episodes of asymptomatic biochemical hypoglycaemia.  By 
contrast, one solitary episode of chest pain occurred during hyperglycaemia 
(blood glucose >11.1mmol/L) and none occurred during euglycaemia. 
2.36 Electrolyte disturbance during hypoglycaemia 
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Hypoglycaemia provokes rapid and rapidly reversible increases in serum 
sodium, chloride and calcium (Caduff et al., 2011).  Hypoglycaemia results in a 
decrease in serum potassium levels; caused by both the insulin itself and the 
counter-regulatory secretion of adrenaline (Heller and Robinson, 2000, 
Petersen et al., 1982).  In contrast to the other electrolytes, the recovery of 
serum potassium is delayed until more than 2 hours after euglycaemia has been 
restored (Caduff et al., 2011, DeFronzo et al., 1980).  
2.37 Can hypoglycaemia result in clinically significant arrhythmia? 
Hypoglycaemia may provoke an arrhythmia in 3 main ways; prolongation of 
the QTc interval (corrected QT interval), rise in intracellular calcium and 
hypokalaemia (Nordin, 2010).  Hypoglycaemia has long been known to affect 
the electrocardiogram with delayed repolarisation being demonstrated by a 
prolonged QT interval (Judson and Hollander, 1956, Lee et al., 2003, Marques 
et al., 1997).  The QT interval is dependent on heart rate and the correction 
method utilised may over or underestimate the actual correct QT interval using 
a subject specific correction formula (Christensen et al., 2010).  Although the 
finding of a lengthened QTc interval has not been invariable, hypoglycaemia 
consistently reduces the T wave amplitude (Robinson et al., 2003, Koivikko et 
al., 2008).  These ECG changes may increase the risk of arrhythmia (Robinson 
et al., 2004).  
Ventricular tachycardia and atrial fibrillation have been reported during 
hypoglycaemia (Chelliah, 2000, Collier et al., 1987).  Cardiac arrhythmias 
have been recorded during spontaneous episodes of nocturnal hypoglycaemia 
(Gill et al., 2009).  Routine ECG screening appears to be of limited use in 
detecting those at risk as no correlation was shown between QTc prolongation 
during euglycaemia and QTc prolongation during hypoglycaemia.  CGM and 
ambulatory ECG recording in 25 participants with T2DM demonstrated that 
bradycardia, atrial and ventricular ectopics were more common during 
hypoglycaemia (especially nocturnal hypoglycaemia); the incidence of 
bradycardia was increased eight fold during nocturnal hypoglycaemia 
compared with euglycaemia (Chow et al., 2014).  
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Sudden death during sleep has been described in people with T1DM, the 
putative mechanism being a significant cardiac arrhythmia induced by 
nocturnal hypoglycaemia (Tattersall and Gill, 1991, Dahlquist and Kallen, 
2005).  Many of these people had no evidence of severe hypoglycaemia-
induced neuronal damage at autopsy, implying that a cardiac arrhythmia had 
been triggered by hypoglycaemia, resulting in sudden death (Fisher and Heller, 
2007).  It is reassuring that despite the high frequency of nocturnal 
hypoglycaemia in young people with T1DM, sudden nocturnal death (“dead in 
bed” syndrome) is rare.  However, it is possible that the presence of a genetic 
mutation (e.g. in a cardiac ion channel) or predisposition may be necessary for 
a cardiac arrhythmia to occur (Start et al., 2007).  A German study of 16 
adolescents with T1DM observed lengthening of QTc during hypoglycaemia in 
all subjects with the greatest increase recorded in the sibling of an adolescent 
who had died from “dead in bed” syndrome (Rothenbuhler et al., 2008).   
2.38 Does previous exposure to hypoglycaemia modify the vascular risk? 
Antecedent hypoglycaemia induces a reduction in baroreflex sensitivity and 
sympathetic response to hypotensive stress, which may predispose susceptible 
individuals to the development of a cardiac arrhythmia (Adler et al., 2009, 
Arbelaez et al., 2008).  Impairment of the autonomic neural control of heart 
rate is associated with an increased risk of mortality (Maser and Lenhard, 
2005). 
2.4 Morbidity and mortality of hypoglycaemia 
Compared with age-matched individuals, adults with T1DM are at substantially 
elevated risk of death with an almost four-fold increased risk of mortality 
(Soedamah-Muthu et al., 2006a).  Self-reported severe hypoglycaemia 
increased the risk of mortality in the next five years in both T1DM and T2DM 
(McCoy et al., 2012).  Under the age of 40, acute diabetes complications (e.g. 
hypoglycaemia or DKA) remain the most common cause of death for people 
with T1DM.  Over the age of 40, cardiovascular disease accounts for more than 
half the cause of deaths in people with T1DM (Tu et al., 2008). 
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Over 23,000 people with T1DM were followed up for between 4 to 25 years.  
Overall, the relative risk of death (standardised mortality ratio) was 4.0 for 
females and 2.7 for males (Laing et al., 1999a).  Looking at the specific cause 
of death, hypoglycaemia was specifically attributed as the cause of death in 
18% of men and 6% of women (Laing et al., 1999b).  A study in Yorkshire of 
people with T1DM diagnosed under the age of 30 reported that 7% of deaths 
were attributed to hypoglycaemia (Feltbower et al., 2008).  Unexpected deaths 
are recognised to occur during sleep in a small number of young adults with 
T1DM, hypoglycaemia was suspected in many of the cases (Tattersall and Gill, 
1991, Weston and Gill, 1999).  A recent case report revealed prolonged 
hypoglycaemia recorded using a CGM device prior to death (Waheed et al., 
2013).  
While the majority of hypoglycaemia episodes do not result in significant 
morbidity beyond the acute event the morbidity associated with hypoglycaemia 
episodes can be substantial and is further detailed in Table 2.3. 
Table 2.3: Morbidity associated with severe hypoglycaemia (McAulay et al., 
2001, Cryer, 2011) 
Cardiovascular 
(Chelliah, 2000, 
Koivikko et al., 2008) 
Neuropsychological (Carter 
and Taylor, 2002)  
Miscellaneous 
Prolongation of QT 
interval 
Atrial fibrillation 
Non-sustained 
ventricular tachycardia 
Silent myocardial 
ischaemia 
Focal/generalised 
convulsion 
Coma 
Hemiparesis; TIAs 
Ataxia, choreoathetosis 
Focal neurological deficits 
Fracture of long 
bones/vertebrae 
Joint dislocation 
Soft tissue injury 
Head injury 
Burns 
Chapter 2 
 99 
Angina 
Myocardial infarction 
Sudden death 
Decortication 
Cognitive impairment 
Behavioural/personality 
change 
Automatism/aggressive 
behaviour 
Psychosis 
Hypothermia 
Hypothermia 
Road traffic accidents 
 
2.41 Morbidity and mortality of hypoglycaemia in children 
A British study found an excess mortality in children with T1DM, 83 out of 
116 deaths were caused by diabetes with DKA being responsible for 69 and 
hypoglycaemia in 7 (Edge et al., 1999).  Nine were found dead in bed with no 
cause proven.  A Norwegian study looking at mortality in childhood onset 
T1DM found hypoglycaemia was responsible for 5% of deaths in early 
adulthood compared with 3-4% in a similar Japanese cohort (Skrivarhaug et 
al., 2006, Morimoto et al., 2013).  The Swedish Childhood Diabetes Register 
showed a significant excess mortality in children with T1DM (Dahlquist and 
Kallen, 2005). Some deaths were clearly related to diabetes with 20 having 
died of diabetic ketoacidosis and at least one from hypoglycaemia following 
alcohol intoxication.  Seventeen were found deceased in bed with no cause of 
death found at autopsy compared with 2 of the control subjects; hypoglycaemia 
was considered but not proven. 
In adults with T1DM nocturnal hypoglycaemia has been shown to increase 
arousal and disturb sleep; somnambulism (sleep walking) triggered by 
nocturnal hypoglycaemia has been reported (Bell, 2010, Bendtson et al., 1992).  
It is concerning that fairly profound (mean glucose nadir 2.0 mmol/L) and 
prolonged (mean 308 minutes) nocturnal hypoglycaemia did not affect sleep 
quality in children with T1DM (Matyka et al., 2000).  Porter et al (1996) 
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reported similar findings, in both studies sleep quality was assessed using 
polysomonography (Porter et al., 1996). 
2.42 Neurological sequelae of hypoglycaemia 
See table 2.3 for possible neurological consequences of acute hypoglycaemia.  
The earliest report of hypoglycaemia resulting in transient hemiparesis was 
published in 1928 (Ravid, 1928).  Acute hypoglycaemia has been shown to 
affect the EEG with a decrease in alpha activity and an increase in delta and 
theta activities.  All changes were reversible on correction of the 
hypoglycaemia (Hyllienmark and Brismar, 2012). 
The vulnerability of different structures within the brain to hypoglycaemia 
appears to vary; the cerebellum is relatively spared.  The hippocampus is 
thought to be more vulnerable and is enlarged in younger adults with a history 
of severe hypoglycaemia compared with sibling controls (Hershey et al., 2010).  
Rat studies have shown that the presence of (untreated) diabetes increases the 
vulnerability of the brain to hypoglycaemia related neuronal injury, particularly 
in the hippocampus (Bree et al., 2009).   
A number of papers have reported a variety of imaging characteristics seen on 
MRI after severe hypoglycaemia resulting in altered consciousness level.  The 
lesions described have varied considerably.  The outcome of such patients is 
often poor with a high mortality rate (Witsch et al., 2012).  An MRI study of 
term infants after neonatal hypoglycaemia found a varied pattern of injury with 
white matter injury not confined to the posterior regions.  Early MRI finding 
were more useful than duration or severity of hypoglycaemia in predicting 
outcomes (Burns et al., 2008).  In neonates with brain damage following severe 
hypoglycaemia, the occipital and parietal lobes were most severely affected 
(Yalnizoglu et al., 2007).  In young children, the age at which hypoglycaemic 
brain injury is sustained affects the pattern of injury seen; from birth to 6 
month, lesions predominantly involved the posterior white matter; between 6-
22 months the basal ganglia, and after 22 months the parietal-temporal cortex 
(Gataullina et al., 2013).   
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Using MRI to look at the structure, rather than function of the brain, has shown 
some differences in those exposed to hypoglycaemia.  In children and 
adolescents with T1DM and a history of hypoglycaemia there was a reduction 
in grey matter volume in the left superior temporal region (Perantie et al., 
2007).  This region has been associated with memory. In adults with T1DM 
cortical atrophy was more common in those with a history of severe 
hypoglycaemia (Perros et al., 1997).  Human subjects with T1DM will also 
have had significant exposure to hyperglycaemia, which may be a confounding 
factor.   
2.43 Type 1 diabetes and cardiovascular mortality 
Microvascular disease was traditionally considered to be a risk of people with 
T1DM while those with T2DM were thought to be at risk of developing 
premature macrovascular disease (Retnakaran and Zinman, 2008).  However, 
although people with T2DM undoubtedly have an increased risk of developing 
premature cardiovascular disease, people with T1DM have a similar level of 
risk for cardiovascular disease when matched for age (Libby et al., 2005, 
Juutilainen et al., 2008).   
Many studies examining the impact of diabetes on cardiovascular outcomes 
either refer to people with T2DM or fail to differentiate between different types 
of diabetes.  The landmark study for people with T1DM was the Diabetes 
Control and Complications Trial (DCCT).  Following 6.5 years of active 
treatment the intensive arm achieved a mean HBA1c of 7.4% compared with 
9.1% in the control group at the cost of a three-fold elevated risk of severe 
hypoglycaemia (DCCT Research Group, 1993).  While the risk of 
microvascular disease was substantially reduced with intensive control, a 
follow-up study showed the effect on macrovascular disease was more modest 
but remained significant (Nathan et al., 2005).  From the age of 30, 
cardiovascular disease is the most common cause of death in both men and 
women with T1DM (Laing et al., 1999b).  The risk of cardiovascular disease is 
substantially elevated in T1DM compared with matched controls, with hazard 
ratios of 3.6 in men and 7.7 in women (Soedamah-Muthu et al., 2006b).   
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In a large prospective study of people with T1DM, after mean 7.3 years of 
follow up, self-reported severe hypoglycaemia did not increase the risk of 
cardiovascular disease (Gruden et al., 2012).  An observational study of people 
with T1DM showed no evidence of a “J” shaped curve; there was no increase 
in vascular events with lower levels of HbA1c (Eeg-Olofsson et al., 2010).   
A direct relationship between hypoglycaemia and cardiovascular events 
remains difficult to demonstrate as blood glucose and cardiac monitoring are 
seldom performed simultaneously.  Speculation continues as to whether 
hypoglycaemia is a causative event or whether it is simply a marker of illness. 
2.5 Chapter summary 
The human body has a number of finely balanced mechanisms aimed at 
maintaining blood glucose concentration within narrow limits.  Acute 
hypoglycaemia provokes pronounced physiological responses, the important 
consequences of which are to maintain the supply of glucose to the brain.  A 
multi-layered defence system protects the normal human and their brains from 
hypoglycaemia; many of these defences are compromised in people with 
T1DM.  
Evidence is accumulating that severe hypoglycaemia can provoke adverse 
cardiovascular outcomes such as myocardial ischaemia or cardiac arrhythmia. 
Clinicians should avoid the exposure of seriously ill patients to low blood 
glucose levels, particularly in those at high risk such as middle-aged people 
who have multiple cardiovascular risk factors, and in frail elderly people.  With 
the improved survival of people with T1DM (as well as the increasing number 
of people with T2DM), this becomes increasingly relevant.  In younger people 
the advent of continuous blood glucose monitoring has allowed more accurate 
documentation of the incidence of hypoglycaemia, particularly at night.  This 
may permit more rational adjustment of insulin regimens to avoid 
hypoglycaemia and reduce the potential risk of inducing a cardiac arrhythmia. 
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Chapter 3: Hypoglycaemia: Effect on cognitive function 
3.1 Introduction 
The profound effects of hypoglycaemia on cognitive function were recognised 
and described soon after the discovery of insulin (Banting et al., 1923).  
Cognitive function involves all aspects of thinking and intellectual activity.  
The effect of diabetes per se on cognitive function has been recently reviewed 
and is outwith the scope of this chapter (Kodl and Seaquist, 2008, McCrimmon 
et al., 2012). 
3.2 Cognitive function testing during hypoglycaemia and its limitations 
In early experiments hypoglycaemia was induced with intravenous boluses of 
insulin which led to a rapid fall and then rise in blood glucose levels (Russell 
and Rix-Trott, 1975).  Blood glucose levels were not adequately controlled and 
so the hypoglycaemic stimuli varied, the glucose clamp technique solved this 
problem (DeFronzo et al., 1979).  Numerous studies have subsequently used 
this technique to examine the effect of hypoglycaemia on cognitive 
functioning.  The stepped clamp does allow multiple blood glucose 
concentrations to be assessed in a single experimental session but is relatively 
arduous for the test subject and there is some evidence that during prolonged 
hypoglycaemia, there may be a degree of acute adaptation (Heller and 
Macdonald, 1996).   
Where most studies now use single-blind, euglycaemia-controlled 
hyperinsulinaemic clamps a number of issues remain (Inkster and Frier, 2012, 
Warren and Frier, 2005): 
• Lack of consensus over appropriate cognitive tests for measurement of 
cognitive function (partly as there is no clear consensus on the 
cognitive processes involved with each)  
• Absence of power calculations (inadequate statistical power might 
result in false negative or type II errors) 
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• Heterogeneity of study cohorts 
• Variable target blood glucose levels (most have a target blood glucose 
during hypoglycaemia of 2.0-3.0 mmol/L) 
• Many glucose analysers utilise the glucose oxidase method; analysis of 
plasma produces a glucose value 10-20% higher than that measured in 
whole blood (Foster et al., 1978).   
• It is often difficult to extrapolate experimental conditions to real life 
scenarios where speed of onset, duration and severity of hypoglycaemia 
may vary 
3.21 Effect of insulin and counter-regulatory hormones 
Insulin is known to cross the blood-brain barrier and enhance cognitive 
function (Park et al., 2000).  However, insulin per se did not affect cognitive 
function during hypoglycaemia during a study of healthy volunteers infused 
with high levels of insulin (2.0 mUnits/kg/hr) compared with low levels of 
insulin (0.35 mUnits/kg/hr) (Fanelli et al., 1994).  This is a point of reassurance 
when testing cognitive function using hyperinsulinaemic hypoglycaemic 
clamps.  
While the blood glucose level may be “clamped”, the counter-regulatory 
responses alter over time with increased levels of counter-regulatory hormones 
but diminished symptom intensity (Kerr et al., 1991).  Counter-regulatory 
hormones such as adrenaline can also act as cognitive enhancers themselves 
(McNay and Cotero, 2010).   Cognitive performance during hypoglycaemia 
was compared against euglycaemia with an infusion of counter-regulatory 
hormones released during hypoglycaemia.  The deterioration in cognitive 
function is a result of hypoglycaemia itself and not increased levels of counter-
regulatory hormones (Kerr et al., 1993).   
3.22 Intra- and inter-individual variation 
There is considerable inter-individual variation in cognitive functioning during 
hypoglycaemia although intra-individual variation is less marked.  Substantial 
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inter-individual variation has been reported in many studies; this demonstrates 
the importance of comparing a participant’s performance during 
hypoglycaemia with their own during euglycaemia (Heller and Macdonald, 
1996, Gold et al., 1995a).  Some commonly used cognitive function tests (e.g. 
paced auditory serial addition task) have high retest reliability with r values 
ranging between 0.69 and 0.95 (Schachinger et al., 2003).  Repeated attempts 
at cognitive function tests are likely to improve performance through 
familiarity until boredom or frustrations occurs (Amiel, 1998, Gonder-
Frederick et al., 1994).  Whilst batteries of cognitive function tests allow 
testing of a bigger variety of cognitive functions, fatigue may result in a 
reduction in performance.   
3.23 Ceiling effect 
Care must be taken to avoid ceiling effects where the performance of the 
subjects is at or almost at the maximum achievable level.  There may be an 
element of “cognitive reserve” which then means that any decremental 
condition (i.e. hypoglycaemia) does not have an appreciable effect on 
performance.  Acute hypoglycaemia failed to induce the expected impairment 
of performance when completing Raven’s progressive matrices (RPM) 
(McAulay et al., 2001, Raven, 1958).  This is surprising as RPM is thought to 
be one of the best indicators of general fluid intelligence, which has a 
substantial association with working memory that is known to be extremely 
sensitive to hypoglycaemia (Marshalek et al., 1983, Ackerman et al., 2002, 
Deary et al., 2003).  The uniformly high test scores for the RPM indicated that 
subjects were achieving close to maximum marks in both hypo- and 
euglycaemia.  By using two more difficult tests (i.e. Raven’s advanced 
progressive matrices and the Alice Heim 5 test), a significant decrement in 
performance was then noted during hypoglycaemia (Warren et al., 2004).  A 
further ceiling effect was demonstrated during a study of visual memory during 
acute hypoglycaemia (Warren et al., 2007). 
3.24 Determining which particular cognitive process is being examined 
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Many cognitive function tests only record the time taken and correct selection 
of the target object, number or letter.  Many of these tests encompass a number 
of cognitive processes.  Figure 3.1 shows the cognitive processes involved in 
the letter selection test; the time taken to complete each step was measured 
using scalp electrodes to detect event-related brain potentials.  A sequence of 
coloured letters was presented, red letter G requires the right hand button and 
red letter N requires left hand button with all other red letters and any green 
letter being ignored.  The event-related brain-potential (ERP) response to 
stimuli starts to differ from the ERP response to irrelevant stimuli (i.e. any 
green letter) between 120-300ms after stimulus presentation (e.g. selection 
negativity or SN).  Response selection is measured by examining the 
contralateral motor cortex and subtracting any responses seen in the ipsilateral 
motor cortex to isolate potentials that are strictly movement related.  The 
resulting potential is referred to as the lateralised readiness potential (LRP) and 
its onset latency can be assumed to reflect the time at which a unilateral motor 
response is selected.  Hypoglycaemia increased both SN and LRP with LRP 
being affected to a greater extent.  During the recovery period LRP continued 
to be affected whereas SN returned to its baseline euglycaemia level (Smid et 
al., 1997). 
 
Figure 3.1: Cognitive processes involved in a letter selection test 
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A more recent attempt was made to separate a reaction time test into the 
multiple cognitive and non-cognitive processes.  The results were separated 
into three components, the quality of information on which a decision is made 
(drift rate), the critical amount of evidence that needs to be accumulated before 
a decision is made (boundary separation) and the time taken by non-cognitive 
processes.  Hypoglycaemia reduced the drift rate but had no effect on the other 
two processes.  This would indicate that hypoglycaemia affects central 
processing rather than the quantity of information required to make a decision 
or peripheral and motor processes (Geddes et al., 2010). 
3.3 Onset and recovery of cognitive impairment 
In adults without diabetes the threshold for the onset of cognitive impairment 
lies between 2.7-3.1mmol/L although occasionally reported at higher blood 
glucose levels (Warren and Frier, 2005).  In adults without diabetes there are 
separate thresholds for symptoms, hormonal counter-regulation and cognitive 
dysfunction.  This is clinically important as it allows individuals to take note of 
warning symptoms and implement remedial action (e.g. carbohydrate 
ingestion), prior to the onset of cognitive dysfunction.  In healthy volunteers, 
the onset of hypoglycaemia was followed by immediate cognitive dysfunction 
although counter-regulatory and symptomatic responses were delayed by 20 
minutes; this lag between cognitive dysfunction and symptomatic response is 
of potential clinical importance (Evans et al., 2000). 
Recovery of cognitive function has been shown to lag behind the restoration of 
euglycaemia despite normalisation of the symptom profile and counter-
regulatory response.  During the recovery phase, Evans et al (2000) only 
measured cognitive function once, twenty minutes after the restoration of 
euglycaemia, four choice reaction time remained impaired whereas 
performance on the Stroop test had returned to baseline (Evans et al., 2000).  A 
stepped hypoglycaemic clamp resulted in a fairly prolonged period of 
hypoglycaemia (i.e. at least 1 hour 45 minutes); once euglycaemia had been 
restored reaction time remained impaired for 45-75 minutes (Blackman et al., 
1992).  A shorter duration of hypoglycaemia (60 minutes) resulted in more 
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rapid recovery of reaction time; complete recovery had occurred 40 minutes 
after the restoration of euglycaemia (Lindgren et al., 1996).   
Following 60 minutes of hypoglycaemia (2.5 mmol/L) recovery of cognitive 
function in subjects with T1DM and normal awareness was examined.  When 
analysed as a group, recovery times varied according to the cognitive task 
being performed; the trail making B task was impaired for up to 10 minutes 
after the restoration of euglycaemia whereas the four choice reaction time was 
impaired for up to 40 minutes.  Impairment persisted for up to 75 minutes in 
participants with normal awareness (Zammitt et al., 2008).  Recovery was 
faster in people with T1DM than control subjects although the precise time 
periods are not stated (Lobmann et al., 2000). 
Strachan et al (2000) examined recovery of cognitive function at 1.5, 9 and 30 
days post severe hypoglycaemia that occurred in the community (i.e. not 
induced in an experimental setting), mostly in subjects with T1DM.  A control 
group with T1DM was also examined with no history of severe hypoglycaemia 
in the preceding year.  Although mood alteration persisted for longer, there was 
little evidence of a “hangover” effect of the severe hypoglycaemic episode on 
cognitive function by 1.5 days after the event with only 1 out of 14 cognitive 
tasks (i.e. block design) still affected (Strachan et al., 2000).  Experimentally 
induced nocturnal hypoglycaemia (2.3-2.7 mmol/L for 1 hour) did not affect 
cognitive function during euglycaemia the next day (King et al., 1998). 
3.4 How rate of descent and duration of hypoglycaemia affects 
cognitive function 
The rate of descent into hypoglycaemia may be important.  A rapid descent 
into hypoglycaemia in subjects with T1DM resulted in greater cognitive 
impairment than a slow descent (i.e. 30 minutes from 5.7 to 2.4 compared with 
90 minutes), although counter-regulatory hormone release was reduced with 
the rapid descent (Fanelli et al., 2003).  Unlike previous studies, subjects were 
studied in the post-prandial condition. 
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The degree of cognitive impairment may be influenced by the duration of 
hypoglycaemia.  During 120 minutes of hypoglycaemia, cognitive function 
started to improve towards the end.  The euglycaemia arm also saw an 
improvement over time, although it is unclear whether this met statistical 
significance, and so a practice effect may have contributed to this improvement 
(Kerr et al., 1989).   Gold et al (1995b) performed cognitive testing on the 
same subjects on 3 occasions, in a random order, at least 2 weeks apart.  The 
participants underwent a euglycaemic clamp as a control session, a 
hypoglycaemic clamp with the cognitive test done immediately after the 
induction of hypoglycaemia and a further hypoglycaemic clamp with a delay in 
cognitive testing until 40 minutes after the induction of hypoglycaemia. 
Although hypoglycaemia predictably impaired cognitive function there was no 
evidence of short term cerebral adaptation (Gold et al., 1995b). 
3.5 Sensitivity of different cognitive processes to hypoglycaemia 
Simple cognitive tasks such as finger tapping or reaction time are not 
significantly affected by hypoglycaemia (Warren and Frier, 2005, Pramming et 
al., 1986).  With many cognitive functions, accuracy is often preserved at the 
expense of speed.  Some evidence of a differential sensitivity does exist with 
working memory being completely abolished during hypoglycaemia with only 
deterioration in short- and long-term memory (Deary et al., 2003). 
3.51 Attention 
Attention can be grouped into 3 major themes: alertness or vigilance 
(maintenance of attention performing long, boring tasks), selective attention 
(ability to preferentially select information from a particular source) and 
orientation which is responsible for engaging, moving and disengaging 
attention in space (Posner and Petersen, 1990).  Using tests of everyday 
attention both visual and auditory selective attention were significantly 
impaired during acute hypoglycaemia in people with and without T1DM 
(McAulay et al., 2001, McAulay et al., 2006a). 
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3.52 Memory 
Memory is the process of storing, encoding and retrieving information and can 
be sub-classified into short-term, long-term, working and sensory memory 
(Baddeley, 1997).  Working memory is often confused with short term 
memory; short term memory requires the maintenance of information in the 
memory over a short period of time (e.g. keeping a telephone number in mind 
while finding the telephone) whereas working memory requires active 
manipulation of processing of information (e.g. calculating and adding a tip to 
a restaurant bill) (Drag and Bieliauskas, 2010).   
Hypoglycaemia substantially disrupts memory formation and recall (Deary and 
Zammitt, 2014).  Immediate (verbal & visual), working memory and delayed 
(verbal & visual) memory were all affected by acute hypoglycaemia in both 
subjects with and without T1DM; working and delayed memory were most 
susceptible to the effects of neuroglycopenia (Sommerfield et al., 2003a, 
Sommerfield et al., 2003b).  Participants were asked to remember visual (e.g. 
line drawing) or verbal (e.g. list of words read aloud) lists both straight after 
(immediate) and after 1 hour has elapsed (delayed).  
Warren et al (2007) separated the acquisition and recall phases of memory 
tasks so that only one occurred during hypoglycaemia.  Both prospective 
memory tasks (where the learning takes places during euglycaemia with the 
recall during hypoglycaemia) and the delayed verbal memory (where the 
learning takes place during hypoglycaemia and the recall during euglycaemia) 
were significantly impaired (Warren et al., 2007).  A further study in healthy 
volunteers assessed whether a period of hypoglycaemia (~60 minutes) between 
the learning and the recall or recognition phase can affect performance of 
various memory tasks.  There was no difference in memory consolidation 
whether subjects were rendered hypoglycaemic or continued under “clamped” 
euglycaemia (Warren et al., 2008).  The authors discuss a number of possible 
explanations, the sample size (n=16) may have been too small according to 
retrospective power calculations, the degree of hypoglycaemia may not have 
been low enough and the period of hypoglycaemia may have occurred too late 
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(i.e. after consolidation had taken place).  In summary hypoglycaemia affects 
both the acquisition and recall phases of memory tasks.   
Functional MRI has been used to demonstrate that regional brain activation is 
different during working memory tasks in people with T1DM compared to 
those with no diabetes despite there being no difference in cognitive 
performance.  Several brain regions were activated to a greater degree in 
T1DM suggesting that recruiting supplementary brain regions may be 
necessary to preserve cognitive performance in T1DM (Bolo et al., 2011).  
3.53 Mood, emotion and motivation 
Mood can be assessed in terms of tense arousal (feeling anxious or nervous 
rather than relaxed or calm) and energetic arousal (feeling lively and active 
rather than tired and sluggish).  Hedonic tone (happiness versus sadness) can 
also be assessed.  The relationship between hypoglycaemia and mood is 
complex. Most people report negative symptoms in association with 
hypoglycaemia such as an increase in “tense tiredness” with a decrease in 
happiness (Gold et al., 1997, Hermanns et al., 2003, Cox et al., 2002a).   
Hypoglycaemia resulted in a negative mood state with reduced energy levels 
and increased anxiety levels (McAulay et al., 2006b).  A specific problem (e.g. 
career prospects) may be viewed significantly more negatively during 
hypoglycaemia (McCrimmon et al., 1999).   
To examine the effect of hypoglycaemia on motivation and cognitive 
interference, the Dundee Stress State Questionnaire was completed before and 
after tests of cognitive function during acute hypoglycaemia on participants 
with T1DM (McAulay et al., 2006b).  Hypoglycaemia decreased task relevant 
and increased task irrelevant interference (i.e. during hypoglycaemia subjects 
were more distracted by matters not relevant to the task in hand).  Self-focus of 
attention was higher during hypoglycaemia; this refers to a state of pre-
occupation and reflection.  
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Nocturnal hypoglycaemia results in increased fatigue and a reduced sense of 
well being the following day (King et al., 1998).  A recent history of 
spontaneous, severe hypoglycaemia (up to 30 days ago) resulted in elevated 
levels of anxiety and depression (Strachan et al., 2000). 
3.54  Visual or auditory function 
Blurring of vision and diplopia are recognised clinical features of acute 
hypoglycaemia (Deary and Zammitt, 2014).  Visual information processing 
tasks and contrast sensitivity were disrupted during acute hypoglycaemia in 
both subjects with and without T1DM (McCrimmon et al., 1996, Ewing et al., 
1998).  In contrast visual acuity or stereoscopic vision was unaffected.  Visual 
evoked potentials are detected by an electrophysiological recording method 
involving the placement of scalp electrodes.  Electrophysiological studies have 
demonstrated the prolongation of visual evoked potentials (P100 and P300 
latencies) during acute hypoglycaemia (Harrad et al., 1985, Blackman et al., 
1990, Blackman et al., 1992).   
Acute hypoglycaemia resulted in a significant deterioration in auditory 
temporal processing and one of three tasks of simple auditory processing (i.e. 
discrimination of single tone loudness) in participants with and without 
diabetes.  Most auditory event-related potentials (AERPs) (N100, P200 and 
P300) were not affected by hypoglycaemia although N240 was reduced in 
amplitude during hypoglycaemia.  In these experiments, two tones of different 
frequencies are delivered through earphones; participants are asked to ignore 
one and to count the other.  The AERP waveforms from the target stimuli were 
recorded (McCrimmon et al., 1997, Strachan et al., 2003).  
3.55 Other cognitive processes 
Geddes et al (2008) examined the effects of acute hypoglycaemia on 
psychomotor function.  People with T1DM were less affected than those 
without; psychomotor function was significantly impaired in 2 out 7 tests in 
people with T1DM compared with 5 out of 7 for healthy volunteers (Geddes et 
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al., 2008).  The reduction in counter-regulatory hormonal response seen in 
those with T1DM may have been beneficial in reducing tremor and improving 
the fine motor control necessary for many of the tests.  An earlier study using a 
less comprehensive test battery had suggested a similar impairment of 
psychomotor function (Schachinger et al., 2003).   
Spatial ability is also affected during acute hypoglycaemia with 5 out of 6 tests 
being significantly affected (Wright et al., 2009).  Peripheral nerve function 
(i.e. conduction velocities and amplitudes of motor action potentials) remains 
intact during hypoglycaemia (Strachan et al., 2001). 
3.6 Cognitive function testing during hypoglycaemia in children 
Neuropsychological testing is possible in the vast majority of children, even 
those who are relatively young. Neuropsychological testing was successfully 
completed in 98% of participants with T1DM aged between 3-10 (Aye et al., 
2011).  Relatively mild acute hypoglycaemia (3.1-3.6 mmol/L) impairs 
cognitive function in children using a range of cognitive tests; the trail making 
test was most affected suggesting that tests requiring planning and decision-
making would be particularly impaired.  Recovery of cognitive function was 
delayed following the restoration of euglycaemia (Ryan et al., 1990).   
“Naturally occurring” acute hypoglycaemic episodes (i.e. those occurring in 
real life rather than an experimental setting) have been shown to impair a 
child’s cognitive ability when asked to complete two brief cognitive function 
tests (mental arithmetic and choice reaction time) during hypoglycaemia 
(Gonder-Frederick et al., 2009). 
3.7 Factors which may moderate cognitive effects 
3.71 Gender and premorbid intelligence 
Many studies have not reported on a differential effect of gender on cognitive 
function during hypoglycaemia (Kodl and Seaquist, 2008).  Using a stepped 
clamp (8.9mmol/L, 5.6 mmol/L and 2.2mmolL), men were more affected than 
women during the digit vigilance test, trail making test, word recall and verbal 
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fluency; these differences persisted after adjustment for confounding factors 
(Draelos et al., 1995).   A greater deterioration in cognitive function during 
acute hypoglycaemia was shown in men compared to women (Gonder-
Frederick et al., 1994).  
It has been postulated that a higher IQ might have a protective effect on 
cognitive functioning during hypoglycaemia because of the concept of 
“cognitive reserve”.  In participants without diabetes there was no difference in 
overall cognitive functioning during hypoglycaemia in those with high and 
average IQ scores; indeed one measure of cognitive function showed less of a 
deterioration in those with average intelligence (Gold et al., 1995a).   
3.72  T1DM 
The effect of having T1DM on cognitive function during hypoglycaemia is of 
clinical importance because of the expectation of experiencing repeated 
episodes of hypoglycaemia as part of everyday life.  Some studies have shown 
a greater decrement in cognitive performance during hypoglycaemia (2.0 
mmol/L) in adults with T1DM compared to controls with similar performance 
during euglycaemia (Wirsen et al., 1992).  Many other studies have failed to 
show a difference between those with and without diabetes in general cognitive 
function during hypoglycaemia (Herold et al., 1985, Widom and Simonson, 
1990, Ferguson et al., 2003).  Studies examining specific cognitive processes 
have also shown no difference between those with and without T1DM.  
Functional MRI showed no difference in regional brain changes during 
hypoglycaemia during passive auditory and visual stimuli in subjects with 
T1DM compared with matched controls (Driesen et al., 2007).  As noted 
earlier, psychomotor function is less affected by hypoglycaemia in participants 
with T1DM, perhaps as a result of reduced counter-regulatory hormone release 
with a reduction in tremor and sweating (Geddes et al., 2008).  
No difference in cognitive performance during hypoglycaemia was observed in 
people with T1DM who had proliferative diabetic retinopathy (as a marker of 
microvascular disease) compared to those without (Wessels et al., 2006).  
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3.73 Glycaemic control and nocturnal hypoglycaemia 
Glycaemic control certainly affects the blood glucose level below which 
counter-regulatory hormones are released.  However there was no difference in 
cognitive function test scores with varying degrees of glycaemic control 
(Widom and Simonson, 1990, Maran et al., 1995).   
A UK based research group failed to show an effect of nocturnal 
hypoglycaemia on cognitive function the following day compared with 
nocturnal euglycaemia in people with T1DM (King et al., 1998).  Nocturnal 
hypoglycaemia following an episode of learning was found to reduce recall the 
following morning (in a euglycaemic state) in people with and without T1DM.  
None of the other cognitive tests revealed any effect of antecedent nocturnal 
hypoglycaemia although mood was significantly lower (Jauch-Chara et al., 
2007).  An earlier study that showed that some measures of cognitive function 
during hypoglycaemia showed less deterioration following nocturnal 
hypoglycaemia than following nocturnal euglycaemia in people with T1DM.  
This suggests an improvement in cognitive function during hypoglycaemia 
with antecedent hypoglycaemia; this could be considered as cognitive 
“preconditioning” (Fanelli et al., 1998b).  Antecedent nocturnal hypoglycaemia 
may benefit selected cognitive functions during subsequent daytime 
hypoglycaemia, episodes of nocturnal hypoglycaemia prior to performance of 
the cognitive tasks appear to have little effect on cognitive function and 
episodes of nocturnal hypoglycaemia in between the learning and recall phase 
of the cognitive tasks may have a detrimental impact.   
3.74 Impaired awareness of hypoglycaemia (IAH) 
People with IAH experience less of a decrement in cognitive function with 
moderate hypoglycaemia (2.5mmol/L) and faster recovery (Zammitt et al., 
2008).  In contrast, an earlier study had shown that subjects with IAH 
experienced a greater decrement in cognitive function during hypoglycaemia 
with a slower recovery (Gold et al., 1995c).  Another study showed no 
differences between those with IAH and normal awareness during various 
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memory tests (Warren et al., 2007).  Methodological differences between the 
studies may account for these discrepant results.  No difference in regional 
blood flow was seen in subjects with IAH compared to those with normal 
awareness (MacLeod et al., 1996).  IAH is discussed further in chapter 4. 
3.75 Sleep, alcohol, illness and medications 
Sleep deprivation did not compound the effect of hypoglycaemia on cognitive 
function (reaction time and auditory evoked potentials) (Jauch-Chara et al., 
2010). 
The addition of alcohol induces an additional reduction in cognitive 
performance during hypoglycaemia but its effect is additive rather than 
synergistic; alcohol induces a similar decrement in cognitive function during 
both euglycaemia and hypoglycaemia (Cheyne et al., 2004). 
Critical illness per se has been shown to impair subsequent cognitive function 
with worse performance across a range of cognitive domains.  Experience of 
hypoglycaemia during critical illness compounds this with worsened 
visuospatial skills compared with matched subjects with no experience of 
hypoglycaemia during critical illness (Duning et al., 2010).  
Detemir is an analogue, long acting insulin that is more lipophilic than human 
insulin and thought to cross the blood brain barrier more readily.  In healthy 
volunteers, despite no difference in counter-regulatory responses, the onset of 
cognitive impairment occurred at a higher blood glucose level with detemir 
compared with human insulin (Rossetti et al., 2008).  The cognitive 
dysfunction was more marked with detemir in some cognitive domains.  It 
could be speculated that the greater cerebral insulin levels may result in a 
greater degree of neuroglycopenia. 
Erythropoietin (or “epo”) is known for its induction of erythropoiesis but it has 
also been shown to increase modestly during hypoglycaemia and may have a 
neuroprotective effect.  Low baseline levels of erythropoietin are associated 
with poorer cognitive function during hypoglycaemia and exogenous 
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administration of erythropoietin has been shown to improve performance in 
choice reaction task but not other commonly used tests of higher cerebral 
function (i.e. trail making test or Stroop test) (Kristensen et al., 2009, 
Kristensen et al., 2013). 
3.76 Driving 
Experimental laboratory studies have demonstrated that cognitive functions 
critical to driving (such as attention, reaction times and hand-eye coordination) 
are impaired during hypoglycaemia (Warren and Frier, 2005, Inkster and Frier, 
2012).  The changes in visual information processing that occur during 
hypoglycaemia could affect visual perception under conditions of limited 
perceptual time and low visual contrast (poor light); this would also have a 
significant effect on driving performance (McCrimmon et al., 1996).  Studies 
using a sophisticated driving simulator have shown that driving performance is 
affected adversely by moderate hypoglycaemia, causing problems such as 
inappropriate speeding or braking, ignoring road signs and traffic lights and not 
keeping to lanes (Cox et al., 1993, Cox et al., 2000).  During simulation 
studies, driving per se required higher dextrose infusion rates to maintain 
normoglycaemia compared to passively watching a driving video; this 
increased metabolic demand in drivers will risk promoting hypoglycaemia, 
particularly if their blood glucose is <5.0 mmol/L (Cox et al., 2002b).  Driving 
and diabetes is discussed further in chapter 8. 
 
3.8 Adaptation to hypoglycaemia 
The effect of antecedent hypoglycaemia on cognitive performance during 
subsequent hypoglycaemia has been the subject of a number of studies (see 
Table 3.1).  The methodology of Boyle et al (1994) differs significantly from 
the other studies listed; 2 stepped hypoglycaemic clamps were performed 
reaching a nadir of 2.5 mmol/L separated by 56 hours of hypoglycaemia (2.9 
mmol/L.  Veneman et al (1993) found that antecedent hypoglycaemia results in 
improved cognitive function; in contrast Hvidberg et al (1996) found 
antecedent hypoglycaemia did not affect cognitive function during 
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hypoglycaemia (both tested participants without diabetes) (Veneman et al., 
1993, Hvidberg et al., 1996).   Other studies have reported that cognitive 
functioning deteriorates less during subsequent hypoglycaemia when preceded 
by hypoglycaemia (Veneman et al., 1993, Mellman et al., 1994, Fruehwald-
Schultes et al., 2000), whereas other have reported no effect (Lingenfelser et 
al., 1993, Robinson et al., 1995, Hvidberg et al., 1996).  Two of these studies 
subjected their control groups to antecedent hypoglycaemia as well as the 
intervention group and so their results may be confounded (Lingenfelser et al., 
1993, Robinson et al., 1995).  
Table 3.1: Effect of antecedent hypoglycaemia on cognitive function during 
subsequent hypoglycaemia 
Lead author & 
year 
Subjects studied Notes Effect 
(Boyle et al., 
1994) 
Healthy 
volunteers 
Stepped 
hypoglycaemic 
clamp 
Blood glucose 
threshold for 
cognitive 
impairment was 
lower with 
antecedent 
hypoglycaemia 
(Fanelli et al., 
1998a) 
T1DM Nocturnal 
antecedent 
hypoglycaemia 
Selective 
beneficial effect 
(Fruehwald-
Schultes et al., 
2000) 
Healthy 
volunteers 
Antecedent 
hypoglycaemia 
on day before 
Selective 
beneficial effect 
(Hvidberg et al., 
1996) 
Healthy 
volunteers 
Antecedent 
hypoglycaemia 
No effect 
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day before 
(Lingenfelser et 
al., 1993) 
T1DM Three short term 
episodes of 
antecedent 
hypoglycaemia 
Selective adverse 
effect 
(Mellman et al., 
1994) 
Healthy 
volunteers 
2 hours of 
antecedent 
hypoglycaemia 
immediately prior 
Selective 
beneficial effect 
(Robinson et al., 
1995) 
Healthy 
volunteers 
Antecedent 
hypoglycaemia 6 
days prior 
No effect 
(Schultes et al., 
2005) 
Healthy 
volunteers 
Two 
hypoglycaemic 
clamps on 1st day, 
further clamp on 
next day (no 
euglycaemic 
clamp) 
Some cognitive 
functions show 
adaptation to 
recurrent 
hypoglycaemia 
(although no 
control for 
practise effect) 
(Veneman et al., 
1993) 
Healthy 
volunteers 
Nocturnal 
antecedent 
hypoglycaemia 
Beneficial effect 
 
3.9 Preservation of cognitive function during hypoglycaemia 
Rosenthal et al (2001) attempted to map out brain activation during cognitive 
function testing.  During simpler tasks (e.g. finger tapping) blood oxygen level-
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dependent (BOLD) functional MRI imaging showed decreased BOLD signal in 
motor related brain areas and increased BOLD signal in left cerebellum and 
right frontal areas.  The more complex four choice reaction time test elicited 
decreased BOLD activation in the motor and visual symptoms with an 
increased BOLD signal in the parietal area.  The increased signals in parietal 
areas may be compatible with additional recruitment of brain areas involved in 
planning to limit cognitive dysfunction (Rosenthal et al., 2001).  Anderson et al 
(2006) used the same imaging technique but employed passive visual 
stimulation (e.g. alternating patterns).  During hypoglycaemia reduced BOLD 
signal was observed, particularly in the occipital areas (Anderson et al., 2006). 
As discussed in chapter 2, alternative fuels to glucose can be utilised by the 
brain during hypoglycaemia.  Ingestion of medium chain fatty acids has been 
shown to lessen the cognitive decrement induced by hypoglycaemia in 
intensively controlled participants with T1DM (Page et al., 2009). 
3.10 Psychological consequences of hypoglycaemia 
The effect of acute hypoglycaemia on mood and anxiety has been discussed 
earlier (section 3.53).  Fear of hypoglycaemia (FoH) can be assessed using 
various validated questionnaires; one of the most widely used is the 
Hypoglycemic fear survey (HFS) or the updated version, HFS-II (Cox et al., 
1987, Wild et al., 2007).  This has been shown to be a reliable and valid 
measure of FoH in adults with T1DM using both the behaviour and worry 
subsections of the survey (see tables 3.2 and 3.2) (Gonder-Frederick et al., 
2011).   
A more recent questionnaire comprises of 15 statements that are rated using a 
1-5 Likert scale.  Using principal components analysis, the 15 statements can 
be grouped into 3 categories (fear, avoidance and interference) (Anarte Ortiz et 
al., 2011).  Several of the diabetes specific quality of life questionnaires also 
include questions to assess fear of hypoglycaemia (e.g. Problems areas in 
diabetes or PAID) (Watkins and Connell, 2004).   
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Fear of hypoglycaemia (FoH) questionnaires compose two subscales; worry 
and behaviour subscales (Tables 3.2 & 3.3).  The worry subscale measures 
aspects of hypoglycaemia that can induce a fearful state and the behaviour 
subscale indicates behaviours that people may engage in to reduce the risk of 
hypoglycaemia.  The two subscales allow researchers to identify whether 
worry actually translates into a change in behaviour (section 4.81 discusses this 
further).  FoH provokes similar levels of anxiety to that of some of the severe 
long-term complications of diabetes (see Figure 3.2).  Hypoglycaemia and 
particularly severe hypoglycaemia impairs quality of life and provokes anxiety 
in both people with diabetes and their diabetologists (Bohme et al., 2013, 
Hendrieckx et al., 2014).  Fear of hypoglycaemia has been identified as the 
strongest barrier to exercise (Brazeau et al., 2008).   
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Table 3.2: Adult HFS-II Behavioural subscales item examples (Gonder-
Frederick, 2013) 
Behaviour Subscale Items Never Rarely Sometimes Often Almost 
always 
To avoid low blood sugar and how it affects me, I … 
Reduce my insulin when my 
blood sugar is low 
0 1 2 3 4 
Measure my blood sugar six 
or more times a day 
0 1 2 3 4 
Limit my exercise/physical 
activity 
0 1 2 3 4 
Make sure there are other 
people around 
0 1 2 3 4 
Kept my blood sugar higher 
than usual when doing an 
important task 
0 1 2 3 4 
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Table 3.3: Adult HFS-II Worry subscales item examples (Gonder-Frederick, 
2013) 
Worry Subscale Items Never Rarely Sometimes Often Almost 
always 
Because my blood sugar could go low, I worry about … 
Not recognising/realising I 
am having a low blood sugar 
0 1 2 3 4 
Not having food, fruit or 
juice available 
0 1 2 3 4 
Passing out in public 0 1 2 3 4 
Having a hypoglycaemic 
episode while alone 
0 1 2 3 4 
Making a mistake or having 
an accident 
0 1 2 3 4 
 
Following severe hypoglycaemia, 84% of people with T2DM and 64% of 
people with T1DM reported increased FoH (Leiter et al., 2005).  FoH scores 
increased in people with T2DM who experience mild or severe hypoglycaemia 
compared with no experience of hypoglycaemia (Stargardt et al., 2009).  
Despite the lower incidence of hypoglycaemia in T2DM; there is an 
association between hypoglycaemia and depressive symptoms along with 
increased anxiety leading to impairment of activities of daily living such as 
driving and working with lower treatment satisfaction scores (Barendse et al., 
2012, Alvarez Guisasola et al., 2008, Lundkvist et al., 2005). 
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Figure 3.2: Attitudes towards different aspects of diabetes, mean values for 
both sexes (Pramming et al., 1991). 
A large Swedish study  (n=764) of people with T1DM showed that frequency 
of severe hypoglycaemia is the dominant factor that increases FoH, scores 
increased significantly if the participant had experienced one or more episode 
of severe hypoglycaemia in the preceding 12 months.  Other significant factors 
included gender (women reported higher scores than men), hypoglycaemia 
awareness (people with impaired awareness reported higher scores) and visits 
to the Emergency department as a result of hypoglycaemia (scores increased 
after one or more visit in the previous 12 months).  Participants with a higher 
HbA1c reported higher scores using the “aloneness” subsection of the survey 
that examines the fear of being alone.  This may suggest that some people 
deliberately relax their glycaemic control to reduce the risk of hypoglycaemia 
when alone (Anderbro et al., 2010).  A Norwegian study also reported greater 
FoH in women compared to men (Gjerlow et al., 2014).  Despite the impact of 
hypoglycaemia on patient’s reported well-being; fear of hypoglycaemia scores 
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have not been shown to affect clinically relevant outcomes consistently such as 
HbA1c (Gonder-Frederick, 2013, Wild et al., 2007).  
Parents of children with T1DM report a high level of fear of hypoglycaemia 
(Patton et al., 2008).  Parental fear of hypoglycaemia leads to poorer glycaemic 
control in their children with T1DM (Haugstvedt et al., 2010).  Fear of 
hypoglycaemia and not episodes of hypoglycaemia per se is associated with 
worse quality of life for children with T1DM.  Children with a greater fear of 
hypoglycaemia had poorer glycaemic control than those with a lower fear of 
hypoglycaemia (Johnson et al., 2013). 
3.11 Long-term effects of hypoglycaemia on cognitive function 
3.111 Effect of severe hypoglycaemia on cognitive function in adults with 
T1DM 
While earlier case-control studies had reported that repeated severe 
hypoglycaemia may result in cognitive sequelae (Langan et al., 1991, Wredling 
et al., 1990, Lincoln et al., 1996) others did not find any association between 
severe recurrent hypoglycaemia and a decrement in cognitive function (Ryan et 
al., 1993).  A history of recurrent, severe hypoglycaemia in people with T1DM 
for the preceding 3 years resulted in lower cognitive function test scores 
compared with a control group with T1DM but no history of recurrent 
hypoglycaemia (Wredling et al., 1990).  One hundred people with T1DM were 
compared with 100 matched controls; verbal and performance IQ scores were 
modestly reduced in the people with T1DM.  When a history of severe 
hypoglycaemia was taken into account the difference between the groups 
disappeared (Deary et al., 1993). 
Follow up of the DCCT cohort found no association between frequency of 
severe hypoglycaemia and long-term cognitive dysfunction in participants 
allocated to the intensive treatment group despite a threefold risk of severe 
hypoglycaemia; the same result was found when cognitive function was re-
examined a mean of 18 years after recruitment to the DCCT (Austin and 
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Deary, 1999, Jacobson et al., 2007).  Severe hypoglycaemia was also not 
associated with any decline in cognitive function in the youngest DCCT 
participants who were aged between 13 to 19 years at recruitment and therefore 
theoretically the most vulnerable (Musen et al., 2008).  An accompanying 
editorial cautions that the DCCT cohort were healthy individuals who were all 
carefully selected to have a low risk of hypoglycaemia; cognitive decline 
would not have been expected in this cohort, even over the 18 year follow up 
period (Frier, 2011).   
A study of adults with T1DM (n=150) failed to show a relationship between 
hypoglycaemia and cognitive dysfunction (Brismar et al., 2007).  After 10 
years of follow up, a smaller Scandinavian study compared people with T1DM 
who were conventionally treated (n=48) with intensive treatment (n=43).  
Cognitive function was unaffected by intensive treatment despite an increased 
number of severe hypoglycaemic episodes (Reichard et al., 1996).   
3.112 Effect of severe hypoglycaemia on cognitive function in older adults 
with T2DM 
Older age has been suggested as a potential time period during which 
hypoglycaemia, and in particular severe hypoglycaemia, may result in 
cognitive decrement. T2DM itself has also been associated with cognitive 
decline, particularly with regard to verbal memory (Strachan et al., 1997).  This 
cohort of people tend to have multiple factors that may affect cognitive 
function (e.g. cerebrovascular disease), not just exposure to hypoglycaemia 
(Messier and Gagnon, 2009).  Following exclusion of some of these 
confounding factors (i.e. duration of diabetes, vascular disease) a self-reported 
history of severe hypoglycaemia in a cohort of more than 1000 people with 
T2DM was associated with poorer cognitive ability (Aung et al., 2012).   The 
Edinburgh type 2 diabetes study also reported that a history of previous severe 
hypoglycaemia either prior to recruitment or during the study was associated 
with impaired cognitive ability at baseline and greater cognitive decline 
respectively (Feinkohl et al., 2014).  Cognitive function testing of a subset of 
the ACCORD cohort showed no difference in performance during the Digit 
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Symbol Substitution test between intensive and conventional glycaemic control 
groups despite the increased risk of severe hypoglycaemia in the intensively 
treated group (Launer et al., 2011). 
A history of severe hypoglycaemia has been associated with an increased risk 
of dementia in people with T2DM although the analysis did not adjust for 
several potential confounders such as subclinical cerebrovascular disease, 
history of alcoholism or epilepsy (Whitmer et al., 2009, Graveling and Frier, 
2009).  An Australian study followed a cohort of non-demented people with 
T2DM for 18 months, no association was found between historical 
hypoglycaemia and cognitive decline.  Eighteen months may have been too 
short a follow-up period, especially as only 7.2% of the cohort reported ever 
experiencing severe hypoglycaemia (Bruce et al., 2009).    
3.113 Effect of T1DM and severe hypoglycaemia on cognitive function in 
children 
Biessels et al (2008) proposed that that there are crucial periods in a person’s 
life when the brain is most susceptible to hypoglycaemia related brain injury: 
early childhood (5-7 years) and older age (>60 years) (Biessels et al., 2008).  
During the period in between, the brain’s development has slowed down or 
stopped and there may be a certain amount of “reserve” cognitive function.  An 
early age of onset of T1DM is the most consistent risk factor for cognitive 
dysfunction in diabetes occurring at different ages (Biessels et al., 2007).  A 
meta-analysis of 2144 children found that T1DM was associated with mildly 
reduced cognitive function scores in many domains compared with matched 
controls.  Learning and memory skills were more affected in children with 
early onset diabetes compared with late onset (age categories unspecified) 
(Gaudieri et al., 2008).  Early onset diabetes (<7 years) also resulted in worse 
cognitive function compared with diabetes onset during adolescence despite a 
similar duration of diabetes (Ferguson et al., 2005).  A study of children aged 
6-15 years with T1DM found no effect of severe hypoglycaemia on cognitive 
function (Wysocki et al., 2003).   
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A meta-analysis of children showed that the only cognitive domain 
significantly affected by a history of hypoglycaemic episodes resulting in loss 
of consciousness or seizures was short-term verbal memory (Naguib et al., 
2009). A randomised controlled trial compared intensive with conventional 
glycaemic control.  Spatial memory performance of the intensively controlled 
group (n=13), with a threefold increased risk of severe hypoglycaemia, was 
worse than the conventional group (n=12) (Hershey et al., 1999).   
Subjects with childhood onset T1DM were compared with matched controls 
(no difference on cognitive function testing done at baseline).  After 12 years 
of follow up, hypoglycaemia with seizure or coma was associated with lower 
verbal IQ and volume reduction in thalamus (Northam et al., 2009).  People 
with childhood onset T1DM and matched controls were followed up for 16 
years.  Those with early (<10 years of age) severe hypoglycaemia had poorer 
cognitive function although no EEG abnormalities were seen in this group 
(Asvold et al., 2010, Asvold et al., 2011).   Figure 3.3 shows that specific 
cognitive domains of problem solving, verbal function and psychomotor 
efficiency were significantly affected by a history of early severe 
hypoglycaemia.  Childhood onset T1DM was associated with lower verbal 
intelligence scores than sibling controls; exposure to severe hypoglycaemia 
reduced spatial intelligence and delayed recall, particularly when severe 
hypoglycaemia was experienced under the age of 5 (Perantie et al., 2008).  
Using a comprehensive battery of cognitive tests, no differences in cognitive 
functioning was found when children with a history of seizure or coma 
following hypoglycaemia were compared to matched controls (Strudwick et 
al., 2005).   
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Figure 3.3: Cognitive relative scores in T1DM subjects with and without early 
severe hypoglycaemia.  Mean cognitive relative scores (difference between 
diabetic subjects and matched controls, with SD controls as unit of measure) in 
adulthood in T1DM subjects with and without early (≤10 years of age).  The 
difference in scores between T1DM subjects with and without early SH is 
significant for the cognitive domains problem solving (−2.2 SD; p < 0.001), 
verbal function (−1.5 SD; p = 0.01) and psychomotor efficiency (−1.3 SD; p = 
0.02), and borderline significant for memory −0.8 SD; p = 0.06) (Asvold et al., 
2010, Bjorgaas, 2012). 
A meta-analysis compared studies of cognitive function in young adults with 
T1DM with matched controls.  Compared with people without T1DM, people 
with T1DM experienced significant lower performance on the following 
cognitive domains: intelligence, speed of information processing, psychomotor 
efficiency, visual and sustained attention, cognitive flexibility and visual 
perception.  Although these differences were significant the effects sizes were 
small to moderate (0.3-0.7).  Reduced cognitive performance appeared to be 
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associated with the presence of microvascular complications but not with 
hypoglycaemia or poor glycaemic control (Brands et al., 2005).   
Children who had been admitted to paediatric intensive care and treated with 
an intensive insulin regimen were compared with those who had received 
standard glycaemic regimen.  Cognitive function testing was performed a 
median 3.9 years after randomisation, no decrement in cognitive function was 
observed with some areas of improved performance such as motor coordination 
and cognitive flexibility (Mesotten et al., 2012). 
3.12 Chapter summary 
The effects of acute hypoglycaemia on general cognitive function has been 
recognised since the first people administered insulin experienced “insulin 
shocks” or hypoglycaemic episodes.  Conducting tests of specific cognitive 
functions in an experimental setting is a complex task with many potential 
pitfalls.  However, acute hypoglycaemia undoubtedly affects many cognitive 
domains with the performance of more complex tasks being preferentially 
affected.  The disrupted cognitive functioning is of clinical relevance because 
of the impact on the performance of many daily tasks.  Hypoglycaemia also has 
negative effects on mood and anxiety levels that may result in an impaired 
quality of life. 
Most studies looking for long-term cognitive decline in young to middle-aged 
adults with T1DM have failed to find an association with severe 
hypoglycaemia.  However young children or older adults may be more 
vulnerable to the effects of severe hypoglycaemia.  Younger children with 
T1DM have specific defects in various cognitive domains when compared to 
matched controls.  Whether T1DM per se has an impact on cognitive function 
or whether it is affected solely as a result of hypoglycaemia remains unclear.   
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Chapter 4: Impaired awareness of hypoglycaemia 
4.1  Introduction 
Impaired awareness of hypoglycaemia (IAH) is an acquired complication of 
insulin therapy, which affects people with T1DM and insulin-treated T2DM, 
whereby the ability to perceive the onset of hypoglycaemia becomes 
diminished or absent (Graveling and Frier, 2010b).  Deficiencies of the 
counter-regulatory hormonal responses to hypoglycaemia usually co-exist.  
The development of IAH and counter-regulatory failure greatly increases the 
risk of severe hypoglycaemia. Scoring systems have been developed that can 
be used in the clinical setting and assist with identification of this group of 
individuals at risk of severe hypoglycaemia.  The mainstay of treatment of IAH 
is the scrupulous avoidance of hypoglycaemia. 
People with T1DM are often less aware of hypoglycaemia, when blood glucose 
was clamped at 2.5 mmol/L, 9 out of 10 participants without diabetes were 
aware that they were hypoglycaemia compared to 4 out of 15 participants with 
T1DM (Heller et al., 1987b).  More than one third of episodes of severe 
hypoglycaemia that occur during waking hours are not accompanied by 
warning symptoms (DCCT, 1991), and many people with insulin-treated 
diabetes develop a syndrome with a spectrum of severity in which their ability 
to identify the onset of hypoglycaemia becomes progressively impaired.  
“Impaired awareness of hypoglycaemia” (IAH) is a preferable nomenclature to 
the widely used “hypoglycaemia unawareness”, which suggests total loss of the 
symptomatic warning response that is seldom observed in clinical practice.  
IAH is an acquired complication of insulin treatment per se, in which the 
perception of the onset of hypoglycaemia becomes diminished or absent.   
4.2 First reports of impaired awareness of hypoglycaemia 
In 1922, very shortly after insulin was first used to treat diabetes, Elliot Joslin 
observed that hypoglycaemia could occur without warning symptoms (Joslin et 
al., 1922).   Fredrick Banting in his 1925 Nobel Laureate lecture stated, “the 
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level at which hypoglycaemic symptoms occur, is slightly higher in the 
diabetic with marked hyperglycaemia ... As a patient becomes accustomed to a 
normal blood glucose, the threshold of these reactions, becomes lower.” 
(Sherwin, 2008).   
“Experience has shown that the severity of symptoms is not always 
proportional to the degree of hypoglycemia” (Maddock and Krall, 1953) 
Maddock and Trimble reported a number of cases where the warning 
symptoms of hypoglycaemia had been lost (Maddock and Trimble, 1928).  
R.D. Lawrence commented that changes in the symptomatology of 
hypoglycaemia often occur after years of insulin treatment; after 5-10 years of 
treatment autonomic symptoms are sometimes lost during hypoglycaemia with 
the person proceeding directly to experiencing neuroglycopenic symptoms 
(Lawrence, 1941).  A 1956 paper reported one of the first systematic studies of 
a cohort of such people with T1DM who had lost their warning symptoms of 
hypoglycaemia.  A prolonged duration of diabetes with a mean duration of 
diabetes of 18 years in the 116 people studied.  The recommended treatment 
was dietary modification with between meal snacks, frequent urine glucose 
testing and regular medical supervision (Balodimos and Foot, 1959). 
“I used to have hunger, sweating, tremor, or blurring of vision; (I) knew 
therefore that a reaction was coming, and I had time to do something about it. 
Lately some (or all) reactions come on without my usual or any other 
warning” (Balodimos and Foot, 1959) 
4.3 Impaired defences against hypoglycaemia in T1DM 
In normal health, when blood glucose falls to a level that may compromise 
cognitive function, glucose counter-regulation is initiated (Figure 4.1). 
Counter-regulation has been previously discussed in Chapter 2 and is triggered 
when blood glucose declines below the lower end of the normal range and is 
preceded by suppression of endogenous insulin secretion.  Hyperinsulinaemia 
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frequently occurs in people with T1DM and persists in the presence of low 
blood glucose due exogenous insulin administration.   
Glucagon and adrenaline (epinephrine) are the most important counter-
regulatory hormones to acute hypoglycaemia. In people with T1DM the 
glucagon response to hypoglycaemia rapidly declines and is lost within five 
years of diagnosis (Gerich et al., 1973).  The adrenomedullary secretion of 
adrenaline (epinephrine) becomes important when these early defensive 
mechanisms are compromised (de Galan et al., 2006b).  In people with T1DM 
who are C-peptide negative, loss of endogenous insulin-secretory capacity and 
the glucagon response to hypoglycaemia underlie the four-fold increase in risk 
of severe hypoglycaemia (Mühlhauser et al., 1998).   
With time, sympatho-adrenal activation becomes critical for protection of the 
brain from hypoglycaemia.  One consequence is the generation of autonomic 
symptoms, the intensity of which is heightened by the secretion of 
catecholamines.  Unfortunately, antecedent hypoglycaemia attenuates 
adrenaline release and moves the glycaemic threshold for its secretion to a 
lower blood glucose level, which both increases the risk of hypoglycaemia and 
reduces the intensity of symptoms generated during hypoglycaemia (Davis and 
Shamoon, 1991).  Reduced cortisol secretion also appears to contribute to 
counter-regulatory failure (Davis et al., 1996). 
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Figure 4.1: Glycaemic thresholds for counter-regulatory hormone release and 
clinical features of hypoglycaemia (de Galan et al., 2006b, Mitrakou et al., 
1991, Schwartz et al., 1987) 
Recurrent hypoglycaemia increasingly impairs the normal defences against 
hypoglycaemia and diminishes the ability to detect hypoglycaemia (i.e. 
hypoglycaemia begets hypoglycaemia).  This phenomenon of progressive 
counter-regulatory failure and loss of awareness of symptoms of 
hypoglycaemia, which co-exist in T1DM (Ryder et al., 1990) has been 
attributed to adverse effects of exposure to recurrent hypoglycaemia on central 
autonomic centres, which then fail to respond effectively to a fall in blood 
glucose.  Cryer has called this syndrome “Hypoglycaemia Associated 
Autonomic Failure (HAAF) and it is thought to result from a failure of 
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centrally mediated counter-regulation (Cryer, 2005).   However, counter-
regulatory hormonal failure is not the direct cause of IAH as avoidance of 
hypoglycaemia results in improved perception of symptoms without restoration 
of the normal counter-regulatory response (Dagogo-Jack et al., 1994).  
Nevertheless, the two are closely related and probably share a common 
pathogenesis as suggested in Figure 4.2.   
 
Figure 4.2: Pathophysiology of IAH & HAAF (adapted from Figure 6.6) 
(Frier, 2014) 
It used to be thought that peripheral autonomic neuropathy was responsible for 
these attenuated responses and was the mechanism underlying IAH.  Several 
studies have shown that autonomic dysfunction is not the primary cause, 
although its presence may contribute to a reduced magnitude of symptom 
intensity (Frier, 2014).  The most powerful argument against the involvement 
of autonomic neuropathy in the development of IAH is that this acquired 
syndrome is a dynamic process that can be worsened by exposure to recurrent 
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hypoglycaemia and improved by scrupulous avoidance of hypoglycaemia, in 
contrast to autonomic neuropathy which, once established, is a permanent 
complication that progresses in severity (Cryer, 2004).  
In people with IAH, adaptation of the brain occurs, shifting the glycaemic 
thresholds for the generation of symptoms, counter-regulatory hormonal 
secretion, and the onset of cognitive impairment to lower blood glucose levels, 
so that more profound hypoglycaemia is required to provoke these responses 
(Frier, 2014).  It is debatable as to whether this is an adaptive or maladaptive 
response.  Various mechanisms have been shown to cause this effect, including 
exposure to antecedent hypoglycaemia, recurrent hypoglycaemia and strict 
glycaemic control.  As a consequence of the increasingly diminished (and 
eventually non-existent) interval between the onset of warning symptoms of 
hypoglycaemia and the development of significant neuroglycopenia, people 
with IAH have a much greater risk of developing severe hypoglycaemia (Gold 
et al., 1994). By contrast, people with poor glycaemic control re-set their 
glycaemic thresholds upwards, i.e. they mount a counter-regulatory response 
and experience symptoms of hypoglycaemia at higher blood glucose levels 
than those with good control, often within a hyperglycaemic range (Boyle et 
al., 1988).  Thus symptomatic responses are initiated at elevated blood glucose 
levels, which is termed “relative hypoglycaemia” (Workgroup on 
Hypoglycemia, 2005).  Interestingly, the glycaemic thresholds of people with 
T2DM who have good glycaemic control but are not treated with insulin are set 
at levels above those of non-diabetic individuals and people with T1DM (Segel 
et al., 2002, Spyer et al., 2000).  This may have a protective effect against the 
development of severe hypoglycaemia. 
4.4 Glucose sensing  
This is discussed in section 2.2.  It is not yet known if glucose sensors in the 
brain can become irreversibly damaged in adults who have suffered from 
longstanding IAH. 
4.5 Neuroimaging studies 
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The effect of hypoglycaemia on the brain can be directly visualised with 
neuroimaging techniques such as positron emission tomography (PET) and 
functional magnetic resonance imaging (fMRI).  Both imaging techniques 
show similar changes in regional blood flow during hypoglycaemia (Arbelaez 
et al., 2013).  Baseline regional cerebral blood flow (measured using SPECT 
during euglycaemia) in the pre-frontal cortex was relatively increased in people 
with diabetes and particularly those with a history of severe hypoglycaemia 
(MacLeod et al., 1994b).   
PET can be used to examine whole brain and regional changes in glucose 
metabolism.  While animal models have indicated that antecedent 
hypoglycaemia increases glucose transport from blood to brain, thus allowing 
the brain to extract glucose more efficiently, this has not been shown in 
humans using PET (Segel et al., 2001).  Global brain glucose content falls 
during acute hypoglycaemia in people with T1DM with and without IAH.  
However, the relative glucose metabolic rate is higher in those with normal 
awareness implying that increased cortical activation may be involved in 
awareness of hypoglycaemia (Bingham et al., 2005).  
Studies of regional brain activation have identified key areas involved in 
glucose homeostasis and thus give insight into the pathophysiology underlying 
hypoglycaemia awareness.  Both PET and fMRI show similar changes in 
regional blood flow during hypoglycaemia with increases in the thalamus, 
medial prefrontal cortex and globus pallidum in healthy volunteers in 
comparison with euglycaemia (Arbelaez et al., 2013). It is postulated that these 
areas might be involved in the physiological and symptomatic response to 
hypoglycaemia.  
Antecedent hypoglycaemia was induced in healthy adults to replicate a state of 
counter-regulatory failure; subsequent hypoglycaemia resulted in increased 
activity of the dorsal midline thalamus, thought to have an inhibitory role in 
reducing counter-regulatory responses following antecedent hypoglycaemia 
(Arbelaez et al., 2008). Using functional MRI during hypoglycaemia (2.8 
mmol/L), the expected increase in thalamic uptake is blunted in people with 
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well-controlled T1DM in comparison to healthy adults; this may be responsible 
for their reduced epinephrine secretion in comparison to healthy adults 
(Mangia et al., 2012).  Using PET, glucose uptake during hypoglycaemia by 
the ventromedial hypothalamus was reduced in people with IAH compared to 
those with normal awareness (Cranston et al., 2001).   
 
Figure 4.3: Cerebral correlates of unawareness (Dunn et al., 2007)  
A: Regions where aware subjects show relatively greater uptake with 
hypoglycaemia than unaware subjects, showing amygdala, cerebellum, and 
brainstem regions.  
B: Regions where aware subjects show relatively lower uptake than unaware 
subjects with hypoglycaemia showing right lateral orbital-frontal cortex.  
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Activation of the amygdala is thought to be an unpleasant subjective 
experience associated with fear and anxiety.  During acute hypoglycaemia, 
[18F]-fluorodeoxyglucose PET scanning showed greater activation in the 
amygdala in people with normal hypoglycaemia awareness compared to those 
with IAH (see Figure 5.3) (Dunn et al., 2007).  These regional changes in 
people with IAH can be considered to be an example of “stress sensitisation”, 
whereby repeated exposure to a specific stress results in a reduced response.  In 
contrast, a relative increase in activation was observed in the lateral 
orbitofrontal cortex during hypoglycaemia in people with IAH; activation of 
these areas is thought to reduce appetite and limit an appreciation of danger 
associated with hypoglycaemia (Figure 4.3) (Dunn et al., 2007). 
4.6  Factors which modulate the counter-regulatory response and 
awareness of hypoglycaemia 
The pathogenesis of counter-regulatory failure is likely to be multifactorial and 
remains unclear with a number of hypotheses having been proposed (de Galan 
et al., 2006b, Cryer, 2013).  Even among healthy individuals without diabetes 
there is significant variation in the glycaemic thresholds below which a 
counter-regulatory response is triggered (Vea et al., 1992).  People categorised 
as unaware experience symptoms and mount a counter-regulatory response at a 
lower blood glucose level than those with intact awareness; for example 
adrenaline section in those with unawareness was triggered at 2.8mmol/L 
compared with 3.9 mmol/L in those with intact awareness (Mokan et al., 1994). 
The contribution of the adrenergic nervous system to this impaired counter-
regulatory response has been assessed using the non-selective alpha-blocker 
phentolamine and the non-selective beta agonist propranolol during the 
preceding episode of hypoglycaemia.  During subsequent (next day) 
hypoglycaemia the expected amelioration of the counter-regulatory response 
that was observed in the control population was not seen for adrenaline, 
noradrenaline and growth hormone.  Cortisol, glucagon and pancreatic 
polypeptide concentrations were reduced as expected with no effect seen from 
the preceding adrenergic blockade (Ramanathan and Cryer, 2011).  Prior 
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infusion of adrenaline did not affect the release of counter-regulatory hormones 
during hypoglycaemia (de Galan et al., 2003).  A cortisol infusion to produce 
levels of plasma cortisol typically seen during hypoglycaemia has been shown 
to impair counter-regulatory hormone release during subsequent 
hypoglycaemia (Bao et al., 2009, Davis et al., 1996).   
Oral ingestion of carbohydrate prior to the induction of hypoglycaemia initially 
blunts the counter-regulatory response but after 90 minutes of hypoglycaemia, 
adrenaline and noradrenaline increased to levels above the control arm (Ertl et 
al., 2008) unlike an earlier study which found no difference (Heptulla et al., 
2001).   
4.61 Antecedent hypoglycaemia 
In participants without diabetes, sustained mild hypoglycaemia of 60 minutes 
duration with a glucose of 3.0mmol/L has been shown to reduce symptomatic 
awareness despite counter-regulatory hormones remaining elevated (Kerr et al., 
1989).  A similar picture was seen in participants with T1DM at the end of 90 
minutes of hypoglycaemia (mean glucose = 2.8mmol/L) (Kerr et al., 1991). 
Antecedent hypoglycaemia has been shown in rigorously designed clamp 
studies to reduce the counter-regulatory response to subsequent hypoglycaemic 
episodes, adrenaline secretion is mostly reliably affected.  This was initially 
shown in healthy volunteers but has also been demonstrated in those with 
T1DM and T2DM (Adler et al., 2009, Heller and Cryer, 1991, Dagogo-Jack et 
al., 1993, Davis and Shamoon, 1991).  The degree of antecedent 
hypoglycaemia affects which counter-regulatory hormones are affected and to 
what degree (Amiel, 2009).  Antecedent hypoglycaemia has also been shown 
to reduce number of symptomatic episodes of hypoglycaemia following the 
experimental period suggesting a reduction in hypoglycaemia awareness 
(Ovalle et al., 1998).  
Duration of antecedent hypoglycaemia was examined with two episodes of 
antecedent hypoglycaemia lasting 5 minutes each compared with two episodes 
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lasting 30 minutes or 120 minutes.  There were no significant differences of the 
counter-regulatory response to subsequent hypoglycaemia with the differing 
duration of antecedent hypoglycaemia although hypoglycaemic symptoms 
were only significantly blunted by the 30 minute or 120 minute duration of 
antecedent hypoglycaemia (Davis et al., 2000b).   
George et al (1995) purportedly examined whether the effect of antecedent 
hypoglycaemia is prolonged comparing counter-regulatory responses during 
hypoglycaemia 2 days after the initial episode compared with 7 days after.  
Due attention to the study design is beneficial; the (30 minute) episode of 
hypoglycaemia after 2 days may have affected the counter-regulatory 
responses during hypoglycaemia after 7 days and was thus acknowledged as a 
potential confounder (George et al., 1995).     
While antecedent hypoglycaemia is known to attenuate the counter-regulatory 
response, antecedent hyperglycaemia does not have the same opposite effect as 
might be expected (Fanelli et al., 1995).   
4.62 Intensive glycaemic control 
Intensive glycaemic control (mean HbA1c 8.1-8.3%) considerably blunts the 
counter-regulatory response to hypoglycaemia compared to those measured 
during periods of poorer glycaemic control (mean HbA1c 11.2-14.6%) (Jones 
et al., 1997, Simonson et al., 1985). 
4.63 Type and route of insulin administration 
Claims in the 1980s that human insulin can cause impaired awareness of 
hypoglycaemia in contrast to animal insulins (Berger et al., 1989) were not 
substantiated by extensive research, and a subsequent meta-analysis and 
Cochrane review have shown no difference in the frequencies of severe 
hypoglycaemia or in IAH between the use of human and animal insulins (Airey 
et al., 2000, Richter and Neises, 2005).   
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Peripheral versus portal administration of insulin has differing effects on the 
release of various counter-regulatory hormones.  Adrenaline and noradrenaline 
are unaffected, whereas glucagon and growth hormone undergo a greater 
increment when insulin is infused peripherally rather than via pancreatic 
insulin secretion (portal) using intravenous tolbutamide.  It is probably 
significant that despite similar peripheral glucose concentrations, peripheral 
insulin concentrations were approximately 50% greater due to the first pass 
hepatic extraction of portal insulin (Lewis et al., 1999). 
4.64 Autonomic neuropathy 
While classical autonomic neuropathy is not primarily responsible for the 
reduction in counter-regulatory responses during hypoglycaemia, its presence 
does diminish counter-regulatory secretion in otherwise similarly matched 
people with T1DM (Meyer et al., 1998). 
4.65 Age 
Age has been suggested as a potential modifier of awareness of 
hypoglycaemia.  Men without diabetes aged 65-80 had lower symptom scores 
with hypoglycaemia than those aged 24-49 years (Brierley et al., 1995).  Men 
with T1DM aged 60-70 were less likely to be aware of hypoglycaemia than 
those aged 22-26 during a glucose clamp study (Matyka et al., 1997).  
4.66 Gender 
A reduction in the amplitude of counter-regulatory hormonal secretion is seen 
in women in comparison with men (Fanelli et al., 1994, Davis et al., 2000c).  
Post-menopausal women on HRT were compared to those not taking HRT with 
a male control group.  Counter-regulatory responses were significantly 
diminished in the group taking HRT compared with both men and those not 
taking HRT.  The counter regulatory responses of the male group and women 
not taking HRT were broadly similar with only a difference in glucagon 
secretion.  This would suggest that oestrogen is the hormone responsible for 
this sexual dimorphism (Sandoval et al., 2003).  Oestrogen is also known to 
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antagonise the effects of growth hormone; women on oral contraceptives 
(OCP) have higher growth hormone levels than those not taking OCPs 
(Rickenlund et al., 2010).  During hypoglycaemia in healthy women, oral 
contraceptive use resulted in significant elevations in growth hormone that may 
help improve awareness of hypoglycaemia (Friedrich et al., 2012). 
4.67 Posture 
Posture affects appreciation of hypoglycaemia.  Standing increases the early 
awareness of hypoglycaemia with a greater increase in symptom scores and 
counter regulatory hormones.  During prolonged hypoglycaemia, the symptom 
score difference was lost although counter regulatory hormones remained 
elevated (Robinson et al., 1994).   
4.68 Type 2 diabetes 
Type 2 diabetes is a heterogeneous disease state ranging from diet controlled 
T2DM to insulin requiring T2DM of long duration.  Participants on oral 
hypoglycaemic therapy with well controlled T2DM of mean 46 months disease 
duration have similar counter-regulatory responses to healthy volunteers 
(Heller et al., 1987a).  A direct comparison of those with T2DM on oral 
hypoglycaemic therapy compared with T1DM of similar disease duration 
(mean 8-9 years) showed an intact glucagon response for those with T2DM.  
Counter-regulatory hormones were released in greater quantity and at a higher 
glucose threshold in T2DM than those with T1DM (Levy et al., 1998).   Six 
months of intensive glycaemic control resulted in a mean HbA1c 6.7% 
compared with a baseline mean HbA1c of 10.2%.  Intensive glycaemic control 
resulted in a general reduction in counter-regulatory hormone release during 
hypoglycaemia, both with and without preceding hypoglycaemia (Davis et al., 
2009).   
4.7 Definition and prevalence of IAH 
The lack of an acceptable clinical definition of IAH has hindered accurate 
ascertainment of the prevalence of IAH and research into this condition.  
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“Awareness” of hypoglycaemia and its progressive impairment represent a 
continuum ranging from normal perception of the onset of hypoglycaemia to 
complete inability to detect its onset (Frier, 2014).  For the purposes of 
developing a clinical scoring system, awareness of hypoglycaemia was 
arbitrarily divided into normal, “partial” and “absent” awareness, where 
“partial” represented diminution of the ability to perceive the onset of 
hypoglycaemia, but without total absence of a symptomatic response (Gold et 
al., 1994, Clarke et al., 1995).  Partial and absent awareness of hypoglycaemia 
combined was present in 25% of a group of 302 people with T1DM (Hepburn 
et al., 1990), which was consistent with other surveys in which the syndrome 
was not precisely defined (Gerich et al., 1991) and more recently the syndrome 
of IAH was identified in 19.5% of a randomly selected cohort of 518 people 
with T1DM attending a secondary care diabetes clinic (Geddes et al., 2008).   
Using the Gold questionnaire the prevalence of IAH was found to be similar at 
17% of a Norwegian cohort of people with T1DM (median diabetes duration 
21 years) (Olsen et al., 2014). 
IAH is less common in people with insulin-treated T2DM with an estimated 
incidence of 8-10% (Henderson et al., 2003, Schopman et al., 2010).  The 
extent to which IAH affects people treated with insulin secretagogues such as 
sulfonylurea therapy is not known.  Although IAH affects a smaller proportion 
of people with insulin-treated T2DM, in view of the number of people now 
affected by T2DM on a global basis, this clinical problem will have a greater 
impact than is currently appreciated.   
4.8  Risk factors for IAH 
Factors that influence the awareness of hypoglycaemia are shown in table 4.1 
although this is not an exhaustive list.  Many episodes of severe hypoglycaemia 
are under-reported by people with IAH.   Furthermore, if blood glucose 
monitoring is infrequent, many episodes of asymptomatic (or biochemical) 
hypoglycaemia are not detected.  Major risk factors that are associated with the 
development of IAH in T1DM include increasing age and duration of diabetes 
and strict glycaemic control (Geddes et al., 2008, Pedersen-Bjergaard et al., 
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2004).  The prevalence of IAH increases from 3% in those with a diabetes 
duration of 2-9 years to 28% for those with a diabetes duration ≥30 years 
(Olsen et al., 2014).  An early insulin pump study showed an impressive 
reduction in HbA1c from a mean of 11.2% to 8.1% with 4-8 months of insulin 
pump therapy; however a significant reduction in counter-regulatory hormone 
release was also noted along with an increased frequency of hypoglycaemia 
(Simonson et al., 1985).   
Table 4.1: Factors influencing awareness of hypoglycaemia (Frier, 2014) 
Internal External 
Physiological 
• Recent glycaemic control 
• Degree of neuroglycopenia 
• Symptom intensity/sensitivity 
Drugs 
• Beta-blockers (non-selective) 
• Hypnotics, tranquillisers 
• Alcohol 
Psychological 
• Focused attention 
• Congruence; denial 
• Competing explanations 
Environmental 
• Posture 
• Distraction 
Education 
• Knowledge 
• Symptom belief 
 
 
4.81 Behavioural factors 
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People with T1DM who have IAH are less likely to adhere to therapeutic 
decisions (e.g. following a suggested management plan following a diabetes 
clinic consultation) (Smith et al., 2009).  Graveling and Frier highlighted two 
earlier studies that are consistent with this observation (Graveling and Frier, 
2010a).  In a 12-month prospective study of the incidence of severe 
hypoglycaemia in 60 people with T1DM (29 with IAH), people with IAH 
worried more about hypoglycaemia than those with normal awareness, but 
failed to modify their behaviour to avoid hypoglycaemia despite recording a 
significantly greater fear of hypoglycaemia on the worry subscale of the 
Hypoglycaemia Fear Survey (section 3.10 discusses fear of hypoglycaemia) 
(Cox et al., 1987, Gold et al., 1994).   
A larger study of 305 people with T1DM, 111 of whom had IAH, found that 
increased worry of hypoglycaemia was exhibited by the people with IAH, 
although again they made no attempt to modify their behaviour to either 
prevent, avoid or correct hypoglycaemia with any greater frequency or 
vigilance than the people who had normal awareness (Hepburn et al., 1994).  
Qualitative research using structured interview in 17 people with IAH 
identified that 13 of the group were not particularly concerned regarding their 
lack of awareness (Rogers et al., 2012).  Three themes emerged: 
1) Normalising hypoglycaemia unawareness: IAH was not viewed as a 
problem, rather as a normal part of having diabetes 
2) Underestimating the effect of hypoglycaemia on activities of daily 
living: Some participants felt they could function normally with a blood 
glucose <3.0 mmol/L 
3) Avoiding the “sick role”: Participants felt treating hypoglycaemia in the 
absence of symptoms was unnecessary and wanted to “get on with life” 
 
It is unclear whether people who develop IAH have a particular personality 
type, or whether their behaviour and approach to self-management are 
influenced by exposure to recurrent severe hypoglycaemia.  The role of 
personality on the behavioural responses to hypoglycaemia merits further 
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investigation, and people with IAH may require psychological counselling to 
help them modify management of their diabetes. 
4.82 Genetic factors 
Genetic predisposition to hypoglycaemia unawareness is now being examined.  
The Gly16 variant of the beta adrenoceptor was thought to result in 
hypoglycaemia unawareness through chronic stimulation of the beta-
adrenoceptor resulting in desensitisation.  In healthy adults antecedent 
hypoglycaemia did not affect beta-adrenoceptor sensitivity in homozygotes for 
Gly16 but increased it in homozygotes for arginine 16 homozygosity 
(Schouwenberg et al., 2011).   Hypoglycaemia unawareness (determined using 
the Clarke method) is increased 3.4 fold in those with T1DM who are 
homozygotes for Gly16 (Schouwenberg et al., 2008). 
4.83 Medications 
Any medication that affects the counter-regulatory response to hypoglycaemia 
could potentially affect hypoglycaemia awareness.  Theoretically beta-blockers 
should reduce counter-regulation and diminish the intensity of symptoms that 
are adrenergically-mediated by suppressing adrenoceptor responses.  In effect, 
selective beta-blockers do not appear to have any significant clinical effect. 
Glucose clamp experiments showed that the threshold for autonomic symptoms 
was shifted to a lower blood glucose level while neuroglycopenic symptoms 
and cognitive function were unaffected (Hirsch et al., 1991).  During moderate 
hypoglycaemia, both selective and non-selective beta-blockers failed to modify 
awareness or symptom intensity during hypoglycaemia (Kerr et al., 1990b).  
Beta-blockers have not been shown to increase the risk of severe 
hypoglycaemia although one study reported that usage of non-selective beta-
blockers was associated with an increased risk of severe hypoglycaemia (ter 
Braak et al., 2000, Morris et al., 1997, Thamer et al., 1999). In summary, beta-
blockers may modify symptomatology (and in particular increase diaphoresis) 
but do not appear to increase the risk of severe hypoglycaemia (Sawicki and 
Siebenhofer, 2001).  
Chapter 4 
 194 
Despite some case reports suggesting a reduction in symptom intensity during 
hypoglycaemia, a glucose clamp study, in which non-depressed, non-diabetic 
subjects were given fluoxetine, demonstrated that counter-regulatory hormone 
release was increased, but with no concurrent change in symptom scores 
(Briscoe et al., 2008).    
4.9 Clinical assessment of IAH 
Glucose clamp studies have been used to determine awareness of 
hypoglycaemia (Mokan et al., 1994) and to demonstrate the hierarchy of 
responses that occur as blood glucose declines.  Autonomic symptoms occur 
before neuroglycopenic symptoms, with a difference of around 0.5 mmol/L 
between the thresholds at which they are generated (Schwartz et al., 1987, 
Mitrakou et al., 1991).   However, this artificial and controlled experimental 
setting bears little relationship to everyday life with its myriad distractions, and 
this small threshold difference is unlikely to be detected by affected individuals 
(Hepburn et al., 1991a, Cox et al., 1993). The most useful method of 
identifying impaired awareness of hypoglycaemia and its importance to the 
individual is to take a careful clinical history.  People with T1DM who state 
that they have IAH are generally correct (Clarke et al., 1995).  
A structured questionnaire of hypoglycaemia experience has been developed to 
confirm the clinical history (Clarke et al., 1995), while a simpler method 
employs a single question and asks the person with diabetes to score their 
awareness on a 7 point Likert scale, where a low score represents normal 
awareness and a high score designates loss of awareness (Gold et al., 1994).  
To be utilised effectively the participant must have experienced hypoglycaemia 
on at least one occasion in the preceding year, and for reasons explained below, 
the answers must be based on experience of hypoglycaemia that occurs during 
waking hours.  These two questionnaires display good concordance in the adult 
population (Geddes et al., 2007).  A third method from Denmark (Pedersen-
Bjergaard et al., 2001), which has attempted to relate symptomatic awareness 
to subjective experience generally over-estimates the frequency of IAH, with 
almost two thirds of people with T1DM being described as having this 
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problem, which is not consistent with clinical experience (Geddes et al., 2007).  
A revised, trichotomised version of this method that subdivided the participants 
into three groups: “aware”, “intermediate” and “impaired”, improved 
concordance with the two established methods (Høi-Hansen et al., 2009), but 
the terminology used in the Danish method is open to misinterpretation.  Use of 
a non-validated assessment of hypoglycaemia awareness failed to show any of 
the expected differences (i.e. tighter glycaemic control, longer duration of 
diabetes) between the aware and non-aware groups (Berlin et al., 2005).   
In both the Clarke and Gold methods a degree of uncertainty exists regarding 
assessment in the middle range, equivalent to a score of 3 in both scales.  It is 
unclear if people with this score have definite IAH, and whether they represent 
people with partial loss of awareness who have yet to progress to expression of 
the full-blown syndrome.  Longitudinal cohort studies would help determine 
the natural history of this condition. 
The semantics of IAH present difficulties and translation of the Clarke and 
Gold methods into languages other than English may introduce anomalies.  The 
method of Clarke et al (1995) has been validated by a Dutch study that also 
utilised prospective blood glucose monitoring and glucose clamps to assess 
hypoglycaemia awareness (Janssen et al., 2000).   
IAH is associated with a 2 to 6 fold higher frequency of asymptomatic 
biochemical hypoglycaemia (capillary blood glucose < 3.5 mmol/L) (Gold et 
al., 1994, Geddes et al., 2008, Schopman et al., 2011).  Continuous glucose 
monitoring (CGM) has demonstrated that much hypoglycaemia remains 
undetected and has suggested that asymptomatic biochemical events are 
fourfold higher in people with IAH compared to those with normal awareness 
(Kubiak et al., 2004, Giménez et al., 2009).  However, despite an increased risk 
of severe hypoglycaemia and evidence of more hypoglycaemia during 
prospective self-monitoring of capillary blood glucose, retrospective blood 
glucose analysis of CGM records for up to 72 hours of monitoring failed to 
identify those with IAH, who had a similar frequency, duration and severity of 
biochemical hypoglycaemia as those with normal awareness. At the time of 
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this particular study the technology was not sufficiently sensitive to reliably 
identify the presence of this syndrome (Choudhary et al., 2010), but 
increasingly sophisticated CGM technology may improve detection by this 
approach. 
4.10 Morbidity and mortality associated with IAH 
Section 2.4 discusses the morbidity and mortality associated with 
hypoglycaemia.  Severe hypoglycaemia may result in many serious forms of 
morbidity including seizure, coma, fractures and joint dislocation and cardiac 
arrhythmias, and is occasionally fatal.  However, although these problems are 
more frequent in people with IAH the frequencies of these morbidities 
associated with severe hypoglycaemia have not been formally estimated.  
People who have impaired awareness of hypoglycaemia have a much greater 
risk of severe hypoglycaemia, up to six fold (Gold et al., 1994, Choudhary et 
al., 2010).   A history of hypoglycaemia unawareness was reported in more 
than half (51%) of people who had suffered a hypoglycaemic coma in the past 
year compared with 21% of those with no history of severe hypoglycaemia (ter 
Braak et al., 2000). 
The strict glycaemic control required during the management of T1DM during 
pregnancy and the increased frequency of hypoglycaemia may result in the 
development of IAH.  Pregnant women with diabetes are subject to 
hypoglycaemia-induced morbidity, particularly in the first trimester, but there 
is no evidence that this harms the foetus (Gold and Pearson, 2007). 
Preclinical markers of atherosclerosis have been shown to be present to a 
greater extent in people with T1DM and IAH compared to those with normal 
awareness.  As well as the expected higher incidence of hypoglycaemia 
subjects with IAH had significantly greater carotid and femoral intima-media 
thickness and reduced flow-mediated brachial dilatation (Gimenez et al., 2011). 
4.11 Effect of alcohol, sleep, exercise and distraction on awareness of 
hypoglycaemia 
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Alcohol is an important risk factor for hypoglycaemia (Potter et al., 1982),   
The clinical features of hypoglycaemia can be mistaken for those of alcohol 
intoxication which may delay appropriate treatment of the hypoglycaemic 
episode.  The risk of hypoglycaemia also extends into the next day following 
alcohol ingestion the evening before (Richardson et al., 2005b).  Despite 
increased counter-regulatory responses in those who had consumed alcohol 
compared with those who had not, during experimental hypoglycaemia, those 
who had consumed alcohol were less likely to recognise that they were 
hypoglycaemic (2 out of 15 versus 11 out of 15 respectively) (Kerr et al., 
1990a).   
Exercise is a recognised risk factor for hypoglycaemia (see chapter 1.61).  
Antecedent exercise blunts the counter-regulatory response to subsequent 
hypoglycaemia in both healthy adults and those with T1DM (Galassetti et al., 
2001a, Galassetti et al., 2003).  Counter-regulatory responses to exercise 
following antecedent hypoglycaemia are also blunted which may mask any 
subsequent hypoglycaemia occurring during the exercise period (Davis et al., 
2000a).  Therefore both exercise and hypoglycaemia have similar blunting 
effects on counter-regulatory hormone release (Sandoval et al., 2006).   
Differing intensities of antecedent exercise have similar effects on counter-
regulatory hormone release to subsequent hypoglycaemia although gender 
specific differences are observed with greater blunting of glucagon, adrenaline 
and noradrenaline release in men (Sandoval et al., 2004, Galassetti et al., 
2001b).  In participants with T1DM, clamping blood glucose levels at 3.9, 3.3 
or 2.8 mmol/L induced progressively greater blunting of counter-regulatory 
responses with each decrement in blood glucose level (Galassetti et al., 2006).   
Sleep is a physiological state where warning symptoms of hypoglycaemia are 
usually absent and presents a particular problem to people with T1DM as many 
severe hypoglycaemic episodes occur during sleep (DCCT, 1991, Jauch-Chara 
and Schultes, 2010).  Symptomatic responses to hypoglycaemia are diminished 
in the supine posture (Hirsch et al., 1991) and the plasma adrenaline response 
is also lower when lying down (Robinson et al., 1994).  Hypoglycaemia in 
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healthy adults during sleep decreases the glucose level below which a counter-
regulatory response is triggered compared to when they are awake (Gais et al., 
2003).  When hypoglycaemia occurs during sleep in people with T1DM 
counter-regulatory responses, particularly the release of catecholamines, are 
markedly attenuated compared with responses when awake (Banarer and 
Cryer, 2003, Jones et al., 1998).  Adults with T1DM experienced less 
disruption to their quality of sleep during hypoglycaemia, spending 77% of the 
time asleep in comparison to 26% in non-diabetic participants (Banarer and 
Cryer, 2003).  During hypoglycaemia only 1 person out of 16 with T1DM 
awoke during hypoglycaemia in comparison to 10 out of 16 of those without 
diabetes (Schultes et al., 2007).   Unrecognised nocturnal hypoglycaemia 
presents a possible explanation why people with T1DM develop IAH, by 
modifying glycaemic thresholds to subsequent hypoglycaemia (Veneman et al., 
1993). 
Driving simulator studies have shown that people with T1DM whose 
symptomatic awareness is not impaired are often unaware of the onset of 
cognitive dysfunction while modest hypoglycaemia is being induced and fail to 
take corrective action (Cox et al., 2000).  Participants failed to recognise both 
deterioration in their driving performance and their current hypoglycaemic 
status, this may be partly attributable to distraction.  People who are distracted 
by a stressful event (i.e. preparing and giving a speech) report lower symptom 
intensity scores during acute hypoglycaemia despite greater counter-regulatory 
hormonal release (Pohl et al., 1998).   
4.12 Effect of IAH on cognitive function 
The effect of hypoglycaemia on cognitive function is discussed in chapter 3.  
People with IAH often state that they do not experience any cognitive 
impairment during hypoglycaemia and are capable of carrying out the usual 
activities of daily living even though they may be exposed to frequent 
asymptomatic hypoglycaemia.  It is sometimes difficult to convince some 
people with IAH both of the scale of the problem and the imperative to avoid 
hypoglycaemia wherever possible, especially when consultations with 
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specialists tend to focus on the necessity of attaining good glycaemic control 
(Rogers et al., 2012).  However, most people with this syndrome are fully 
cognisant of the dangers that it imposes, and the threat to retaining their driving 
licence and some forms of employment.  
The evidence for the effect of acute hypoglycaemia on cognitive function is 
conflicting.   The glycaemic threshold for cognitive dysfunction is re-set at a 
lower blood glucose level, in the same way as those for generation of 
symptoms and the stimulation of counter-regulatory hormonal secretion 
(Hepburn et al., 1991b, Mokan et al., 1994).  Zammitt et al (2008) reported that 
cognitive function is less affected during moderate hypoglycaemia and 
recovery is quicker in people with IAH compared to people with normal 
awareness and T1DM (Zammitt et al., 2008). Other studies have also 
demonstrated that cognitive dysfunction occurs at lower blood glucose levels in 
those with IAH compared to those with normal awareness or people without 
diabetes (Fanelli et al., 1993, Mokan et al., 1994).  In contrast, people with 
IAH have been shown to perform less well on a limited number of cognitive 
function tests applied during both euglycaemia and hypoglycaemia (Hepburn et 
al., 1991b). More profound cognitive dysfunction during acute hypoglycaemia 
was observed in those with IAH compared to those with normal awareness 
(Gold et al., 1995). 
The long-term effects of exposure to repeated episodes of hypoglycaemia are 
discussed in chapter 3.11.  Exposure of the brain to repeated episodes of 
hypoglycaemia over many years in people with T1DM had no apparent effect 
on long-term cognitive function in the DCCT/EDIC study (Jacobson et al., 
2007).  People with T1DM and a history of severe hypoglycaemia had greater 
cognitive impairment that those with no history of severe hypoglycaemia 
(MacLeod et al., 1994a).   Few studies have examined the long-term effects on 
cognitive function in people who have developed impaired awareness of 
hypoglycaemia, which is associated with a very much high frequency of severe 
hypoglycaemia (Gold et al., 1994, Geddes et al., 2008). Animal studies have 
shown that antecedent moderate hypoglycaemia can protect the brain against 
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subsequent severe hypoglycaemia with evidence of less neuronal damage 
(Puente et al., 2010).  While people with IAH may develop a lesser degree of 
cognitive impairment during mild acute hypoglycaemia, because profound 
neuroglycopenia is a more common occurrence, it seems likely that this will be 
detrimental to cognitive function in the long term.   
4.13 Management of IAH 
The mainstay of treatment of IAH is the complete avoidance of 
hypoglycaemia, which is of course very difficult to achieve.  Reducing the 
frequency of hypoglycaemia can be attempted by various measures as shown in 
table 4.2.  Hypoglycaemia awareness can be restored by scrupulous avoidance 
of hypoglycaemia, although this may be at the cost of jeopardising glycaemic 
control (Cranston et al., 1994, Fritsche et al., 2001).  An Italian study 
demonstrated an improvement in counter-regulatory response after six months 
of strict avoidance of hypoglycaemia reduced the frequency of hypoglycaemia 
from 20 episodes to 2 episodes per participant, per month (Fanelli et al., 1997).  
Hypoglycaemia avoidance can lead to a significant improvement in 
hypoglycaemia symptom scores during exposure to subsequent hypoglycaemia 
(Fritsche et al., 2001).   
Table 4.2: Treatment strategies for people with IAH (Frier, 2007) 
• Frequent blood glucose monitoring (including nocturnal measurements) 
• Avoid blood glucose values < 4.0mmol/L 
• Revise blood glucose targets upwards (e.g. pre-prandial target 6.0-12.0 
mmol/L & bedtime > 8.0 mmol/L 
• Avoid HbA1c being within non-diabetic range 
• Use predominantly short-acting insulins (basal bolus regimen; CSII; 
insulin analogues) 
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• Regular snacks between meals and at bedtime, containing unrefined 
carbohydrate 
• Appropriate additional carbohydrate consumption and/or insulin dose 
adjustment before exercise 
• Learn to identify subtle neuroglycopenic cues to low blood glucose 
 
4.131 Hypoglycaemia avoidance programmes 
Long-term effectiveness of these hypoglycaemia avoidance programmes was 
demonstrated in a small cohort (n=4) three years after a period of 
hypoglycaemia avoidance for three months.  During hypoglycaemia, the 
symptom scores remained higher than baseline but less than those achieved 
immediately after the period of hypoglycaemia avoidance (Dagogo-Jack et al., 
1999).  Hypoglycaemia avoidance programmes are labour intensive for both 
patient and clinician as they tend to require frequent monitoring of blood 
glucose including measurements at night; the frequent insulin dose adjustments 
may take months to implement (Heller, 2008).  The HYPOcompass study is 
described in more detail in section 4.132, the education programme reinforced 
4 key points: 
• Never delay hypoglycaemia treatment 
• Recognise personalised times of increase risk 
• Detect subtle symptoms 
• Confirm low glucose levels through regular self monitoring; 
particularly for nocturnal hypoglycaemia 
Despite the improvement in symptom scores, deficient counter-regulatory 
hormonal responses to subsequent hypoglycaemia are relatively unaffected 
(Dagogo-Jack et al., 1994, Fritsche et al., 2001) although a more recent study 
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reported increased adrenaline secretion to hypoglycaemia following a six 
month intervention study aimed at hypoglycaemia avoidance (Leelarathna et 
al., 2013).  This illustrates a divergence between continuing subnormal 
counter-regulatory response and an improvement in symptomatic responses, 
which suggests that other factors are probably important in promoting the 
symptomatic recovery.  
4.132 CSII or CGM as adjuncts in the management of IAH 
The recent HYPOcompass study was a multifactorial randomised controlled 
trial comparing multiple daily injection therapy with CSII and conventional 
SMBG with real time CGM in people with T1DM and IAH.  No reduction in 
hypoglycaemia awareness was seen when comparing CSII with multiple daily 
injection therapy or real time CGM with conventional SMBG (Little et al., 
2014).   
Substitution of nocturnal continuous subcutaneous insulin infusion (CSII) for 
isophane (NPH) insulin at bedtime resulted in a lower frequency of 
hypoglycaemia.  Warning symptoms and counter-regulatory responses were 
improved during subsequent acute hypoglycaemia (Kanc et al., 1998).  CSII 
was used for 24 months in a cohort in which 95% had established IAH and had 
experienced two or more episodes of severe hypoglycaemia in the preceding 
two years.  The participants reported fewer episodes of severe hypoglycaemia, 
an improved quality of life, unchanged glycaemic control and an improved 
symptomatic response to experimentally-induced hypoglycaemia (Giménez et 
al., 2010).  
Real time CGM has been trialled as a “glucose alert” system.  Adolescents with 
IAH were randomised to CGM or usual care for 4 weeks, although rates of 
hypoglycaemia were not reported, the CGM group exhibited an increased 
counter-regulatory response to hypoglycaemia at the end of the study period 
(Ly et al., 2011). 
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Over six months an Australian study of people with T1DM and IAH (assessed 
using the Clarke method) compared standard CSII with CSII in combination 
with CGM the latter utilising an automated low glucose suspend feature.  The 
combination treatment was shown to reduce hypoglycaemia requiring third 
party assistance (9.5 events versus 34.2 events per 100 patient months in the 
intervention group and control group respectively) and hypoglycaemia 
resulting in coma or seizure (0 over six months compared with 6 events over 
the same time period) (Ly et al., 2013).  The intervention group therefore 
received two interventions compared with the control group, i.e. CGM and low 
glucose suspend.  This study demonstrated that CGM with a low glucose 
suspend feature can reduce hypoglycaemia in targeted patient populations.  
4.133 Diabetes treatment regimens 
One potential advantage of long-acting insulin analogues is their association 
with a lower rate of nocturnal hypoglycaemia (Horvath et al., 2007).  
Hypoglycaemia induced by insulin detemir generated higher symptom scores 
when compared with human insulin although the difference in total symptom 
scores only just achieved significance (p=0.048) and the study was not blinded 
to insulin type (Tschritter et al., 2009).   
Administration of bolus doses of glucagon at times of impending 
hypoglycaemia lowered the frequency of hypoglycaemia (Castle et al., 2010).  
Islet cell transplantation resulted in a decline in prevalence of IAH from 87% 
before transplantation to 13% post-transplantation; the blood glucose threshold 
that was required to trigger symptoms of hypoglycaemia increased from 2.3 
mmol/L to 3.2 mmol/L (Leitão et al., 2008). 
4.134 Other medications 
Although it has been suggested that people with IAH may have reduced 
sensitivity to beta agonists, one study has shown that beta-adrenoceptor 
sensitivity is preserved (De Galan et al., 2006a).  Beta agonists (e.g. 
terbutaline) have been shown to significantly reduce nocturnal hypoglycaemia 
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at the cost of inducing morning hyperglycaemia (Raju et al., 2006, Cooperberg 
et al., 2008).   Beta agonists have therefore been suggested as possible 
therapeutic options (De Galan et al., 2006c).   
Caffeine has been shown to augment symptom intensity and improve counter-
regulatory responses (Kerr et al., 1993). A double-blind, placebo controlled 
study using CGM showed that caffeine reduces the total duration of nocturnal 
hypoglycaemia; the 250mg of caffeine used is equivalent to the mean daily 
caffeine intake in the UK (Richardson et al., 2005a).  Functional MRI shows 
250mg of caffeine can restore regional brain activation normally lost during 
acute hypoglycaemia (Rosenthal et al., 2007).  However, the daily doses 
required may not make this a practical proposition in treating people with IAH.   
Infusion of the opioid antagonist (naloxone) during antecedent hypoglycaemia 
has been shown to restore counter-regulatory responses to subsequent 
hypoglycaemia to normal levels in healthy adults (Leu et al., 2009, Vele et al., 
2011).  Naloxone infusion also prevents the blunting of counter-regulatory 
responses to subsequent hypoglycaemia seen with antecedent exercise (Milman 
et al., 2012).   
4.14 Chapter Summary 
Impaired awareness of hypoglycaemia is an acquired syndrome associated with 
the use of insulin and exposure to hypoglycaemia that is common in people 
with T1DM and is observed less frequently in insulin-treated T2DM.   It should 
be defined by the loss of ability to perceive the onset of hypoglycaemia, which 
is usually manifested by a reduced intensity and number of symptoms and a 
change in symptom profile.  Asymptomatic biochemical hypoglycaemia occurs 
more frequently and people with established IAH have a much higher risk of 
developing severe hypoglycaemia.   
In those affected, cognitive dysfunction is less pronounced during acute 
hypoglycaemia and recovery is more rapid.  However, the glycaemic 
thresholds for the generation of symptoms, counter-regulatory hormonal 
Chapter 4 
 205 
secretion and cognitive impairment are re-set at lower blood glucose levels as a 
result of cerebral adaptation, but this allows little opportunity for correcting 
hypoglycaemia when blood glucose falls to dangerously low levels, and 
neuroglycopenia rapidly supervenes which prevents appropriate self-treatment.   
Exposure to antecedent hypoglycaemia, especially repeated episodes, is an 
important factor in the pathogenesis of IAH.  Neuroimaging has allowed 
identification of key areas of the brain that are involved in maintaining glucose 
homeostasis and responding to hypoglycaemia.  Two methods are currently 
available for the assessment of awareness of hypoglycaemia in adults, which 
can be used to identify people with impaired awareness.  
As antecedent hypoglycaemia appears to have an important role in the 
pathogenesis of IAH, scrupulous avoidance of hypoglycaemia appears to be 
crucial in maintaining defences against the development or progression of IAH.  
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Chapter 5  Treatment and prevention of hypoglycaemia 
5.1 Acute treatment of hypoglycaemia 
The treatment of hypoglycaemia requires ingestion of quick-acting 
carbohydrate to restore euglycaemia.  The quick-acting carbohydrate should be 
followed up longer-acting carbohydrate either in the form of a snack or a meal 
if due (Walden et al., 2013).  Adherence to treatment guidelines is often poor 
with only 35-40% of people adhering to these treatment recommendations 
(Sommerfield et al., 2003, Banck-Petersen et al., 2007).  Correct initial 
treatment of hypoglycaemia (i.e. ingestion of an appropriate amount of fast 
acting carbohydrate) was only reported by 50% with 37% over-treating and 
13% under-treating; women had better compliance than men (Banck-Petersen 
et al., 2007). 
5.11 Evidence for oral treatment options 
There is limited evidence regarding the quantity of quick-acting carbohydrate 
required to successfully treat an episode of hypoglycaemia.  The initial 
quantities chosen were the result of expert consensus subsequently backed up 
with glucose clamp studies (Brodows et al., 1984, Slama et al., 1990).  
Vindedzis et al (2012) compared 15g versus 20g and found that 32-63% of 
episodes resolved after one treatment with 15g carbohydrate compared with 
55-89% of episodes with 20g carbohydrate (Vindedzis et al., 2012).  Larsen et 
al (2006) used continuous glucose monitoring (CGM) to monitor 125 adults 
with T1DM over 6 days; they defined adequate treatment as ingesting 10-20g 
of quick-acting carbohydrate (Larsen et al., 2006).   They reported that 30% of 
hypoglycaemic episodes were under-treated and 38% were over-treated.  
Participants that were under-treated had a 57% chance of remaining 
hypoglycaemic at the repeat test, this compares with 30% for those adequately 
treated and 26% for those over treated.   This reinforces the suggestion that 
treatment of hypoglycaemia with less than 10g of quick-acting carbohydrate is 
likely to be inadequate. 
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Chocolate is no longer recommended for the treatment of hypoglycaemia.  
Chocolate contains quick-acting carbohydrate and fat, the addition of fat has 
been shown to slow the absorption of quick-acting carbohydrate (Cedermark et 
al., 1993, Shively et al., 1986).  Given a choice of a range of foods, people are 
more likely to choose high fat rather than high carbohydrate foods (e.g. 
muffins) after hypoglycaemia with a significant increase in caloric intake in 
comparison with placebo (Dewan et al., 2004).  Sugar or sucrose is also less 
commonly recommended as it takes longer to affect blood glucose levels than 
glucose (Georgakopoulos et al., 1990).  Orange juice (which contains fructose) 
remains a popular treatment for hypoglycaemia.   The results of two studies 
using a modified glucose clamp technique have suggested that orange juice 
may not be the most effective treatment in adults with T1DM; almost double 
the amount of orange juice was required to produce a similar increment 
compared with glucose tablets (Slama et al., 1990, Brodows et al., 1984).   The 
total sugar content of any fruit juice varies according to the ripeness of the 
fruit, the season it is picked and the addition of any sugar when packaged 
(Slama et al., 1990).   A more recent study showed that fructose (in the form of 
a fruit bar) was less effective than sucrose in successfully treating 
hypoglycaemia in children with T1DM.   The fibre in the bar may have slowed 
down the absorption of the fructose, reducing its efficacy as a treatment for 
hypoglycaemia (Husband et al., 2010).  By contrast, a recent “real-world” 
study of children with T1DM attending a diabetes camp found orange juice to 
be as effective as other treatments (McTavish and Wiltshire, 2011). 
Several studies have examined the time interval between treatment and re-
testing to confirm resolution of hypoglycaemia.  All are supportive of a 
minimum interval of at least 10 minutes before retesting to ensure resolution of 
hypoglycaemia (McTavish and Wiltshire, 2011).  Slama et al (1990) concluded 
that repeating carbohydrate intake every 5-10 minutes would not allow 
adequate time for the treatment to take effect thus leading to over treatment 
(Slama et al., 1990).   Vindedzis et al (2012) reported when hypoglycaemia 
was treated with 20g of carbohydrate that 55% were adequately treated after a 
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5 minute wait, compared with 89% after a 10 minute wait (Vindedzis et al., 
2012). 
5.12 Evidence for parenteral treatment options 
Intramuscular glucagon and intravenous dextrose in varying concentrations are 
the main treatment options.  A randomised trial of people attending the 
Emergency department with hypoglycaemia found glucagon almost as 
effective as intravenous dextrose with no difference in adverse events (e.g. 
vomiting) although recovery of blood glucose levels was slower with glucagon 
(Collier et al., 1987, Patrick et al., 1990).  Faster recovery of blood glucose 
levels using intravenous dextrose compared with intramuscular glucagon were 
shown in two subsequent studies into the pre-hospital treatment of 
hypoglycaemia (Howell and Guly, 1997, Carstens and Sprehn, 1998).  
Repeated administration of glucagon is not advised, only 1% of people 
responded to a second injection of glucagon who had not responded to the first 
injection (MacCuish et al., 1970).  Glucagon may be less effective in those 
people with depleted glycogen reserves such as those with impaired hepatic 
function (i.e. people with an excessive alcohol consumption).  In summary 
glucagon is effective and can be a useful treatment option, especially out with 
the hospital setting.  However, the slower recovery and higher treatment failure 
rate makes intravenous dextrose the preferred option. 
The increment in blood glucose after administration of 50% glucose varies 
widely between individuals with hypoglycaemia.  The mean increment in 
participants with diabetes was 9.8 mmol/L with a large standard deviation of 
4.4mmol/L (Adler, 1986).  There is a paucity of evidence comparing 10% or 
20% dextrose with 50% dextrose.  Moore and Wollard (2005) administered 5g 
aliquots of either 10% or 50% glucose at 1-minute intervals to people with 
hypoglycaemia until recovery of consciousness level had occurred.  
Participants were selected on the basis of confusion or impaired consciousness 
level sufficient to make treatment with oral carbohydrate inadvisable.  Using 
10% dextrose resulted in lower post treatment glucose levels (6.2 versus 9.4 
mmol/L) (Moore and Woollard, 2005).   
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The risk of extravasation injury with any hypertonic solution may make 10% 
dextrose safer than 50% dextrose (Wood, 2007).  Dextrose 10% preparations 
are considerably less hypertonic than the 50% preparation and therefore less 
destructive to the venous endothelium (Nolan, 2005).  A Japanese study using 
rabbit ears found that increasing the duration of infusion decreased the 
tolerance of peripheral veins to solutions of increased osmolality (Kuwahara et 
al., 1998).  Ten percent glucose has an osmolality of 506mOsm/L compared 
with 2522mOsm/L for 50% dextrose (Nehme and Cudini, 2009).  For these 
reasons 10% or 20% dextrose solutions are preferred (Walden et al., 2013). 
5.2 Behavioural strategies to reduce hypoglycaemia risk 
People with diabetes may utilise strategies such as eating extra snacks or 
avoiding exercise to avoid hypoglycaemia that while undoubtedly effective in 
the short term, are not ideal behaviours as part as a long term treatment strategy 
(Bohme et al., 2013).  A low GI snack following evening exercise (compared 
with an isocalorific high GI snack) has been shown to reduce the risk of early 
nocturnal hypoglycaemia but not late nocturnal hypoglycaemia (Campbell et 
al., 2014).   
In Germany an intensive insulin regimen combined with a structured teaching 
programme improved glycaemic control without causing a higher rate of severe 
hypoglycaemia; this involved a 5-day course of inpatient tuition that is not 
feasible in most countries (Muhlhauser et al., 1987).  Long-term follow up of 
over 9000 adults showed an improved HbA1c (7.3% vs. 8.1%) and a lower 
incidence of severe hypoglycaemia (Samann et al., 2005).  From this earlier 
work more focussed programmes evolved which concentrated on 
hypoglycaemia anticipation, awareness and treatment.  Blood glucose 
awareness training reduced both severe hypoglycaemia and fear of 
hypoglycaemia (Schachinger et al., 2005).  Use of a similar programme in 
people with a history of severe hypoglycaemia lowered the incidence of severe 
hypoglycaemia without compromising glycaemic control (Cox et al., 2004).   A 
different training programme for the recognition and management of 
hypoglycaemia demonstrated a reduction in mild hypoglycaemia with 
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improved hypoglycaemia awareness (assessed using the Clarke method) 
although in comparison to the control group, who received more generalised 
structured education, there was no reduction in severe hypoglycaemia 
(Hermanns et al., 2007).  Extended follow up at 31 months showed a 
significant reduction in severe hypoglycaemia (Hermanns et al., 2010).   
In the UK, more generalised structured education programmes such as DAFNE 
(Dose Adjustment for Normal Eating) may be beneficial in reducing 
hypoglycaemia.  Although no reduction in severe hypoglycaemia was reported 
by the original RCT, a later study showed that severe hypoglycaemia was 
reduced from 15 events per year to 6 per year in the 124 participants analysed 
(Keen et al., 2012, Dafne Study Group, 2002).  While effective, these 
programmes are resource and time intensive.   
Some of the less helpful behavioural modifications exhibited by people with 
IAH have been previously discussed in section 4.81.  A recent Norwegian 
study reported the expected association between longer duration of diabetes 
and lower intensity of autonomic symptoms.  The novel finding was that 
people with IAH experienced a lower intensity of autonomic but not 
neuroglycopenic symptoms (Olsen et al., 2014).  People with IAH may 
selectively pay greater attention to neuroglycopenic symptoms to herald the 
onset of hypoglycaemia, perhaps as a defence mechanism against their reduced 
autonomic symptom intensity.   
5.3 Alternative type or delivery of insulin to reduce risk of 
hypoglycaemia 
Various strategies can be employed to reduce the incidence of nocturnal 
hypoglycaemia, including bedtime snacks and adjustment of insulin regimens.   
5.31  Human insulin 
The introduction of human insulin led to claims that human insulin diminished 
the symptomatic responses to hypoglycaemia although the methodology was 
subsequently criticised (Teuscher and Berger, 1987, Hepburn and Frier, 1989).  
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A systematic review of 52 randomised controlled trials (RCT) found no 
evidence that treatment with human insulin affected the frequency, severity or 
symptoms of hypoglycaemia (Airey et al., 2000).  A subsequent Cochrane 
review also concluded that there was no increased risk of hypoglycaemia with 
human insulin (Richter and Neises, 2005).   
5.32  Analogue insulin 
A comparison of human insulin with analogue insulin concluded that they 
result in the same counter-regulatory and symptomatic response to 
hypoglycaemia (Frier et al., 2000).  Insulin analogues have proved useful in 
limiting risk of nocturnal hypoglycaemia (Vardi et al., 2008). Direct 
comparisons between insulin analogues are limited.  The BEGIN study 
compared degludec with glargine and found no difference in overall rates of 
hypoglycaemia but a reduction in nocturnal hypoglycaemia (Heller et al., 
2012).  A meta-analysis of the phase 3 trials comparing degludec with glargine 
also found a reduction in nocturnal hypoglycaemia (Ratner et al., 2013). 
A Cochrane review of short acting insulin analogues compared with short 
acting human insulin found comparable rates of overall hypoglycaemia 
(Siebenhofer et al., 2009). 
5.33 Continuous subcutaneous insulin infusion 
Continuous subcutaneous insulin infusion (CSII or “insulin pump”) therapy 
aims to replicate more closely the normal physiology of insulin secretion 
compared with that achieved using multiple insulin injections (Pickup, 2012). 
A meta-analysis reported a significant reduction in severe hypoglycaemia 
compared with multiple daily injections (rate ratio 4.19, 95% confidence 
interval 2.86-6.13) (Pickup and Sutton, 2008).   A reduction in severe 
hypoglycaemia for CSII in comparison to basal bolus insulin regimen was also 
reported by the most recent Cochrane review (Misso et al., 2010).  Nocturnal 
CSII use has been shown to reduce the frequency of nocturnal hypoglycaemia 
compared to bedtime NPH insulin (Kanc et al., 1998). 
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According to the NICE guidelines one of the main criteria for CSII is that 
attempts to achieve target HbA1c levels (<8.5%) with multiple daily injections 
(i.e. basal bolus insulin regimen) have resulted in disabling hypoglycaemia.  
Disabling hypoglycaemia is defined as the repeated and unpredictable 
occurrence of hypoglycaemia that results in persistent anxiety about recurrence 
and is associated with a significant adverse effect on quality of life (NICE, 
2008).  
5.34 Islet transplant 
Islet cell transplant has been shown to improve adrenaline secretion and 
normalise glucagon secretion and hypoglycaemia symptom recognition during 
hypoglycaemia (Kendall et al., 1997).   
5.4 Blood glucose monitoring to reduce hypoglycaemia 
Cox et al (2007) developed an algorithm that analyses SMBG (self monitoring 
of blood glucose) data.  If five SMBG readings were available in the 24 hours 
before an episode the algorithm predicted 63% of episodes of severe 
hypoglycaemia for people with T1DM and 75% of episodes for people with 
T2DM; this fell to 58% in T1DM and 60% of T2DM if only 3 SMBG readings 
were available (Cox et al., 2007). 
Using predictive algorithms, CGM systems can provide warning of impending 
hypoglycaemia and have been shown to reduce nocturnal hypoglycaemia by 
84% in adolescents and adults (Buckingham et al., 2010, Dassau et al., 2010).   
The pros and cons of CGM are discussed in a recent review article, however a 
Cochrane review of continuous glucose monitoring (CGM) showed no 
difference in the risk of severe hypoglycaemia between CGM and intermittent 
self-monitoring of capillary glucose (Langendam et al., 2012, Hermanides et 
al., 2011).   A more recent retrospective audit of people with unawareness of 
hypoglycaemia who received CGM for at least 1 year showed a significant 
reduction in nocturnal hypoglycaemia (Choudhary et al., 2013).    
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The combination of an insulin pump (CSII) and CGM has long been suggested 
as a possible treatment option for people with T1DM.   Manual closed loop 
delivery has been shown to reduce nocturnal hypoglycaemia and more recently 
automated closed loop delivery has also been shown to reduce nocturnal 
hypoglycaemia (Hovorka et al., 2010, Phillip et al., 2013, Choudhary et al., 
2011).  An automated pump suspend feature stops the delivery of insulin when 
the linked CGM device detects blood glucose levels in the hypoglycaemic 
range.  Nocturnal hypoglycaemia is more likely to be affected by this feature 
than daytime hypoglycaemia as low glucose suspend only stops basal infusion 
and cannot reverse the effects of a recent bolus such as that given preceding 
meals.   
CGM that utilises an automated low glucose suspend feature was compared 
with standard CGM in people with T1DM on CSII with no history of severe 
hypoglycaemia in the preceding 6 months (Figure 5.1) (Bergenstal et al., 
2013).  A reduced frequency of nocturnal hypoglycaemia was observed (31.8% 
reduction) while glycaemic control remained unchanged.  
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Figure 5.1: Percentage of nocturnal CGM readings <3.9mmol/L in people 
with and without a glucose suspend function on their insulin pumps 
(Bergenstal et al., 2013).  Reproduced with permission from New England 
Journal of Medicine, Copyright Massachusetts Medical Society. 
5.5 Adjunctive treatment to reduce the risk of hypoglycaemia 
Glucagon administration during times of impending hypoglycaemia in people 
with both CGM and CSII has been shown to reduce the frequency of 
hypoglycaemia (Castle et al., 2010).   
A number of medications have been shown to reduce hypoglycaemia such as 
terbutaline or caffeine (Cooperberg et al., 2008, Debrah et al., 1996, 
Richardson et al., 2005). Terbutaline has been shown to reduce the risk of 
nocturnal hypoglycaemia at the expense of morning hyperglycaemia (Raju et 
al., 2006).  Heller (2008) provides a fairly recent review of the various 
available treatments that have been considered (Heller, 2008). 
The realisation that the brain can utilise alternative fuels for cerebral 
metabolism, especially during hypoglycaemia has led to the idea that an 
infusion of one of these fuels might have a protective effect.  A lipid infusion 
containing soybean oil, egg phospholipid and glycerol resulted in reduced 
counter-regulatory hormonal response but had no effect on cognitive function 
(Evans et al., 1998).  
5.6 Chapter summary 
Oral glucose ingestion is the cornerstone of treatment of mild hypoglycaemia.  
Optimal treatment requires careful attention to the type and amount of 
carbohydrate consumed and some commonly used treatments are less effective 
than others (i.e. chocolate).  Rechecking blood glucose levels to ensure 
resolution of hypoglycaemia is also important along with due attention to 
identifying the cause and preventing a recurrence.  Parenteral treatments of 
hypoglycaemia are usually effective although care most be taken with 
hypertonic 50% glucose solutions. 
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Behavioural modification programmes can provide sustained reductions in the 
incidence of hypoglycaemia but are often resource and time intensive for both 
the patient and healthcare professionals.  Different insulin types and delivery 
devices have also shown some benefit and are likely to show further benefits 
with improved technology (i.e. CSII combined with CGM and low glucose 
suspend). 
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Chapter 6:  Acute hypoglycaemia and executive cognitive 
functioning in adults with and without diabetes 
6.1  Introduction 
The human brain is dependent on glucose as its energy source; acute hypoglycaemia 
results in neuroglycopenia with subsequent cognitive impairment.  Individuals with 
T1DM are exposed to an average of two episodes of self-treated hypoglycaemia per 
week (Pedersen-Bjergaard et al., 2004).  The effect of hypoglycaemia on cognitive 
function has been previously discussed in chapter 3 and the next paragraph provides 
a brief summary.   
In general, performance on complex cognitive tasks deteriorates when blood glucose 
declines below 3.0 mmol/L (Mitrakou et al., 1991, Maran et al., 1995).  Previous 
studies have demonstrated that, for complex tasks, accuracy is often preserved at the 
expense of speed (Warren and Frier, 2005).  The impairment of cognitive function is 
reversible, although full recovery requires between 20 to 75 minutes after the 
restoration of euglycaemia (Evans et al., 2000, Zammitt et al., 2008).  Acute 
hypoglycaemia has been shown to impair various cognitive domains including 
memory, attention, information processing, psychomotor function, and spatial ability 
(Sommerfield et al., 2003a, Warren et al., 2007, Wright et al., 2009, Geddes et al., 
2008).  However, the effect of hypoglycaemia on executive cognitive function, 
which is important for everyday functioning, has received little systematic study.   
Despite many attempts, executive function lacks an accepted universal definition.  
Executive function is an umbrella term that incorporates a number of complex, 
interdependent cognitive processes that allow an individual to plan, initiate, 
sequence, monitor and inhibit complex behaviour (American Psychiatric 
Association, 1994, Lezak et al., 2004, Goldstein and Naglieri, 2014). Executive 
functions have also been defined as mental functions associated with the ability to 
engage in purposeful, organised, self-regulated and goal-directed behaviour 
(McCloskey et al., 2008).  Phineas Gage, a railway foreman, was one of the most 
famous suffers of impaired executive function after he suffered an accident in 1848 
when an iron rod pierced his frontal lobe.  After a period of recovery his personality 
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was altered; he had become disinhibited with a loss of social inhibition (Harlow, 
1848, Ratiu et al., 2004).  
Executive function allows a person to organise thoughts, prioritise tasks, manage 
time efficiently and make decisions.  It is therefore vital for the performance of many 
everyday activities such as composing a shopping list.  In children with diabetes, 
inadequate executive functioning has been linked to poorer adherence to treatment 
(McNally et al., 2010, Bagner et al., 2007); a subsequent study reported only 
reported this association for boys and not for girls (Graziano et al., 2011).   
Executive functioning is demonstrated by a number of cognitive process that are 
moderately correlated with each other but clearly separable (Miyake et al., 2000).  
Response “inhibition” is a classic example that refers to the deliberate suppression of 
an automatic response.  Cognitive flexibility or “shifting” which requires the transfer 
of attention between different tasks or instruction sets and “updating” refers to a 
process by which incoming information is monitored for relevance to an active task 
(Rucker et al., 2012, Miyake et al., 2000).  Updating, inhibition, shifting and a fourth 
factor, word fluency have been identified using factor analysis as four sub-groups of 
executive function in studies of cognitive ageing (Fisk and Sharp, 2004).   
Executive function is not localised to one particular area of the brain (Miller, 1984), 
although evidence from neuroimaging studies suggests that the frontal lobes of the 
brain (and their connections to other regions) are closely associated with this 
cognitive domain (Elliott, 2003).  Frontal cortex lesions are known to result in poorer 
executive functioning (Goel and Grafman, 1995), although the relationship is 
complex as there is limited correlation between severity and location of frontal lobe 
lesions and functional outcome (Keifer and Tranel, 2013).   
Several studies have utilised various measures of executive function and shown areas 
of worse performance in people with T2DM compared to participants without 
diabetes (Lowe et al., 1994, Grodstein et al., 2001, Hewer et al., 2003), poorer 
glycaemic control was also associated with worse executive function (de Wet et al., 
2007).  People with T2DM scored lower in the inhibition measure with no 
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differences in the other cognitive domains compared to control subjects (Bottiroli et 
al., 2014). 
Many of the commonly used marker tests used during “clamp” studies examine some 
aspect of executive function and performance is impaired during hypoglycaemia in 
participants with T1DM (Draelos et al., 1995).  The present study examined the 
effects of acute hypoglycaemia on executive function in adult humans with and 
without T1DM, using a well-validated test battery (Delis et al., 2001, Homack et al., 
2005, Wechsler, 1981).  Performance was examined, in a counterbalanced design, 
under euglycaemic and hypoglycaemic conditions.  
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6.2  Research design and methods 
6.21 Participants 
Sixteen adults with T1DM and 16 adults without diabetes were studied.  Baseline 
demographics are shown in table 6.1 (see below).  The groups were matched for age 
and body mass index.  Participants with diabetes were recruited from the diabetes 
clinic at the Royal Infirmary of Edinburgh and had no history of macrovascular or 
microvascular disease.  Digital retinal screening was used to exclude diabetic eye 
disease, peripheral neuropathy was excluded using clinical examination and 
nephropathy was excluded by the absence of microalbuminuria.  Participants without 
diabetes were recruited by e-mail and paper advertisements within the local hospital 
and university.  None of the participants had a history of seizures, head injury, 
psychiatric disorder, or alcohol or drug abuse.  Participants were on no medication 
other than insulin or the oral contraceptive pill.  Other exclusion criteria included 
impaired awareness of hypoglycaemia (Gold et al., 1994), colour blindness, 
pregnancy, a co-existing systemic disease or malignancy.  
HbA1c was measured by high performance liquid chromatography (non-diabetic 
reference range 5.0-6.05% (31-43 mmol/mol); Bio-Rad Laboratories, Munich, 
Germany) and was Diabetes Control and Complications Trial-aligned.  All 
participants gave written consent before participating in the study, which had been 
approved by the local medical ethics advisory committee. 
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Table 6.1: Baseline demographic characteristics of participants 
 Participants 
without diabetes 
Participants with 
diabetes 
p value 
n 16 16 n/a 
Age (years) 29.0 (26.0-31.4) 29.9 (25.3-35.5) 0.83 (t-test) 
BMI (kg/m2) 24.2±2.9 25.5±2.6 0.22 (t-test) 
Male/female 7/9 10/6 0.48 (Fisher’s exact 
test) 
Duration of diabetes 
(years) 
n/a 9.2 (4.5-11.9) n/a 
HbA1c (% 
(mmol/mol)) 
n/a 7.7±0.9 (61±9.8) n/a 
CSII (insulin pump) n 
(%) 
n/a 3 (18.8%) n/a 
Data are median (interquartile range) and means ± SD unless otherwise indicated 
CSII = Continuous Subcutaneous Insulin Infusion 
 
6.22 Study procedure  
Experimental sessions were performed in the Wellcome Trust Clinical Research 
Facility at the Royal Infirmary of Edinburgh.  Participants attended for two 
experimental sessions at least two weeks apart.  Participants with T1DM were 
required to monitor their blood glucose frequently for the 48 hours preceding each 
experimental session, which was postponed if they had recorded a blood glucose 
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level <3.5mmol/L or had experienced symptoms suggestive of hypoglycaemia.  
Sessions commenced at 08:00h and all participants fasted overnight.  Participants 
with T1DM omitted their morning fast-acting insulin or switched off their insulin 
pump.   
During each session a modified hyperinsulinaemic glucose clamp was performed 
(DeFronzo et al., 1979).  To arterialise any blood samples, the non-dominant arm 
was wrapped in a warmed blanket with a retrograde intravenous cannula inserted into 
the forearm (Gallen and Macdonald, 1990).   By raising the temperature of the 
sampling vein, “arterialised” blood samples were obtained for analysis of blood 
glucose concentrations.  Even under hypoglycaemic conditions the difference in 
glucose concentrations between arterialised and arterial blood is clinically 
insignificant (0.1 mmol/L) (Liu et al., 1992).  Arterialised venous blood has therefore 
been shown to be satisfactory surrogate of arterial glucose estimation (Wahab et al., 
1992).   
An additional cannula was inserted into the non-dominant antecubital fossa to infuse 
insulin (Human Actrapid, Novo Nordisk Pharmaceuticals, Crawley, UK) and 20% 
dextrose.  Both intravenous cannulae had to be sited in the non-dominant arm of the 
participant to leave their dominant arm free to perform the various cognitive tasks.  
To minimise the possibility of cross contamination the infusion cannula was placed 
in the antecubital fossa with the anterograde cannula used for sampling sited 
upstream in the dorsum of the hand. 
Insulin was infused at a constant rate of 1.5mUnit/kg/min using a Gemini PCI pump 
(Alaris Medical Systems, San Diego, California).  Blood samples were taken at 5-
minute intervals and analysed using a glucose oxidase method (2300 Stat, YSI, 
Yellow Springs, OH).  The YSI blood glucose analyser is used by many clinical 
laboratories and avoids the problems of inaccuracy using handheld measurements of 
capillary blood glucose, particularly when sampling blood glucose concentrations 
<4mmol/L (Graveling, 2010).  The dextrose infusion rate was adjusted based on the 
prevailing blood glucose concentration to maintain the arterialised blood glucose 
concentration within the target range.   
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Two experimental conditions (hypoglycaemia and euglycaemia) were studied in a 
single blind, random counterbalanced order.   Figure 6.1 shows the order of each 
experimental session.  Initially arterialised blood glucose was maintained at 4.5 
mmol/L for 30 minutes, it was then either maintained at 4.5 mmol/L throughout (the 
euglycaemia condition), or lowered over 20 minutes to 2.5 mmol/L (the 
hypoglycaemia condition).  The experimental condition lasted for 60 minutes, after 
which euglycaemia was restored.  Participants consumed a meal on completion of the 
study.  
 
Figure 6.1: Experimental session outline 
6.23 Hypoglycaemia scores 
Participants scored their symptoms at baseline and during the experimental period 
using a subjective, validated questionnaire, the Edinburgh Hypoglycaemia Symptom 
Scale.  This measures the intensity of commonly experienced hypoglycaemic 
symptoms graded on a 7 point Likert scale (1 = not present, 7= very intense); these 
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symptoms have been grouped previously into autonomic, neuroglycopenic and 
malaise sub-groupings (Deary et al., 1993, Likert, 1932, Carifio and Perla, 2007).  
Mean scores are not significantly affected whether using 5 or 7 data points are used 
although the mean score is slightly higher with 10 point scales (Dawes, 2008).   
6.24 Baseline intelligence and educational achievement 
The National Adult Reading Test (NART) tests the pronunciation of 50 
phonologically irregular English words and is widely used as an estimate of peak 
intellectual ability (Deary et al., 2004, Crawford et al., 2001).  Educational 
achievement was determined by whether a participant had secondary school, degree 
or doctoral level qualifications. 
6.25 Cognitive function tests 
Tests of executive function were performed during both experimental conditions.  
All tests were from the Delis-Kaplan Executive Function (D-KEFS) test suite and are 
described below.  The D-KEFS is a well validated series of tests which 
comprehensively assess the domain of executive functions and is suitable for adults 
with a range of ability levels (Delis et al., 2001, Homack et al., 2005, Delis et al., 
2004, Goldstein and Naglieri, 2014).  The D-KEFS increases processing demands by 
using more complex versions of common cognitive tests (i.e. using a trail making B 
test which covers two pages of A4 rather than one) to avoid a ceiling effect 
encountered by previous studies examining different aspects of cognitive function 
(Swanson, 2005).  
Practice effect was controlled for by counterbalancing the order of the experimental 
conditions (euglycaemia before hypoglycaemia and vice versa) and counterbalancing 
the parallel forms of the tests (battery A before battery B and vice versa) using a 
Latin Square (Davidson et al., 2003).  This study design was chosen to minimize 
many of the previous criticisms of cognitive function testing during hypoglycaemia 
(Heller and Macdonald, 1996).  Order effects were sought, although from prior 
experience in cognitive testing in hypoglycaemic clamp studies, none are usually 
found.  
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The Digit Symbol Substitution Test (DSST) (from the Wechsler Adult Intelligence 
Scale III-UK) and Trail Making B (from the Delis-Kaplan Executive Function 
System) tests were used as ‘marker’ cognitive tests that are reliably affected by 
moderate hypoglycaemia (Wechsler, 1981, Reitan, 1958).  The DSST is a test of 
coding performed at speed, and for each mistake five points were subtracted from the 
score achieved to give an overall score.  Trail Making B, also a test of executive 
function, tests a wide range of cognitive processes including complex attention, 
visual scanning, psychomotor speed and mental flexibility (Salthouse, 2011).  The 
test is a modification of the classic test originally developed by Partington (Brown 
and Partington, 1942) and requires the participant to switch back and forth between 
connecting numbers and letters in sequence (e.g. 1-A-2-B-3-C); it covers two pages 
which increases spatial scanning demands.  Time taken (in seconds) was subtracted 
from 200; for each mistake five additional points were subtracted to give a total 
score. 
6.26 Executive function tests 
Verbal fluency (category switching):  This test requires both rapid retrieval from 
semantic knowledge and cognitive flexibility to allow switching between categories.  
Participants were required to generate words, alternating between two different 
semantic categories (e.g. fruit and furniture).  The outcome variable was the total 
score with one point awarded for each correct pair named during the time limit. 
Sorting test:  Based on the Wisconsin Card Sorting Test (Berg, 1948), this test is 
designed for isolating and measuring multiple components of concept-formation and 
problem-solving abilities.  Each participant was shown two groups of three cards 
each and was then required to state how the two groups were sorted (e.g. one card set 
shows singular words and the other displays plural words).  Outcome variables were 
the total score, with four points awarded for each correct description, and time taken.      
Twenty questions test:  The participant is presented with a stimulus page depicting 
pictures of 30 common objects (e.g. banana, airplane or bowl).  The participant must 
ask the fewest number of yes/no questions possible in order to identify the unknown 
target object.  The ideal response would eliminate half of the remaining objects.  This 
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test assesses the participant’s ability to perceive the various subcategories (e.g. land-
based objects and those that fly).  By incorporating feedback from previous answers, 
participants can formulate a yes/no question to eliminate the maximum number of 
objects.  One point was awarded for each correctly phrased question with a lower 
score denoting better performance.  Participants performed this test twice, outcome 
variables included combined score and total time taken.  Analysis of the quality of 
responses was then made in a quantitative manner to give the third outcome variable.  
Subjects scored five points for an answer which eliminated half of the remaining 
objects, four points for a response that eliminated ± 1 of half the remaining objects, 
three points for ±2, two points for ±3, 1 point for ±4 and 0 points for ±5.  So if there 
were 8 remaining objects and a response eliminated 3 objects then that question 
would score 4 points for that response.  This score was then divided by the number of 
questions taken to determine the correct object; this gave the third outcome variable.   
Tower test:  Edouard Lucas is credited with devising the “Tower of Hanoi” in 1883.  
The tower test is derived from this and assesses several key executive functions 
including spatial planning and maintaining an instructional set (Goel and Grafman, 
1995).  Participants must build the designated tower in the fewest number of moves 
possible by moving differently sized disks across three pegs.  Four towers of 
increasing difficulty were constructed during each experimental session; to avoid a 
practice effect a parallel version of equivalent difficulty was created by shifting each 
piece to the right.  One point was awarded for each move taken; therefore a lower 
score denoted better performance.  Outcome variables were the combined score for 
all four towers and the total time taken.     
Colour-Word Interference Test (Stroop):  Based on the classic Stroop procedure, 
these four tests assess the participant’s ability to inhibit an overlearned verbal 
response (i.e. name the ink colour of the word instead of reading the printed word) 
(Stroop, 1935).  The first two (baseline) tasks require the participant to name blocks 
of colour (Stroop 1) and read colour words printed in black ink (Stroop 2).  The third 
task prints colour words in a different colour (Stroop 3), e.g. the word “red” printed 
in blue ink (inhibiting).  The fourth task involves asking the participant to switch 
back and forth between naming ink colours and inhibiting (Stroop 4), this tests both 
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inhibition and cognitive flexibility.  Time required for completion became the score 
for that task; four seconds were added for an uncorrected error and two seconds for a 
corrected error.  Five combined task scores were calculated (Table 6.2).   
Stroop A is the sum of all four tasks and Stroop B is the sum of the first two tasks and 
an indication of performance in key lower level skills (i.e. reading and naming).  
Stroop C and Stroop D demonstrate any effect on executive functioning while 
attenuating the impact of any deficit in more basic cognitive functioning (i.e. reading 
printed words).  The “Stroop Interference Effect” (Stroop C) indicates the increase in 
time taken to perform the task requiring an inhibited response compared with simply 
reading or naming the ink colour (Van der Elst et al., 2006).  Stroop E demonstrates 
the additional time required to switch between tasks (cognitive flexibility) while 
attenuating the effect of inhibition.  Many of the Stroop tests rely on colour 
discrimination, this has been shown previously to be unaffected by moderate 
hypoglycaemia although may become impaired with more profound hypoglycaemia 
(Hardy et al., 1995, Harrad et al., 1985).   
6.27 Statistical Analysis 
A general linear model (repeated measures ANOVA) was used.  Glycaemic 
condition (euglycaemia or hypoglycaemia) was the within-participant factor 
(repeated measure).  Order of session (euglycaemia followed by hypoglycaemia or 
vice-versa), order of test battery (test battery A followed by battery B or vice versa) 
and diabetes status (participants with or without diabetes) were between-participants’ 
factors with the NART score as a covariate.  Effect sizes were calculated using 
Cohen’s d to assess the extent of any cognitive decrement caused by hypoglycaemia 
(d=0.2 small, d=0.5 medium, d=0.8 large) (Cohen, 1988).  All analyses were 
performed using Microsoft Excel 2010 (Redmond, Washington, USA) and SPSS 
version 18.0 (SPSS, Chicago, USA) both for Windows.  Unless otherwise stated, 
data are expressed as mean±SD and p<0.05 was considered to be significant.
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6.3  Results 
6.31  Blood glucose   
Target blood glucose levels were achieved for both the hypoglycaemic (2.45±0.11 
mmol/L) and euglycaemic (4.54±0.09 mmol/L) conditions; glucose levels were 
similar in participants with or without diabetes (p=0.23 and p=0.11 respectively, t-
test). 
6.32  Symptom scores   
Autonomic symptom scores increased from 10.6±4.1 during euglycaemia to 22.6±9.3 
during hypoglycaemia (p<0.001, Cohen’s d 1.68).  Neuroglycopenic symptom scores 
increased from 10.8±5.5 to 19.6±8.7 (p<0.001, Cohen’s d 1.22).  Malaise symptom 
scores increased from 2.5±1.3 to 3.4±1.8 (p=0.004, Cohen’s d 0.63).   
6.33 Educational achievement and baseline intelligence 
Nine (56.3%) healthy volunteers had doctorate level qualifications compared with 
four (25.0%) participants with diabetes (p=0.20, Pearson Chi Square).  Mean NART 
scores were significantly lower in participants with diabetes than those without 
(36.3±3.8 and 40.5±5.4 respectively, p<0.02, t-test).  As expected, National Adult 
Reading Test (NART) scores (taken at baseline) did not differ significantly between 
the two experimental sessions (p=0.18, t-test).   
6.34 General cognitive function tests 
Performance during hypoglycaemia was significantly impaired in both the trail 
making and DSST (see Figure 6.2) (p<0.001 for both, Cohen’s d 1.16 for trail 
making and 0.84 for DSST).  No significant difference on these tests was observed 
between people with, and without, diabetes (trail making p=0.67 and DSST p=0.11).   
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Figure 6.2: General (“marker”) cognitive test scores 
6.35 Executive function tests 
No significant effects were found for order of session (hypoglycaemia followed by 
euglycaemia or vice versa).  The only significant effects for diabetes status were for 
the Stroop A (p<0.05), Stroop B (p<0.05) and verbal fluency (p<0.03) tasks; 
performance during both euglycaemia and hypoglycaemia of participants with 
diabetes was worse than those without diabetes.  
 Performance during hypoglycaemia was significantly impaired on every measure of 
executive function examined other than Stroop E, both in terms of scores achieved 
and time taken (Tables 6.2 & 6.3).  Hypoglycaemia significantly prolonged the time 
to completion in all of the tests where time was not fixed.  The high Cohen’s d values 
(>0.8) indicate that hypoglycaemia induced decrements with large effect sizes (see 
table 6.2 & 6.3 for Cohen’s d values).   
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Table 6.2: Stroop test results* 
Name Calculation 
(see below  
for 
description of 
Stroop 1 to 4) 
Euglycae
mia time 
(seconds) 
Hypoglyca
emia time 
(seconds) 
Eu- vs. hypo-
glycaemia 
Diabetes 
status 
(Diabetes 
versus non-
diabetes) (p 
value) 
p 
value 
Cohen
’s d 
Stroop 
A 
All 4 scores 
combined 
148.4±29.
9 
198.1±47.8 <0.00
1 
1.25 0.047 
Stroop 
B 
Mean of 
Stroop 1 & 2 
24.0±4.1 31.8±7.3 <0.00
1 
1.32 0.045 
Stroop 
C 
Stroop 3 – 
Stroop B 
22.0±9.7 29.3±14.3 0.003 0.60 0.66 
Stroop 
D 
Stroop 4 – 
Stroop B 
31.8±11.5 42.8±19.2 <0.00
1 
0.69 0.09 
Stroop 
E 
Stroop 4 – 
Stroop 3 
9.8±10.0 13.5±19.8 0.22 0.24 0.18 
Data are mean±SD. Significance level was p<0.05; Cohen’s d was calculated as an 
estimate of effect size. 
Stroop 1: naming blocks of colour; Stroop 2: reading words; Stroop 3: naming ink 
colour of words (e.g. “blue” printed in red ink); Stroop 4: alternating between 
naming ink colour of words and reading the printed word. 
*Stroop is scored using seconds to complete, a lowers score denotes better 
performance 
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Table 6.3: Executive function test scores and times 
Ex
ec
ut
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e 
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nc
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n 
te
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ae
m
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 sc
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e 
H
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ly
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em
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 sc
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e 
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- 
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. 
hy
po
-
gl
yc
ae
m
ia
* 
Eu
gl
yc
ae
m
ia
 ti
m
e 
(s
ec
on
ds
) 
H
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og
ly
ca
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ia
 ti
m
e 
(s
ec
on
ds
) 
Eu
- 
vs
. 
hy
po
-
gl
yc
ae
m
ia
 
p 
va
lu
e 
C
oh
en
’s
 d
 
p 
va
lu
e 
C
oh
en
’s
 d
 
Verbal 
fluency 
8.
7±
2.
0 
6.
3±
2.
0 
<0
.0
01
 
1.
21
 
Ti
m
e 
ta
ke
n 
is
 a
 
co
ns
ta
nt
 
Sorting test 
24
.4
±4
.7
 
19
.5
±4
.9
 
<0
.0
01
 
1.
02
 
19
9.
9±
5
1.
5 
26
2.
0±
8
9.
4 
<0
.0
01
 
0.
85
 
Twenty 
questions** 
11
.8
±2
.5
 
13
.8
±3
.8
 
0.
00
1 
0.
62
 
66
.2
±3
1.
0 11
3.
1±
6
3.
2 
<0
.0
01
 
0.
94
 
Tower Test 
(combined)
** 
94
.1
±1
8.
0 
11
4.
6±
23
.8
 
<0
.0
01
 
0.
97
 
27
7.
3±
95
.9
 
35
1.
9±
84
.5
 
<0
.0
01
 
-0
.8
3 
Data are mean±SD. Significance level was p<0.05; Cohen’s d was calculated as an 
estimate of effect size. 
*main effect of glycaemic condition 
**lower score indicates better performance 
 
The lower performance scores achieved during hypoglycaemia in the Stroop test 
were not simply because of slower information processing, participants made a 
significantly greater number of errors during hypoglycaemia compared with 
euglycaemia with significant increases in both self-corrected and uncorrected errors 
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(Table 6.4).  Participants with diabetes made significantly more uncorrected errors 
during Stroop A than participants without diabetes. 
Table 6.4: Stroop A (combined) error rates 
 Euglycaemia Hypoglycaemia Eu- vs hypo-
glycaemia (p 
value) 
Diabetes status 
(Diabetes versus non-
diabetes) (p value) 
Self-
corrected 
1.5±1.41 3.87±2.58 p<0.001 p=0.88 
Uncorrected 0.41±0.84 1.94±2.46 p<0.001 p<0.04 
Total 1.91±1.96 5.81±3.93 p<0.001 p=0.24 
Data are mean±SD. Significance level was p<0.05. Unpaired t test 
 
In the twenty questions test, responses given during hypoglycaemia are often of a 
poorer quality, e.g. asking very specific questions that would only eliminate one or 
two of the remaining objects (i.e. does it fly? is it a bowl? is it orange?).  Food words 
are remembered at a slower rate during hypoglycaemia than non-food words (Brody 
et al., 2004).  Analysis of the quality of responses showed that scores during 
hypoglycaemia were significantly lower than during euglycaemia (see methods for 
scoring system) (5.11±1.40 and 6.24±1.48 respectively, p=0.003, unpaired t test). 
Significant glycaemic condition by diabetes status interactions were observed for 
Stroop A, Stroop B and the sorting test (time taken) (p=0.02, p=0.002 and p=0.004 
respectively).  This suggests that in these tests, the effects of hypoglycaemia differ 
significantly between participants with, and without, diabetes.  Participants with 
diabetes were affected by hypoglycaemia to a greater degree than those without 
diabetes (Figures 6.3 & 6.4).  When the NART scores are entered as a covariate, 
participants with diabetes continued to experience a greater detrimental effect of 
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hypoglycaemia than those without diabetes in the sorting test (p=0.02) and Stroop B 
(p=0.01), but not for Stroop A (p=0.12).   
 
Figure 6.3: Time taken to complete the sorting test (mean(SE)) during 
hypoglycaemia and euglycaemia according to diabetes status; a lower score denotes 
better performance.  Diabetes: participants with diabetes; ND: participants without 
diabetes. 
Chapter 6 
 264 
 
 
Figure 6.4: Comparison of performance (mean(SE)) during Stroop A & B during 
hypoglycaemia and euglycaemia according to diabetes status; a lower score denotes 
better performance. Diabetes: participants with diabetes; ND: participants without 
diabetes.  
Significant glycaemic condition by diabetes status interactions were observed for 
uncorrected errors for Stroop A suggesting that the effects of hypoglycaemia differ 
significantly between participants with, and without, diabetes, Participants with 
diabetes were affected by hypoglycaemia to a greater degree than those with diabetes 
and made more self-corrected errors (Figure 6.5).   
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Figure 6.5: Number of self-corrected errors during Stroop A (mean(SE)) during 
hypoglycaemia and euglycaemia according to diabetes status.  Diabetes: 
participants with diabetes; ND: participants without diabetes 
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6.4  Discussion 
The present study has demonstrated that acute hypoglycaemia markedly impairs 
performance in almost all the aspects of executive function tested in adults with, and 
without, T1DM.  All domains of executive function were significantly impaired 
except for Stroop E.  Where the time taken was a variable rather than a constant, the 
completion time was significantly longer.  The generally large Cohen’s d values 
(>0.8) indicate that hypoglycaemia accounted for a large part of the variation in 
results.    
It is debatable as to whether the decrement in processing speed is solely responsible 
for the observed impairment in executive function (Albinet et al., 2012).  However, 
the present study has demonstrated more specific decrements; the quality of the 
responses was poorer during hypoglycaemia.  In the twenty questions test subjects 
more likely to ask closed questions (i.e. does it have rotor blades?), that would only 
eliminate a small number of the remaining objects.  This trait has been previously 
noted in people with frontal lobe lesions compared with matched controls with the 
latter asking more open-ended questions (Baldo et al., 2004).  In the Stroop test the 
number of errors, both uncorrected and self-corrected, were greater during 
hypoglycaemia.  This suggests that during hypoglycaemia, subjects were less aware 
of an error being made and so were less likely to correct the error; this has been 
shown previously in driving simulator studies in which participants were less likely 
to correct any driving errors when hypoglycaemic (Cox et al., 2000).   
During euglycaemia, glucose is the main source of energy for the brain.  Alternative 
substrates may be utilised during hypoglycaemia as energy sources, although in 
general they ameliorate, but do not reverse, the effects of neuroglycopenia (Beall et 
al., 2012).  Administration of some of these alternative fuels (e.g. amino acids or 
lactate) has been shown to reduce the decrement in cognitive performance observed 
during hypoglycaemia (Rossetti et al., 2008, Page et al., 2009).  In these studies 
insufficient information was given to determine whether there had been a significant 
improvement in the quality of the answers given. 
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Glycaemic targets were maintained and symptom scores incremented appropriately 
during hypoglycaemia.  The expected decrement in performance during 
hypoglycaemia in the cognitive ‘marker’ tests was consistent with the results of other 
similar studies (Geddes et al., 2008, Sommerfield et al., 2003a, Warren and Frier, 
2005).   Previous studies have shown that several domains of cognitive function are 
impaired during acute hypoglycaemia, including memory and spatial awareness 
(Sommerfield et al., 2003b, Wright et al., 2009).  Previous research also 
demonstrated that performance of complex cognitive tasks is preferentially impaired 
by hypoglycaemia, while simpler tasks such as finger tapping or reaction time are 
less affected (Warren and Frier, 2005, Geddes et al., 2008).   
The executive function tests that were used in the present study examined a series of 
diverse yet interdependent complex cognitive processes.  The category switching part 
of the verbal fluency test examined cognitive switching abilities similar to those 
examined by trail making B.  The sorting test examined concept-formation and 
problem solving abilities.  The twenty questions test assessed the ability to perceive 
sub-categories within the list of objects presented.  The tower test assessed spatial 
planning and the ability to maintain an instruction set.  All of these cognitive tests 
were impaired during hypoglycaemia.  Increasing age has been shown to reduce both 
generalised processing speed and specific executive functioning (Albinet et al., 2012, 
Troyer et al., 2006, Van der Elst et al., 2006).  The groups were well matched in 
terms of age.  While executive function might deteriorate over the age of 60 years, 
significant deterioration due to age would not be expected with the relatively young 
study cohort (mean age 29.9 years). 
The Stroop test uses a series of combined scores to give an indication of performance 
in both lower and higher level cognitive functioning (table 6.2); Stroop C, D & E can 
all be considered measures of executive function that aim to remove any contribution 
from a more basic processing deficit. Stroop C measures the classic interference 
effect and Stroop D measures interference and cognitive flexibility; both showed a 
moderate effect size.  Stroop E was the only executive function measured not 
affected by acute hypoglycaemia.  Stroop E represents the additional time taken to 
switch between tasks and is thus a measure of cognitive flexibility; it is noteworthy 
Chapter 6 
 268 
that other measures of cognitive flexibility such as verbal fluency and trail making B 
were impaired by hypoglycaemia.   
The cognitive processes affected will impinge on performance of everyday activities.  
Impaired ability to switch between semantic categories and retrieval from semantic 
knowledge would interfere with planning and make it difficult to construct a list of 
items suitable for a specific purpose (e.g. for a camping trip).  In such a scenario, 
impaired spatial planning and failure to maintain an instructional set would make 
loading a car or erecting a tent more difficult to undertake.   
Compared with their performance during euglycaemia, participants with diabetes 
experienced a greater detrimental effect of hypoglycaemia than those without 
diabetes in the sorting test (time taken), Stroop A (both in terms of scores achieved 
and number of uncorrected errors) and Stroop B.   Higher baseline intelligence is 
known to improve performance during the Stroop test; the effect of higher 
intelligence scores (in adults) on performance during the sorting test is less clear cut 
(Van der Elst et al., 2006, Arffa, 2007).  Whereas the groups with and without 
diabetes were otherwise well matched (table 6.1), the significantly lower NART 
scores (a measure of crystallised intelligence) that were documented in the 
participants with diabetes may have been a confounding factor.  However, when the 
NART scores are entered as a covariate, participants with diabetes continued to 
experience a greater detrimental effect of hypoglycaemia compared to those without 
diabetes in the sorting test (time taken) and for Stroop B, but not for Stroop A.  
Differential effects of hypoglycaemia between people with and without diabetes 
were found in a different cognitive domain, psychomotor function.  However, in that 
study, the detrimental effect of hypoglycaemia was greater in participants without 
diabetes (Geddes et al., 2008).  The mechanism underlying this differing effect of 
diabetes status of performance during hypoglycaemia is unknown.    
The euglycaemic and hypoglycaemic hyperinsulinaemic clamp is a well-established 
tool in clinical research providing a standardised environment with only one variable 
(i.e. blood glucose concentration) between the two experimental sessions (DeFronzo 
et al., 1979).   
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A possible weakness of the present study is that time constraints allowed each test of 
cognitive function to be performed only once during each experimental session.  
Tests to assess several cognitive domains take time to perform and it has been 
suggested that cognitive adaptation may occur when exposure to hypoglycaemia is 
relatively prolonged (Kerr et al., 1991, Kerr et al., 1989), although this premise has 
been disputed (Gold et al., 1995, Evans et al., 2000).  Gold et al reported no 
improvement in cognitive function after 40-60 minutes of hypoglycaemia and 
similarly Evans et al reported no cognitive adaptation after 90 minutes of 
hypoglycaemia.  Cerebral adaptation to hypoglycaemia, which results in a lesser 
magnitude of impairment of cognitive function, is a feature of people with type 1 
diabetes who have impaired awareness of hypoglycaemia (Zammitt et al., 2008); 
individuals with this acquired syndrome were excluded from the study.   
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6.5 Chapter summary 
The present study provides further evidence of a global impairment of most high-
level cognitive functions during hypoglycaemia.  Both speed of information 
processing and the quality of answers given were adversely affected by 
hypoglycaemia.  The executive functioning of people with diabetes was affected by 
hypoglycaemia to a greater extent than those without diabetes.  Executive function is 
essential for many activities (such as driving, analysing data or planning events); its 
disruption during hypoglycaemia will have a profound effect on the functioning of a 
person with diabetes.   
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Chapter 7:  Prevalence of impaired awareness of hypoglycaemia and 
identification of predictive symptoms in children and adolescents 
with type 1 diabetes 
7.1  Introduction 
Hypoglycaemia is the commonest side-effect of insulin therapy and interferes with 
everyday activities (Gonder-Frederick et al., 2009).  Cognitive impairment associated 
with hypoglycaemia may prevent a child from seeking help and so delaying 
treatment.  Severe hypoglycaemia is inversely associated with age (Wagner et al., 
2005) and glycaemic control (Davis et al., 1998), but is not strongly associated with 
duration of diabetes (Blasetti et al., 2011, Davis et al., 1997).  Continuous glucose 
monitoring (CGM) has suggested that nocturnal hypoglycaemia occurs 
approximately every third night and is associated with strict glycaemic control and 
younger age (Juvenile Diabetes Research Foundation Continuous Glucose 
Monitoring Study, 2010). 
In adults, recurrent hypoglycaemia increasingly impairs the normal defences against 
hypoglycaemia and diminishes the ability to detect hypoglycaemia.  The glycaemic 
threshold at which autonomic symptoms are triggered is re-set at a lower blood 
glucose level.  Cognitive dysfunction can then precede the onset of autonomic 
symptoms and interfere with the ability to initiate corrective action (Graveling and 
Frier, 2010).   
In adults, symptoms experienced during hypoglycaemia show substantial inter-
individual variation but broadly can be categorised into autonomic, neuroglycopenic 
and non-specific symptoms (Deary et al., 1993).   The blood glucose level at which 
these symptoms are generated is associated with inter- and intra-individual variation 
according to factors such as level of glycaemic control and exposure to antecedent 
hypoglycaemia (McAulay et al., 2001).  The symptoms of hypoglycaemia differ in 
children, particularly with respect to age and pubertal status (Ross et al., 2005).  
While autonomic symptoms cannot be distinguished from neuroglycopenic 
symptoms by neither children nor their parents, behavioural changes (e.g. becoming 
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naughty or irritable) often alert a parent or carer to the onset of hypoglycaemia (Ross 
et al., 1998, McCrimmon et al., 1995). 
Impaired awareness of hypoglycaemia (IAH) is a syndrome in which the ability to 
detect the onset of hypoglycaemia is diminished or absent and is discussed further in 
chapter 4 (Graveling and Frier, 2010).  Counter-regulatory hormonal failure is not 
the direct cause of IAH as avoidance of hypoglycaemia results in improved symptom 
perception without restoration of the normal counter-regulatory response (Dagogo-
Jack et al., 1994).  Nevertheless, the two are closely related, usually co-segregate and 
probably share a common pathogenesis (Ryder et al., 1990).    In adults, IAH carries 
up to a six-fold higher risk of severe hypoglycaemia (Gold et al., 1994, Geddes et al., 
2008).  
The prevalence of true IAH is uncertain in children.  The recognition of 
hypoglycaemia involves a complex interplay of psychological and physiological 
factors.  Some children may fail to interpret symptoms and react appropriately; this 
does not mean that they do not experience symptoms of hypoglycaemia.  The present 
study investigated the prevalence of IAH in children with T1DM using two methods 
of assessing awareness status that have good concordance in adults with T1DM 
(Geddes et al., 2007).  Secondary aims were to assess the frequency and 
symptomatology of hypoglycaemia in children and to determine which symptom 
group best predicts awareness of hypoglycaemia. 
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7.2  Methods 
7.21 Participants 
Children and adolescents attending paediatric diabetes clinics in the Lothian region 
of Scotland were recruited; the clinic population was approximately 340 and had a 
mean DCCT-aligned HbA1c of 71 mmol/mol (8.62%) in the year of survey.  
Inclusion criteria were T1DM of at least six months duration and measurement of 
blood glucose three or more times per day with no exclusion criteria.  Permission for 
the study was obtained from the Lothian ethics advisory committee. 
Each participant and one of their parents were asked to complete baseline 
questionnaires with a researcher present to answer any queries; the participant 
completed their questionnaire without assistance from their parent(s).  The questions 
were read out to the participants if the participants were unable to read it for 
themselves; the questions were not paraphrased.  The baseline questionnaire is 
reproduced in appendix one.  Recognising that the paediatric population often 
requires assistance to treat hypoglycaemia, severe hypoglycaemia was subdivided 
into events requiring third party assistance and those requiring hospital attendance.   
Awareness of hypoglycaemia was assessed using two validated questionnaire-based 
methods that have been compared in adults, designated the “Clarke” and “Gold” 
methods, after the first author of each paper (Clarke et al., 1995, Gold et al., 1994, 
Geddes et al., 2007).  The Clarke questionnaire uses eight questions to determine 
awareness status whereas the Gold questionnaire uses a simple 7-point Likert scale 
(1 = always aware of hypoglycaemia, 7 = never aware of hypoglycaemia).  Both 
methods result in a score between 1 and 7.  American terminology was modified 
where necessary to reflect British vocabulary.  Although not explicitly stated in the 
original papers the original validation of both the Gold and Clarke questionnaires 
gave 3 possible awareness outcomes: “aware” for a score of 1 or 2 and “impaired” 
for a score of 4 or more with participants who scored 3 placed in an undetermined or 
“intermediate” awareness category.  When submitted for publication, careful 
discussion based on comments received during the peer review process regarding 
reducing the number of awareness states led to the intermediate (score = 3) and 
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impaired awareness (score ≥4) groups being amalgamated.  With both methods a 
score is calculated; a score of 1 or 2 was classified as aware, a score of 3 or more 
classified as IAH.  
Typical clinical features observed by parents and experienced by children during 
hypoglycaemia were based on a previous study by our group (Ross et al., 1998); in a 
similar cohort of children and parents, good correlation existed between clinical 
features perceived by the children and observed by their parents.  Because parents 
cannot directly observe some of the possible symptoms (e.g. headache) they were 
encouraged to use their own observations and determine which symptoms were 
present in conversation with their children.  Although pallor is a sign, all clinical 
features in this present paper are referred to as “symptoms” to maintain consistency 
with previous literature (Ross et al., 1998, McCrimmon et al., 1995).  Symptom 
intensity was estimated using a 7-point Likert scale (1=symptom not present, 7=very 
intense) (Likert, 1932).   
Based on the first few responses of the child to the baseline questionnaire, it was left 
to the discretion of the parent and the researcher as to whether the participant was 
likely to understand the remaining questions.  If it was evident that they did not 
understand the questions, then only the parental questionnaire was completed.  
Participants were asked to record blood glucose at least three times per day, for four 
weeks.  For any blood glucose readings <4 mmol/L, both the parent and participant 
were asked to complete hypoglycaemia questionnaires prospectively, to document 
blood glucose, hypoglycaemia recognition (self, third party or meter), assistance 
required (self-treated, third party or hospital attendance) and symptoms experienced 
(using a 7-point Likert scale).  This biochemical level was chosen to determine 
potential hypoglycaemic events because 4.0 mmol/L is the alert level for avoidance 
of hypoglycaemia recommended by Diabetes UK, the principal diabetes charity in 
the UK.  The hypoglycaemia questionnaires for both children and their parents form 
appendix two. 
Retrospective review of case records and growth charts were used to determine 
whether peak height velocity (PHV) or menarche had been achieved.  Male 
participants were classified as pre-pubertal if they were <10.5 years old when 
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surveyed and those aged ≥10.5 years who had not reached PHV within 6 months of 
survey were considered to be of uncertain pubertal status.  Male participants were 
considered pubertal if PHV was achieved within six months of survey.  Female 
participants were classified as being pre-pubertal if they were <9.5 years old and 
those aged ≥9.5 years who had not achieved PHV were considered to be of uncertain 
pubertal status.  Female participants were considered pubertal if they had reached 
menarche or PHV.  
7.22 Specimen processing 
HbA1c was measured by ion exchange HPLC using a haemoglobin testing system 
(Bio-Rad Laboratories, Munich, Germany; non-diabetic reference range 31-43 
mmol/mol (5.0-6.05%); results were DCCT-aligned. 
7.23 Statistical analysis 
Results were analysed using SPSS (version 18 for Windows, SPSS, Chicago, IL) and 
R, version 2.10 (R Development Core Team, 2010).  Categorical variables were 
analysed using Fisher’s exact test and continuous variables using an unpaired t-test.  
Spearman’s rank correlation was used to analyse reported symptoms and method of 
assessing awareness status.  Principal Components Analysis was used to examine 
how symptoms aggregate; the number of factors was determined using a scree plot.  
A loading of >0.3 was considered significant (a loading is the strength of a given 
variable’s relationship with the underlying factor and may take a value from -1.0 to 
+1.0).  Multinomial logistic regression models were used to predict which aggregate 
of symptoms best predicts awareness status.  Data are shown as median (range) or 
mean±SD, unless otherwise stated.  A p value <0.05 was considered to be significant.    
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7.3  Results  
7.31  Participant demographics 
The actual response rate to the invitation handed out by clinic staff is not known.  
The local clinic population of 340 would be expected to attend clinic 3 or 4 times per 
year.  An estimate of the response rate would be about 40%, perhaps 200-250 
children would have been invited to participate over the five-month period.  Ninety-
eight participants completed the baseline questionnaire; 57 completed blood glucose 
diaries prospectively and questionnaires about any episode of hypoglycaemia that 
had occurred over the subsequent four weeks.  The principal reason given for non-
completion was time constraint.  No significant baseline differences between 
completers and non-completers were found.  Approximately half of the participants 
(n=52, 52.5%) were taking a biphasic insulin in the morning followed by a short-
acting insulin before their evening meal and a basal (long-acting) insulin in the 
evening.    Most other participants (n=44, 44.4%) used a basal bolus insulin regimen 
and one used CSII with an insulin pump.   
7.32 Awareness status  
Satisfactory completion of the questionnaire by the child was deemed to have 
occurred if their awareness status according to the Clarke method could be 
determined.  Awareness status could be determined in 70 children (98.6%) aged nine 
or over but in only seven (25%) under the age of nine.  Table 7.1 shows baseline 
demographics by awareness status (Clarke method); both younger age and younger 
age at diagnosis were significant predictors of IAH.  No difference in awareness 
status was found between different insulin regimens (basal-bolus vs. biphasic, 
p=0.81, Fisher’s) or between those completing versus those not completing the 
period of blood glucose monitoring (p=0.14, Fisher’s).  
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Table 7.1: Baseline characteristics of study participants 
Awareness status (Clarke 
method) 
Aware Impaired 
Awareness of 
Hypoglycaemia 
p value 
n (% female) 76 (52.6%) 22 (45.5%) p=0.63 
Current age (years) 12.0 (10.5-13.3) 8.2 (5.7-10.5) p=0.0001 
Duration of diabetes (years) 4.1±3.2 3.2±2.0 p=0.24  
Age at diagnosis (years) 7.4 (4.1-10.1) 4.2 (2.7-6.7) p=0.012  
HbA1c at clinic 
(mmol/mol(%)) 
74±9 (8.9±1.0) 72±9 (8.7±1.0) p=0.46  
Family history of T1DM* (n 
(%)) 
8 (10.5%) 3 (13.6%) p=0.71  
Data are median (interquartile range) or mean ± SD unless otherwise indicated 
*parent or sibling with T1DM 
 
7.33 Clarke and Gold Methods compared  
Figure 7.1 displays a comparison of self-reported or parentally determined awareness 
status using both the Gold or Clarke methods.  Using the Clarke method, 22 (22.4%) 
parental responses indicated that IAH was present compared with 67 (68.4%) 
parental responses using the Gold method.  A significant association was observed 
between the parents’ and children’s responses when using the Clarke method 
(p=<0.001, rs=0.55, Spearman’s) but no positive correlation was found using the 
Gold method (p=0.28, rs=0.12, Spearman’s).  No linear correlation was found 
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between the two methods (p=0.14) with little or no positive correlation (p=0.14, 
rs=0.25, Spearman’s).   
Figure 7.1: Percentage classified as having impaired awareness of hypoglycaemia 
according to Clarke or Gold methods using parental or child responses (of those 
able to answer) 
Previous studies have demonstrated that young people with IAH have an increased 
risk of hypoglycaemia requiring medical attention (Ly et al., 2009).  While this was 
evident when participants were classified using the Clarke method (see below), it 
was not apparent when using the Gold method (Aware vs. IAH, p=1.00, Fisher’s).  
Similarly, no significant increase was observed in hypoglycaemia requiring third-
party assistance between those with normal awareness or IAH using the Gold method 
(p=0.08, Fisher’s).  Therefore the Gold method did not show any of the expected 
differences in baseline demographics between awareness states.   
The methods section (section 7.21) discusses the cut-off used to define impaired 
awareness of hypoglycaemia.  During the publication process (see Appendix 4 for 
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published manuscript) peer reviewers commented on the number of groups used to 
define awareness status and the cut off used.  If a cut-off of 4 or greater is used to 
define impaired awareness of hypoglycaemia then 9.2% (n=9) of participants had 
impaired awareness of hypoglycaemia using the Clarke method and 35.7% (n=35) 
had impaired awareness using the Gold method.  Table 7.2 shows the proportion of 
participants requiring 3rd party assistance or hospital admission using the revised cut-
off.  Using the Gold method table 7.2 illustrates that the proportion requiring 3rd 
party assistance or hospital attendance is very similar whether a participant is 
categorised as having normal or impaired awareness; this is at odds with the 
expectation that the impaired awareness group would have a greater risk of 
significant hypoglycaemia.  Using the Clarke method, despite the small numbers in 
the impaired group, the difference between the groups requiring 3rd party assistance 
remains significant (p=0.001, Fisher’s) but there is no significant difference between 
the groups in terms of requiring admission to hospital (p=0.23, Fisher’s). 
Table 7.2: Proportion of participants requiring 3rd party assistance or hospital 
admission according to awareness status (using score of ≥4 for both methods) 
 Required 3rd party 
assistance 
Required hospital 
admission due to 
hypoglycaemia in the 12 
months preceding the 
survey 
Normal awareness of 
hypoglycaemia using 
Clarke method n(%) 
29 (32.6%) 21 (23.6%) 
Impaired awareness of 
hypoglycaemia using 
Clarke method n(%)* 
9 (100%) 4 (44.4%) 
Normal awareness of 
hypoglycaemia using Gold 
24 (38.1%) 16 (25.4%) 
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method n(%) 
Impaired awareness of 
hypoglycaemia using Gold 
method n(%) 
14 (40.0%) 9 (25.7%) 
 
For the reasons outlined above, the Clarke method, assessed using parental 
responses, was considered a more effective and reliable predictor of awareness status 
in this paediatric cohort and so was used hereafter to categorise awareness status.   
7.34 Recognition and frequency of hypoglycaemia  
Participants completed a mean of 4.4 tests per day over the four week period with 
mean (±SD) blood glucose 9.7 mmol/L (±4.8) with no difference in testing frequency 
between awareness states (p=0.67, t-test).  Almost all participants (97%) experienced 
hypoglycaemia (defined as blood glucose <4.0mmol/L) while more than two thirds 
(70.2%) had experienced at least one blood glucose <3.0mmol/L.  Over the four 
week period the mean (±SD) number of blood glucose readings <4.0mmol/L and 
<3.0mmol/L were 10.2 (±7.3) and 2.3 (±2.6) respectively.  Table 7.3 shows the mean 
number of blood glucose readings per participant according to awareness status.  The 
number of blood glucose readings less than 3.0mmol/L, per participant, was not 
affected by insulin regimen (basal-bolus vs. any biphasic, p=0.70, t-test), awareness 
status (p=0.11, t-test), age (<10 years compared with >12.65 years, p=0.93, t-test), 
HbA1c <69mmol/mol (8.5%) compared with >78mmol/mol (9.3%), p=0.65, t-test) 
or duration of diabetes (<2 years compared with ≥5 years, p=0.18, t-test).   
Table 7.3: Frequency of hypoglycaemia according to awareness status 
Biochemical cut 
off (capillary 
blood glucose) 
Mean number of hypoglycaemic episodes over 4 week period 
per participant 
 Aware IAH t test 
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BG<4.0 mmol/L 11.0±6.9 8.9±7.9 p=0.72 
BG<3.5 mmol/L 6.7±5.6 4.0±3.5 p=0.34 
BG<3.0 mmol/L 2.7±2.9 1.44±1.1 p=0.11 
Data are mean ± SD 
 
During the period of prospective monitoring, hypoglycaemia questionnaires were 
completed for 490 of 583 (84.0%) episodes of hypoglycaemia recorded in the 
participants’ blood glucose diaries; three of these events required hospital admission.  
Hypoglycaemia was most frequently reported in the late afternoon with 31.8% 
(n=156) of events occurring between 15:00h and 18:59h, and was least commonly 
reported overnight with 9.2% (n=45) of episodes between 23:00h and 06:59h (Figure 
7.2).   
Figure 7.2: Number of hypoglycaemic episodes occurring according to time of day 
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Participants with normal awareness were more likely to recognise hypoglycaemia 
themselves, with 48.2% of hypoglycaemic events being recognised by children in the 
aware group compared with 37.5% in the IAH group (p<0.05, Fisher’s).  All parents 
(or another third party) were poor at recognising hypoglycaemia with 3.7% of 
parents recognising hypoglycaemia in the aware group compared with 6.3% in the 
IAH group (p=0.29, Fisher’s); the remaining episodes were incidental findings on 
routine biochemical testing (Figure 7.3). 
Figure 7.3: Source of recognition of each hypoglycaemic episode according to 
awareness status 
7.35 Hypoglycaemia requiring third-party assistance or hospitalisation   
Third-party assistance was more commonly required in those categorised as having 
IAH (Figure 7.4) and in younger participants (p=0.0001, t-test).  Increasing 
independence of children as they became older was demonstrated: 82% of the lower 
age tertile required assistance to treat hypoglycaemia in the preceding six months 
compared with 15% of the upper age tertile (p=0.0001, Fisher’s).   Hospital data 
were reviewed for each participant in the 12 months preceding clinic attendance.  
Seven participants (7.1%) required hospital treatment for hypoglycaemia-related 
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events in the 12 months before admission, one participant attended twice.  Two of 
these episodes were associated with seizure and six participants required in-patient 
admission.  A significantly greater proportion of participants with IAH required 
hospital treatment compared with those with normal awareness (Figure 7.4).  
Accurate retrospective parental recall of hypoglycaemia requiring hospital treatment 
was demonstrated with eight parents reporting hypoglycaemia requiring hospital 
attendance in the preceding 12 months; one parent falsely attributed the primary 
cause of the admission to hypoglycaemia. 
 
Figure 7.4: Proportion of participants requiring 3rd party assistance or hospital 
admission according to awareness status (p values given above, Fisher’s) 
7.36 Symptomatology of hypoglycaemia   
Symptoms listed in the hypoglycaemia questionnaires are reproduced in appendix 
two.  The most commonly reported symptoms by children were trembling (82.3%) 
and weakness (70.6%) (Figure 7.5).  Parents more commonly observed behavioural 
symptoms including irritability (66.7%) and aggressiveness (46.5%) (Figure 7.6); 
p<0.001 
p=0.006 
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pallor as a feature of hypoglycaemia was reported by just over half of the parents 
(51.5%).    
Certainly in adults, loss or diminution of symptoms is thought to be a fundamental 
part of the development of IAH.  Participants with IAH were more likely to report 
loss of symptoms with normal awareness when compared with those with IAH 
(31.8% versus 7.9% respectively, p=0.008, Fisher’s).  Diabetes duration or current 
age did not affect the likelihood of symptom loss (p=0.10 & p=0.19 respectively, t-
test).   
 
Figure 7.5:  Most frequently reported clinical features by children 
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Figure 7.6: Most frequently reported clincial features by parents 
Principal components analysis (PCA) was used to identify subgroups of symptoms.  
Two separate PCAs were performed; scree plots suggested that parentally reported 
symptom data could be adequately explained by four components and self-reported 
symptoms by three components.  The respective number of components was then 
extracted using PCA, followed by Varimax rotation with Kaiser Normalization.  
Using parental reporting the symptoms segregated into “autonomic”, 
“neuroglycopenic”, “behavioural” and “non-specific” rotate components and using 
self-reporting the symptoms segregated into “autonomic/neuroglycopenic”, 
“behavioural” and “non-specific”.  Once segregated into these components, the 
loading patterns were used to form symptom scores for each rotated component.   
Parentally reported symptom intensity scores were significantly lower in participants 
with IAH for autonomic symptoms (p=0.006, t-test) but not for neuroglycopenic or 
behavioural symptoms (p=0.09 and p=0.20 respectively, t-test).  
Multinomial logistic regression is a classification method used to predict the 
possibilities of the different possible outcomes of a categorically distributed variable, 
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given a set of independent variables.  Multinomial logistic regression models were 
fitted to data using the “mlogit” library of “R” (R Development Core Team, 2010).  
Parentally reported symptom subgroups (“behavioural”, “neuroglycopenic”, 
“autonomic” and “non-specific”) were compared as predictors of awareness using 
four models to predict the probability of a particular outcome (i.e. parentally reported 
awareness of hypoglycaemia), from the factor score in each of the four symptom 
classes.  Factor scores for each of the four symptom classes were conventionally 
derived from factor analysis by regression method.  Each model is a multinomial 
logistic regression model of a symptom subgroup in which the factor score is the 
predictor of a multinomial outcome consisting of two awareness states; aware and 
impaired.  Consequently each model estimated a slope coefficient representing 
change in relative risk of choosing aware over impaired for unit increase in the factor 
score.  The model-predicted probability of the particular outcome choice "aware" 
was obtained from the relative risks over a range of factor scores.   
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Figure 7.7: Probability of each symptom group predicting awareness status (Clarke 
method using parental responses) 
Figure 7.7 shows the model-predicted probability of choosing aware over impaired 
as a function of the factor score in each of the four symptom groups.  The best fitting 
model used behavioural symptoms as a predictor and was the only model to achieve 
significance (p<0.01), according to the chi-squared likelihood ratio test comparing 
the full model with an intercept-only model (Nagelkerke R-squared for the 
behavioural model was 0.18).  The behavioural group of symptoms was therefore the 
best predictor of awareness status.  The same procedure was then used to compare 
how the behavioural symptom group predicted hypoglycaemia awareness as 
determined by the Clarke and Gold methods, either self- or parentally-reported; the 
two that used the Clarke method were significant (p<0.05).  The use of behavioural 
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symptoms and the Clarke method, whether obtained from the parent or the child's 
observations, were better at predicting awareness status than the Gold method 
(Figure 7.8). 
 
Figure 7.8: Probability of predicting awareness status using behavioural symptoms 
using the different methods and assessors of hypoglycaemia awareness 
7.37 Effect of puberty on hypoglycaemic symptoms   
A greater proportion of female participants in the present study had reached puberty 
in comparison with male participants (62.8% vs. 47.9% of participants respectively).  
Participants of uncertain pubertal status were excluded from further analysis (n=9 
(9.1%) of whom 5 were male).  Total symptom scores increased significantly in 
participants that had reached puberty (pre-pubertal vs. pubertal or post-pubertal, 
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p<0.001 for both parental and self-reporting of symptoms, t-test).  Sweating and 
trembling showed the largest increments in symptom score (Figure 7.9).  
  
Figure 7.9: Change in intensity of symptoms scores (sweating and trembling) with 
pubertal status 
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7.4 Discussion 
In the present study, two questionnaires used in adults to assess hypoglycaemia 
awareness were applied to a paediatric cohort to evaluate their value in assessing 
awareness status in children and adolescents.  In contrast to observations in adults in 
which these two methods showed good concordance (Geddes et al., 2007), the results 
correlated poorly in children with T1DM (Figure 7.1).  When categorised using the 
Clarke questionnaire, participants with IAH had a significantly greater risk of 
requiring third-party assistance or hospital admission to treat hypoglycaemia, thus 
identifying an “at risk” subset of children that was not identified using the Gold 
method.  Children may have difficulty in comprehending the solitary wide-ranging 
question of the Gold method compared with the closed and specific questions of the 
Clarke method.  
7.41 Prevalence of IAH 
The prevalence of IAH obviously depends on the cut off chosen to represent 
impaired awareness.   Both the current study and the Ly et al study reduced the 
number of possible awareness states from 3 to 2 (Ly et al., 2009).  The Ly et al study 
amalgamated the normal awareness and intermediate awareness group and therefore 
a score ≥4 was taken to indicate impaired awareness rather than ≥3 used in the 
current study.  In children with T1DM of relatively short duration (mean 3.9 years), 
the present study indicated a prevalence of IAH of 22.4% (using the Clarke method 
with a cut off of ≥3) falling to 9.2% when using the Clarke method with a cut-off of 
≥4.  An Australian study (mean duration of diabetes 5.4 years, mean age 12.8 years) 
used the Clarke method and reported a slightly higher prevalence of 29%; in both 
studies, the participants with IAH were significantly younger.  In the Ly et al study 
the older age and longer duration of diabetes in participants may have affected the 
percentage of participants assessed as having IAH.  The development of IAH was 
attributed to progressive counter-regulatory hormonal failure, although no 
relationship was found between IAH and duration of diabetes.  As in the present 
study, IAH was associated with a higher frequency of severe hypoglycaemia (37.1 
vs. 19.3 episodes per 100 patient years) (Ly et al., 2009).   
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A Hungarian group used a single question to determine awareness status; the 36.9% 
of participants who were “sometimes” or “never” aware of hypoglycaemia were 
classified as having impaired awareness (Barkai et al., 1998).  The DirecNet study 
group claimed that Hypoglycaemia Associated Autonomic Failure (HAAF) was 
present in one third (Diabetes Research in Children Network Study et al., 2009).  
Limitations with the DirecNet study design make the results difficult to interpret; the 
mean blood glucose nadir in this cohort with good glycaemic control, may not have 
been sufficiently low to provoke a counter-regulatory response (Graveling et al., 
2010).  While counter-regulatory hormonal failure does co-segregate with IAH in 
adults with T1DM it is not the cause of IAH per se (Dagogo-Jack et al., 1994, Ryder 
et al., 1990).  Taken as a whole, the above studies would suggest that the prevalence 
of impaired awareness in children is 22-37%. 
7.42 Identification of hypoglycaemia 
Hypoglycaemia may be difficult to identify in a younger age group because of 
limited vocabulary and an inability to describe subjective sensations as specific 
symptoms.  In the Australian study only children between the ages of 10-12 years 
and their parents were both asked to complete the questionnaire; older children 
completed the questionnaire by themselves while the parents did this on behalf of the 
younger children (Ly et al., 2009).  The present study demonstrated that children 
aged 9 years or above can provide sufficient information to allow an accurate 
assessment of their awareness status and that their assessment closely matched that 
of their parents.   
All participants in the present study, but particularly those with IAH, were poor at 
self-identification of hypoglycaemia with most episodes being detected by an 
observer or by biochemical measurement.  This suggests that asymptomatic 
hypoglycaemia is common, and this has been confirmed using CGM (Juvenile 
Diabetes Research Foundation Continuous Glucose Monitoring Study, 2010, Amin et 
al., 2003).  Other studies have reported poor recognition of hypoglycaemia, with 
parents and children failing to detect hypoglycaemia in >50% and >40% of 
instances, respectively (Gonder-Frederick et al., 2008).  A much earlier study also 
noted that both parents and children were poor at estimating their blood glucose level 
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and recognising hypoglycaemia (Eastman et al., 1983).   A very recent study using 
CGM in children <7 years old found that only 32% of hypoglycaemic events were 
detected (Sundberg and Forsander, 2014).   
Parents were also poor at recognising hypoglycaemia in the current study (Figure 
7.3).  Factors that might impair a parent’s ability to recognise a hypoglycaemic 
episode in their child might include distraction, educational attainment and the level 
of independence of the child with regard to self-management of their diabetes.  
Parents’ retrospective recall of hypoglycaemia requiring hospital treatment was 
confirmed to be robust for up to 12 months. 
7.43 Frequency of hypoglycaemia 
Almost all participants experienced at least one episode of confirmed hypoglycaemia 
(blood glucose <4.0mmol/L) over a 4-week period with two thirds experiencing at 
least one blood glucose <3.0 mmol/L.  This compares with 52% experiencing at least 
one blood glucose ≤3.0mmol/L over three months in a Finnish study (Tupola and 
Rajantie, 1998).  The present study reported the lowest frequency of hypoglycaemia 
when children were asleep.  However, overnight blood glucose testing was not 
undertaken routinely and so only symptomatic episodes causing the participant to 
awaken were identified.  This would underestimate the frequency of nocturnal 
hypoglycaemia.  Catecholamine responses to hypoglycaemia are attenuated or absent 
during sleep and asymptomatic nocturnal hypoglycaemia is common (Juvenile 
Diabetes Research Foundation Continuous Glucose Monitoring Study, 2010, Jones et 
al., 1998).  
7.44 Symptoms experienced during hypoglycaemia 
Commonly experienced symptoms during hypoglycaemia in children have been 
documented previously, with strong agreement in terms of symptom intensity being 
demonstrated between children and their parents (McCrimmon et al., 1995, Ross et 
al., 1998).  Good concordance between parental and self-reported hypoglycaemia 
symptoms was noted in 40 pairs of children and parents with a similar age, disease 
duration and level of glycaemic control (Chiarelli et al., 1998).  In the present study 
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pallor was observed by 51.5% of parents, consistent with previous reports 
(McCrimmon et al., 1995).   
In a cohort of T1DM adults with a short duration of diabetes (mean 3.9 years), with 
the exception of glucagon deficiency, the prevalence of counter-regulatory hormonal 
deficiencies would be anticipated to be low (Cryer, 2012).  A small proportion of the 
present study cohort (n=11, 11.1%) had a clear diminution or absence of 
hypoglycaemia symptoms; hormonal responses were not measured so co-existing 
counter-regulatory failure cannot be excluded.  With increasing duration of diabetes 
and exposure to antecedent hypoglycaemia, some reduction in symptom intensity 
might be expected; this is apparent in adults with T1DM, where the prevalence of 
IAH rises progressively with duration of diabetes (Pramming et al., 1991, Olsen et 
al., 2014).   
Principal components analysis (PCA) was used to show the latent structure of 
hypoglycaemic symptoms.  As reported previously (McCrimmon et al., 1995), the 
children were unable to distinguish between autonomic and neuroglycopenic 
symptoms, resulting in three symptom subgroups (“behavioural”, 
“neuroglycopenic/autonomic” and “other”) in comparison to four subgroups with 
parental reporting.  In contrast, comparative factor analysis performed by a Canadian 
group segregated symptoms into 3 subgroups for both adults and children 
(“behavioural”, “neuroglycopenic/autonomic” and “other”) with no separation of 
neuroglycopenic and autonomic symptoms (Amin et al., 2014).  Tupola et al (1998) 
did not ascertain the full contribution of behavioural symptoms when assessing 
episodes of hypoglycaemia (Tupola and Rajantie, 1998).  Multinomial logistic 
regression showed that autonomic and behavioural symptom groups, whether 
experienced by the child or perceived by the parent, could be used to predict 
awareness status using the Clarke method (Figure 7.8).  In contrast with the adult 
population, behavioural symptoms were the most useful in predicting awareness 
status, which may suggest that a behavioural component may contribute to the 
development of IAH.  Behavioural symptom intensity was not significantly reduced 
in participants with IAH.   
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Parental involvement has been shown to increase frequency of SMBG and improve 
glycaemic control although a need to transfer responsibilities to the child is 
recognised (Anderson et al., 1997, Palmer et al., 2004).  Coping strategies would 
need to take into account the level of cognitive maturity of each child with T1DM; 
the quality of the parent-adolescent relationship is an important factor (Band and 
Weisz, 1990, Berg et al., 2011).  Social conflict between peers was shown in a 
review of qualitative studies to have an impact on glycaemic control with a beneficial 
effect noted with good relationships (Palladino and Helgeson, 2012, Pendley et al., 
2002). 
7.45 Impact of puberty on hypoglycaemic symptoms 
When the effect of puberty on hypoglycaemia symptomatology was examined 
previously in a small group of children and adolescents with T1DM, sweating was 
not observed during hypoglycaemia in pre-pubertal children (Ross et al., 1998).  
Maturation of sweat glands occurs during puberty, which may augment the sweating 
response.  In the present study symptom intensity increased significantly with 
puberty in all symptom categories, with scores for trembling and sweating showing 
the largest increments.  The generally higher symptom scores could be attributed to 
increased physical and emotional maturity.  The effect of ageing on symptom scores 
has been reported previously (Tupola and Rajantie, 1998), and with increasing 
independence and self-treatment, a parent would become less cognizant of the type 
and intensity of the symptoms experienced by their child.  
7.46 Study limitations 
The main limitations of the present study are the small sample size and completion 
rate of 58%.  Despite these limitations, many findings were highly significant and 
consistent with those reported previously.  Care was taken to obtain answers from 
children without the help of their parents although inevitably children did attempt to 
seek some guidance from their parents.  Parents were asked to let their children 
answer but non-verbal communication may have influenced some of the answers.  
Performing the interviews separately might have helped but may have been less 
acceptable to the participants and their parents.   
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The present study was pragmatic, so nocturnal blood glucose testing was not 
obligatory and CGM was not utilised as neither are part of routine clinical care.  The 
frequency of asymptomatic hypoglycaemia may therefore have been underestimated, 
particularly during sleep.  Continuous glucose monitoring technology may have been 
useful rather than self-monitoring of capillary blood glucose to provide a more 
complete picture of participants’ glycaemic profiles.  In particular it would have 
provided more information regarding asymptomatic episodes of hypoglycaemia 
particularly at night.  There are however issues with the performance of CGM in the 
hypoglycaemic range and sensor failure rates may have been higher in children not 
used to wearing the blood glucose sensors.  Real time CGM is also likely to affect 
the participant and their parent’s behaviour, for example being alerted to the 
occurrence of asymptomatic hypoglycaemia.  The CGM data would therefore ideally 
have been blinded rather than real-time. 
An Australian group conducting a similar study had reduced the number of 
awareness states from 3 to 2 previously.  In retrospect defining the impaired 
awareness group with a cut off of 4 or more would have allowed easier comparison 
with the Ly et al (2009) group.  Both studies can be criticised for having an 
unvalidated group (the “aware” group in the Ly et al study and the “impaired” group 
in the current study).  
In retrospect, pubertal assessment using a recognised staging method would have 
reduced the proportion of participants in whom pubertal status was uncertain (Tanner 
and Whitehouse, 1976).  This would have allowed more accurate assessment of the 
impact of puberty on hypoglycaemic symptom experienced and their intensity.  
Pubertal screening is not routinely performed as part of the usual clinic visit and so 
would have required additional examination.  The participants may have found this 
embarrassing and been less likely to take part in the study.  
From clinical practice we know that scrupulous avoidance of hypoglycaemia can 
restore hypoglycaemia awareness.  The assessment of impaired awareness was only 
done once, at baseline.  An assumption was made that the awareness state of the 
participant would not change over the four-week monitoring period.  This criticism 
could also be levelled at many other studies that fail to reassess awareness status over 
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much longer periods of study.  A repeat of the baseline questionnaire at the end of 
the study period could have been considered.   Longitudinal assessment of awareness 
status and how it changes with respect to age and pubertal status merits further 
research in the paediatric age group. 
 
 
Chapter 7 
 307 
7.5 Chapter Summary 
In summary, the recognition of hypoglycaemia by children with T1DM is a dynamic 
process.  Various factors, including the distraction of concurrent physical or mental 
activities can delay recognition of hypoglycaemia and corrective action.  The 
underlying pathophysiological mechanisms of IAH include a blunted sympatho-
adrenal response combined with altered cognitive and behavioural responses to 
hypoglycaemia.  Each factor is modulated by a variety of mechanisms and so may 
alter in importance with each child as they progress through adolescence into 
adulthood.  Increasing physical and mental maturation may result in improved ability 
to identify and appreciate the significance of early warning symptoms, allowing 
earlier corrective action to be taken.   
In contrast with the adult population, the ability to predict awareness status is 
strongest when behavioural symptoms are used.  Behavioural patterns are therefore 
particularly important in the recognition of hypoglycaemia in children and introduce 
the concept of a “voluntary” component to hypoglycaemia awareness.  Behavioural 
modification techniques could be used to make a potentially rewarding activity (the 
child receives increased parental attention and a sugary snack) less attractive.  
Placing more emphasis on the significance of behavioural symptoms, rather than the 
traditional autonomic symptoms (e.g. sweating and shaking), may improve the ability 
of parents and health care professionals to identify hypoglycaemia.  Clinicians may 
consider utilising the Clarke questionnaire to screen for IAH allowing the 
identification of an “at risk” cohort within their paediatric clinic population.  The 
awareness status of children may change over time and therefore longitudinal studies 
are required to characterise any temporal changes associated with hypoglycaemia 
awareness.   
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Chapter 8: Hypoglycaemia and driving in people with insulin-
treated diabetes:  self-treatment and adherence to recommendations 
for avoidance  
8.1  Introduction 
8.11 Effect of hypoglycaemia on driving performance 
Hypoglycaemia is a common side effect of insulin therapy for diabetes and can 
interfere with everyday activities such as driving (Frier et al., 1980, Eadington and 
Frier, 1989, Inkster and Frier, 2013, Stork et al., 2006).  Laboratory studies have 
demonstrated that cognitive functions critical to driving (such as visual information 
processing, attention, reaction times and hand-eye coordination) are impaired by 
hypoglycaemia (Warren and Frier, 2005, Inkster and Frier, 2012).  Studies using 
driving simulators have shown that driving performance (i.e. inappropriate speed or 
braking, ignoring road signs and traffic lights and not keeping to lanes) is affected 
adversely by moderate hypoglycaemia (Cox et al., 1993, Cox et al., 2000).  During 
simulation studies driving itself required higher dextrose infusion rates to maintain 
euglycaemia compared to watching a driving video; this increased metabolic demand 
predisposes drivers to hypoglycaemia (Cox et al., 2002).  The decision to drive may 
also be impaired, particularly in those with impaired awareness of hypoglycaemia 
(IAH).  During a driving simulator study only 4.2% of those with T1DM and normal 
awareness stated that they would drive while hypoglycaemic compared to 42.9% 
with T1DM and IAH (Stork et al., 2007).   
Those with T1DM and a history of driving mishaps in the previous 12 months were 
compared to those with T1DM but no history of mishaps (Cox et al., 2010, Cox et 
al., 2003a).  Save for a greater risk of severe hypoglycaemia in the later study, the 
groups were well matched in terms of duration of diabetes, age and glycaemic 
control.  The driving performance of those with a history of driving mishaps 
deteriorated to a greater extent during hypoglycaemia thus perhaps identifying a 
subset of drivers particularly vulnerable to poor driving performance during 
hypoglycaemia. 
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8.12  Diabetes and the risk of road traffic accidents (RTAs) 
A recent review article has examined this subject in detail (Inkster and Frier, 2013).  
Many studies have reported that overall RTA rates appear to be no higher in diabetic 
drivers (Stevens et al., 1989, Songer et al., 1988, Cox et al., 2006) whereas some 
studies have reported an increased risk of RTAs in drivers with diabetes (Songer and 
Dorsey, 2006, Cox et al., 2003b).  The discrepancy is probably as a result of 
considerable heterogeneity of study design.  The most recent UK based study showed 
that drivers with insulin treated diabetes were not at increased risk (Lonnen et al., 
2008).  A potential confounding issue was that the percentage holding a driving 
licence in diabetic and non-diabetic populations was not determined (Major et al., 
2009).   
The largest study examining RTA risk in drivers with diabetes analysed data from 
the entire adult Norwegian population (3.1 million) for just over 2 years with just 
over 170,000 taking diabetes medication (Skurtveit et al., 2009).  People with insulin 
treated diabetes had a slightly increased risk of RTAs compared with the total 
population with an odds ratio of 1.4 (1.2-1.6), it is worth noting that those taking 
medication for peptic ulcers or gastro-oesophageal reflux (neither thought to affect 
driving performance) had a similar elevation in risk with an odds ratio of 1.3 (1.2-
1.4).  A meta-analysis of data from all these studies failed to show a significant 
increase in accident rates with a non-significant risk ratio of 1.26 (Bieber-Tregear et 
al., 2011).  
The Canadian National Population Health Survey (large, representative and 
longitudinal study of Canadians) used self-reporting of diabetes status, insulin 
treatment and RTA occurrence.  The proportion of those with diabetes and/or treated 
with insulin was not significantly increased in those who self reported a history of 
RTAs in the preceding 12 months (Vingilis and Wilk, 2012). 
Part of the reasoning behind why many studies have failed to show a significant 
difference in RTA rates at a population level between people at risk of 
hypoglycaemia (mainly those with insulin treated diabetes) and the general driving 
population is that many countries introduce additional restrictions on drivers with 
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insulin-treated diabetes.  Patients with diabetes may also voluntarily restrict their 
driving activities to avoid putting themselves at risk.  In addition, the cause of each 
RTA is usually multifactorial and there may be difficulty in controlling for 
concomitant fatigue, weather conditions, drug or alcohol use.   
8.13 Hypoglycaemia and the risk of RTAs 
Hypoglycaemia is recognised to be the cause of some crashes, people with a history 
of road traffic accidents exhibited poorer working memory during hypoglycaemia 
compared with no history of accidents (Campbell et al., 2010).  Perhaps the most 
consistently identified factor that increases risk of RTAs in people with diabetes is 
severe hypoglycaemia; a history of severe hypoglycaemia in the preceding two years 
increased the risk of accident four-fold (Cox et al., 2009, Redelmeier et al., 2009).  
Cox et al (2009) prospectively followed 452 drivers for 12 months who reported 
monthly on any driving mishaps.  Driving mishaps included a variety of driving 
related incidents including experiencing automated driving, someone else taking over 
driving and experiencing disruptive hypoglycaemia while driving.  When adjusted 
for mileage severe hypoglycaemia, experience of hypoglycaemia while driving and a 
previous history of an RTA within the last 2 years were associated with an increased 
risk of driving mishap (Cox et al., 2009).  Tighter glycaemic control (HbA1c of 
57mmol/mol versus 63mmol/mol) also increased the accident risk although to a 
lesser extent than a history of severe hypoglycaemia, type of diabetes was not stated 
although with a mean age of diagnosis of 31.6 years and 80% receiving insulin 
therapy many will have had T1DM (Redelmeier et al., 2009).   
The road traffic accident risk in people with T2DM who do not take insulin therapy 
is increased almost two-fold in people who have previously required medical 
attention for hypoglycaemia compared to those with no history of hypoglycaemia 
requiring medical attention; this difference persisted despite adjustment for potential 
confounders (Signorovitch et al., 2013).  Cox et al (2009) found a slightly increased 
accident rate in those with insulin pump therapy although an earlier study had found 
no difference in road traffic accidents rates was observed between different insulin 
treatments (e.g. CSII) (Harsch et al., 2002, Cox et al., 2009).  
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8.14 Driving regulations for drivers with insulin-treated diabetes in the UK 
In the United Kingdom driving licences are either issued as Group 1 licences (i.e. 
ordinary driving licence for cars, light vans or motorcycles) or Group 2 licences (i.e. 
vocational which allows lorries or buses to be driven).  Treatment for diabetes is the 
reason for medical notification in almost 1 in 4 of such driving licences issued in the 
United Kingdom (UK); approximately 575,000 active licences with 13% being for 
Group 2 licences (Parkes et al., 2014).  The European Union has issued directives on 
driving regarding the issuing of driving licences to individuals with diabetes.  The 
most recent directive follows a European Working Group on Driving and Diabetes 
with the aim of harmonising the driving regulations applied by member states 
(Second European Working Group on Diabetes and Driving, 2006, The European 
Parliament and the Council of the European Union, 2006).   
In 2012 the Driver and Vehicle Licensing Agency (DVLA) introduced the 
requirement that any driver with diabetes and a Group 1 licence who experienced 
more than one episode of severe hypoglycaemia in any 12 month period must inform 
the DVLA and be advised not to drive (Gallen et al., 2012).  This change in 
legislation would mean that 44% of the intensively treated and 17% of the 
conventionally treated DCCT cohort would have lost their licences at some point 
during the trial period (Kilpatrick et al., 2013).  A recent study in Denmark has 
shown that following implementation of this legislation self-reported rates of severe 
hypoglycemia have fallen by 55%, suggesting that the licensing change will 
encourage concealment of severe hypoglycemia (Pedersen-Bjergaard et al., 2014). 
 The requirements for people with a Group 2 licence are more stringent; they must 
report any severe hypoglycaemic episode and may have their licence revoked after 
one event.  
In the UK, the DVLA receives 30 police notifications per month regarding driving 
incidents related to hypoglycaemia while driving (Major et al., 2009).  Consequently, 
careful avoidance of hypoglycaemia is recommended before and during driving 
(American Diabetes Association et al., 2014).  This advice is particularly relevant for 
drivers receiving intensive insulin therapy, who may experience hypoglycaemia 
more frequently.   
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Anecdotal reports suggest that many diabetic drivers do not follow all or any of these 
local recommendations, or those issued by the DVLA, the government body 
responsible for issuing driving licences (DVLA, 2014).  Many drivers also claim to 
have received no advice on driving safety from health care professionals or the 
DVLA. However, the DVLA supplies a fact sheet with this advice with each renewal 
of a period restricted licence (i.e. every 1-3 years) (DVLA, 2014).   
8.15 Study aims 
The primary aims of the present study were therefore to assess awareness of, and 
adherence to, these recommendations for safe driving in people attending our clinic. 
In the UK, diabetes is considered to be a prospective disability for medical fitness to 
drive, and ordinary driving licences are period-restricted for insulin-treated drivers. 
A secondary objective was to determine how many drivers had declared their insulin-
treated diabetes to the national licensing authority (DVLA) and to their motor 
insurance company. 
It is important to note that this study predates the changes in driving regulations 
introduced in the UK in 2012. 
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8.2  Methods 
A structured questionnaire was used to interview adults with diabetes attending 
outpatient clinics at the Department of Diabetes at the Royal Infirmary of Edinburgh.  
No patient identifiable information was collected, only anonymous data was 
analysed.  Ethical approval for the study was obtained from the local Research Ethics 
Committee. 
8.21  Subjects 
People were eligible if they had been treated with insulin for at least one year, held a 
current UK driving licence, had driven within the preceding year and intended to 
drive in future. In total, 205 people were approached without selection during a two-
month period, and 202 questionnaires were completed.  Diabetes type was recorded, 
with 115 having T1DM, and 87 having T2DM treated with insulin, 11 of the latter 
group were taking a combination of oral hypoglycaemic agents and bedtime isophane 
insulin.  One driver held a C1 licence, which permits the driving of commercial 
vehicles up to 7.5 tonnes, is subject to more strict medical assessment, and must be 
reviewed annually. Subject characteristics are shown in Table 8.1. The cohort 
appeared to be reasonably representative of the clinic’s population of people with 
insulin-treated diabetes in terms of sex, age and type of diabetes.   
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Table 8.1: Subject characteristics 
Characteristic All subjects 
(n=202) 
T1DM (n=115) T2DM (n=87) 
Number (%) male 143 (70.8%) 73 (63.5%) 70 (80.5%) 
Age (years) 51 (21-81) 44 (22-78) 58.5 (34-81) 
Diabetes duration 
(years) 
14 (1-55) 17 (1-55) 11.5 (1-35) 
Insulin therapy 
(years) 
10 (1-55) 17 (1-55) 5 (1-32) 
HbA1c (%)* 8.3 (5.0-14.0) 8.2 (5.0-14.0) 8.4 (5.9-11.0) 
HbA1c 
(mmol/mol)* 
67 (31-130) 66 (31-130) 68 (41-97) 
Data other than sex are given as median (range) 
*HBA1c DCCT aligned; local non-diabetic range: 31-43 mmol/mol (5.0-6.05%) 
 
8.22  Questionnaire 
Participants were asked about their employment, driving habits, awareness of 
hypoglycaemia, experience of hypoglycaemia in general, experience of 
hypoglycaemia while driving and any associated accidents, blood glucose testing in 
relation to driving, and self-treatment of hypoglycaemia while driving. In most cases 
questions were not open-ended, but offered a choice of answers from which the 
participant selected the most appropriate. The questionnaire is reproduced in 
appendix three. Testing blood glucose before driving was defined as a measurement 
up to 30 min before the start of the journey. Participants rated their hypoglycaemia 
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awareness using a validated scale from 1 (always aware) to 7 (never aware); ratings 
of 3 or higher were considered to indicate impaired awareness (Gold et al., 1994).  
To minimise ethical concerns that the driver might reveal unsafe driving practices, 
once the questionnaire was completed, an information sheet regarding safe driving 
practice and diabetes was given to all participants. 
8.23  Statistics 
For simplicity, questionnaire response options were combined into smaller numbers 
of categories for analysis.  Data are presented as numbers of subjects (%) unless 
stated otherwise.  Categorical variables were compared using the chi-square test with 
Yates’ correction, with one degree of freedom.  Between-group means were 
compared using independent-sample t-tests.  Statistical significance was accepted at 
p<0.05. 
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8.3  Results 
8.31  Employment and annual mileage 
One hundred and fifty-one participants (74.8%) were in employment.  Eighty 
(53.0%) reported that driving was necessary for their job.  Estimated total annual 
mileages were reported as follows: fewer than 5 000 miles: 68 drivers (33.7%); 5 000 
to 10 000 miles: 69 drivers (34.2%); 10 000 to 20 000 miles: 49 drivers (24.3%); 
more than 20 000 miles: 16 drivers (7.9%). 
8.32 Declaration to licensing authority and motor insurer   
Almost all participants (195, 96.5%) were aware of the statutory requirement to 
inform the DVLA of their insulin treatment, but 12 of these individuals reported that 
they had not done so.  A further eight of the 195 participants who were aware of the 
requirement reported that they had declared, but held licences that were not period-
restricted; these individuals had presumably not reported their change from oral 
hypoglycaemic medication to insulin therapy.  The remaining seven participants 
either were unsure, or believed that there was no statutory requirement, despite 
which six had declared to the DVLA.  In total, therefore, 21 participants (10.4%) 
appeared not to have declared that they had insulin-treated diabetes. 
Almost all participants (194, 96.0%) were aware that they should report their 
diabetes and insulin treatment to their motor insurance company, and 196 (97.0%) 
said that they had done so. 
8.33 Blood glucose testing habits in relation to driving  
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Figure 8.1: Reported frequencies of carrying a glucometer while driving  
Figure 8.1 shows the participants’ estimated frequencies of carrying glucose meters 
with them when driving.  Sixty-six participants (32.7%) said that they always have a 
glucose meter with them when driving, and 77 (38.1%) reported never carrying one. 
The remainder indicated that they would take a meter on some journeys, or only on 
long journeys.  In respect of testing blood glucose before driving, only six 
participants (3.0%) reported that they always test, with a further 22 (10.9%) reporting 
that they test on at least half of journeys. The majority (121, 59.9%) reported either 
that they never test before driving, or test only if they experience symptoms of 
hypoglycaemia. The reported testing frequency tended to increase with the length of 
the journey undertaken (Table 8.2).   
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Table 8.2:  Association between frequency of blood testing before driving, and 
journey duration (percentages sum across rows) 
Journey duration 
(hours) 
Testing frequency 
Never Occasionally: <1 in 
2 journeys 
Regularly: >1 in 2 
journeys 
Long (>2) 70 (34.7%) 42 (20.8%) 70 (44.6%) 
Medium (0.5-2) 109 (54.0%) 63 (31.2%) 30 (14.9%) 
Short (<0.5) 137 (67.8%) 55 (27.2%) 10 (5.0%) 
 
Participants were also asked whether they measure blood glucose during journeys 
when driving.  Most participants (155, 76.7%) reported that they never test, and the 
remainder reported either that they would test occasionally or test during long 
journeys. 
8.34 Perceived blood glucose for safe driving   
Participants were asked what blood glucose level they considered to be the minimum 
for safe driving.  A value of 4.0 mmol/L or higher was given by 151 (74.8%), 42 
(20.8%) gave a value between 3.0 and 3.9 mmol/L, and nine (4.5%) considered 
levels below 3.0 mmol/L to be compatible with safe driving. 
8.35 Experience of hypoglycaemia while driving  
Sixty-four drivers (31.7%) had experienced hypoglycaemia while driving at some 
time previously, with 27 (13.4%) reporting episodes within the preceding year.  
Seven participants reported having had accidents at some time that they attributed to 
hypoglycaemia.  Details of these individuals and the accidents are shown in Table 
8.3.  
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Table 8.3: Road traffic accidents attributed to hypoglycaemia 
Subject 
A
ge (years) 
Sex 
Type of diabetes 
D
uration 
of 
insulin 
therapy 
D
am
age 
from
 
accident 
H
ypo 
aw
areness 
score (G
old, 1994) 
B
G
 
testing 
before 
driving 
C
arbohydrate kept in 
car? 
1 31 M 1 31 Vehicle & 
people 
4 Never Never 
2 53 M 1 36 Vehicle 5 Occasionally Always 
3 53 D 2 15 Vehicle 2 Never Always 
4 57 M 1 32 Vehicle 3 Regularly Always 
5 61 M 1 16 Vehicle & 
people 
1 If 
symptomatic 
Always 
6 63 M 1 32 None 4 Never Always 
7 64 F 2 10 Vehicle 2 Never Always 
 
8.36 Treatment of hypoglycaemia while driving 
Figure 8.2 shows the participants’ reported frequencies of keeping carbohydrate in 
the vehicle when driving.  Carbohydrate was kept available at all times by 177 
participants (87.6%), with a further 20 (9.9%) doing so intermittently. 
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Figure 8.2: Reported frequencies of carrying carbohydrate in the motor vehicle 
Participants were asked whether they would stop driving to treat hypoglycaemia, and 
how long they would wait before resuming their journey.  The majority (192, 95.0%) 
reported that they would stop, but 13 of these (6.4%) reported that they would 
resume driving immediately after eating a snack.  Most participants (128, 63.4%) 
indicated that they would wait between 10 and 30 minutes, and only 28 (13.9%) 
reported that they would wait for 30 minutes or more before recommencing driving. 
8.37 Subgroup comparisons  
Diabetes type   
The 115 participants with T1DM were compared with the 76 participants with 
T2DM who were receiving full insulin therapy.  A larger proportion of participants 
with T1DM were in employment than those with T2DM (88.7% vs 56.3%; χ2=27.5, 
p<0.001). 
Drivers with T1DM were more likely to report experiencing frequent symptomatic 
hypoglycaemia (more than once per week) than T2DM drivers (37.7% vs 15.7%; 
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χ2=10.1, p=0.001), and were more likely to have experienced hypoglycaemia while 
driving (44.4% vs 17.1%; χ2=15.2, p<0.001).  Participants with T1DM reported 
never testing blood glucose before driving less frequently than those with T2DM 
(39.1% vs 61.8%; χ2=9.5, p=0.002), and more frequently reported testing before at 
least half of journeys (20.9% vs 5.3%; χ2=8.9, p=0.003). 
Hypoglycaemia awareness   
Of the 190 participants with previous experience of hypoglycaemia, 144 (75.8%) 
were classified as having normal awareness, and 46 (24.2%) as having impaired 
awareness.  Most (n=35) of the latter group rated their state of awareness as 3 or 4 on 
a scale of 7.  The drivers with impaired awareness were more likely to have suffered 
an episode of severe hypoglycaemia (requiring assistance) within the preceding year 
than the 144 with normal awareness (34.8% vs 13.2%; χ2=10.8, p=0.001).  Compared 
with those with normal awareness, fewer of the drivers with impaired awareness 
reported that they never measure blood glucose before driving (34.8% vs 52.8%; 
χ2=4.5, p<0.05), with more reporting testing before at least half of journeys 
undertaken (23.9% vs 11.1%; χ2=4.7, p<0.05).  A similar proportion of each group 
had previous experience of hypoglycaemia while driving (30.6% normal vs 43.5% 
impaired awareness; p=0.15). 
Glycaemic control and previous experience of hypoglycaemia when driving   
No significant differences were observed when the cohort was divided on the basis of 
glycaemic control (HbA1c above and below the median) or previous experience of 
hypoglycaemia. 
8.38  Minimum safe practice 
One hundred (49%) of the participants admitted to one or more of the following:  
• never measuring blood glucose before any journey of any duration;  
• never carrying carbohydrate in the car;  
• not stopping if developing hypoglycaemia while driving;  
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• the belief that the minimum blood glucose for safe driving was below 3.0 
mmol/L. 
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8.4 Discussion 
8.41 Compliance with informing DVLA and motor insurers 
In the present survey, almost all drivers had informed the DVLA and their insurer of 
their insulin treatment, which represents a substantial improvement over the last 30 
years (Frier et al., 1980, Frier et al., 1984).  A few drivers with T2DM had neglected 
to inform the DVLA of their conversion to insulin.  Drivers with diabetes treated 
with oral antidiabetic medication are less likely to declare to the licensing authority 
(Steel et al., 1981), and it is important that this statutory obligation should be re-
emphasised at the time of conversion to insulin.  
8.42 Experience of hypoglycaemia while driving 
Previous experience of hypoglycaemia while driving was reported by nearly a third 
of drivers, which is consistent with previous surveys in Edinburgh (Frier et al., 1980, 
Eadington and Frier, 1989) and Belfast (Stevens et al., 1989).  More recently a 
prospective survey reported that over a 12-month period, 41% of drivers reported 
experienced “disruptive” hypoglycaemia while driving.  It is noteworthy that the 
mean number of episodes reported by each of these drivers was 2.7 with a range of 1-
26 (Cox et al., 2009).  This would suggest that a subset of drivers experience 
hypoglycaemia while driving on a frequent basis. 
8.43 The decision to drive including testing blood glucose levels before and 
during driving 
To assess the safety of driving, a driver with insulin-treated diabetes needs to know 
their blood glucose with some accuracy, and appreciate the minimum level 
compatible with safe driving.  Estimates of blood glucose based on symptoms are 
unreliable (Pramming et al., 1990, Weinger et al., 1995, Cox et al., 1985), and this 
has also been shown for subjects with T1DM in the context of driving.  In a 
laboratory study by Weinger et al. (Weinger et al., 1999), 38% of subjects felt able to 
drive safely when their blood glucose was 2.8 mmol/L, and in a driving simulator 
study three quarters of subjects recognised neither the impairment of their driving 
performance, nor the presence of hypoglycaemia, at blood glucose levels as low as 
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2.8 mmol/ l (Cox et al., 2000).  It is therefore preferable that a decision to drive 
should be based on an actual measurement of blood glucose.  Similar findings were 
observed by Clarke et al. in a prospective study, and diabetic drivers also reported 
feeling safe to drive on around 25% of occasions when they had already estimated 
that they were very hypoglycaemic (below 2.2 mmol/ l), suggesting that some errors 
of judgement result from misperceptions about the safety of driving while 
hypoglycaemic (Clarke et al., 1999).  Automated behaviour as a result of 
hypoglycaemia (i.e. becoming disorientated, getting lost or arriving at their 
destination with no memory of how they got there) was reported by 18% of drivers 
(Cox et al., 2009).  In vehicle monitoring has been suggested as a possible solution 
using technologies such as CGM linked to the car’s display systems (Kerr and 
Olateju, 2010). 
While it is reassuring that three quarters of drivers (74.8%) in the present survey 
gave an appropriate estimate of the minimum blood glucose for safe driving, i.e. 4.0 
mmol/ l or higher, this leaves a significant minority who still regard lower levels of 
blood glucose to be acceptable.  It is disconcerting that almost 60% of participants 
reported that they never test blood glucose before driving, or test only if they feel 
hypoglycaemic.  When completing the questionnaire, many drivers mentioned that 
they do not test when they believe hypoglycaemia to be very unlikely, such as 
immediately after a meal.  Although testing before driving was more common in 
participants with impaired hypoglycaemia awareness, only a small minority in this 
high-risk group reported regular testing.  Most participants (77%) also reported never 
testing during journeys of any length, indicating a lack of vigilance even when the 
risk of hypoglycaemia is not negligible.  This is particularly relevant in view of the 
metabolic demands of driving itself (Cox et al., 2002). 
Failure to measure blood glucose could have major medico-legal consequences.  In a 
previous prosecution in the Edinburgh Sheriff Court, the defendant, a driver with 
T1DM, was found guilty of causing death by dangerous driving while 
hypoglycaemic, and was strongly criticised because he had not measured his blood 
glucose before driving.  In passing judgement, the Sheriff stated that there is a risk 
associated with diabetes and driving, and consequently the privilege of a driving 
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licence carries a responsibility to ensure safety by measuring blood glucose.  This 
demonstrates the discrepancy between the limited criteria that must be met for a 
person with insulin treated diabetes to obtain a licence, and the more rigorous 
standards that may be demanded by a court of law.  It is important that health care 
professionals should be aware of this divergence of standards, and ensure that the 
potential legal ramifications are communicated to their patients. 
8.44 Treatment of hypoglycaemia that occurs while driving 
Appropriate treatment of hypoglycaemia while driving is vital.  Most respondents in 
the present survey carried carbohydrate with them, but very few would wait for more 
than 30 min after self-treatment before resuming their driving, although previous 
studies have demonstrated that cognitive function may not recover until 45 min or 
more after restoration of euglycaemia (Evans et al., 2000, Blackman et al., 1990, 
Gonder-Frederick et al., 1994).  The time required for recovery of sufficient 
cognitive function for driving has not been fully determined and drivers should be 
advised to err on the side of caution. 
It is disconcerting that several drivers who have had accidents while hypoglycaemic 
reported persistently unsafe practice.  Two self-rated their awareness of 
hypoglycaemia as impaired, and yet reported that they never test blood glucose 
before driving. While this behaviour can be regarded as irresponsible, they 
fortunately comprise a very small minority in this survey.  However, a large 
proportion of respondents were failing in some essential aspect of safe practice.  
Although the definition of safe practice is debatable, any of the following is 
unsatisfactory: never measuring blood glucose before driving; never carrying 
carbohydrate when driving; not stopping the vehicle to treat hypoglycaemia while 
driving; and belief that a blood glucose level below 3.0 mmol/L is compatible with 
safe driving.  Almost half of the participants were failing to meet one or more of 
these basic standards in the current study; a study conducted in New Zealand 
reported that 33% of drivers failed to meet one or more of these criteria (Bell et al., 
2010). 
8.45 Subsequent changes in the DVLA guidance 
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In the United Kingdom, when the medical fitness to drive of insulin-treated diabetic 
drivers is being evaluated for the issue or renewal of ordinary (non-vocational) 
licences, the DVLA may require some information from the applicant’s medical 
attendant.  This is usually limited to determining whether the applicant has normal 
awareness of hypoglycaemia and has recently suffered disabling hypoglycaemia.  
When this study was conducted there was no obligation to test before driving for 
those holding ordinary (Group 1) licences. 
Since this study was conducted the guidance for drivers with insulin treated diabetes 
has changed from guidelines issued by Diabetes UK to regulations issued by the 
DVLA (current regulations are reproduced in Table 8.4, the regulations affecting 
non-insulin treated drivers have also been included).  A major change is that people 
with insulin treated diabetes can apply for Group 2 driving licences; at the time of 
study only C1 licences could be applied for by people on insulin treatment and so 
none of the people interview had group 2 licences.  
Chapter 8 
 334 
 
Table 8.4: Current standards of fitness to drive for people with diabetes (DVLA, 
2014) 
Group 1 entitlement (cars, motorcycles) Group 2 entitlement (lorries, buses) 
Insulin treated Insulin treated 
DVLA must be notified 
Must have adequate awareness of 
hypoglycaemia 
Must not have had more than one 
episode of hypoglycaemia requiring the 
assistance of another person in the 
preceding 12 months 
There should be appropriate blood 
glucose monitoring (no more than 2 
hours before the start and every 2 hours 
when driving) 
Must not be regarded as a likely source 
of danger to the public when driving 
The visual standards for acuity and visual 
field must be met 
DVLA must be notified 
No episode of hypoglycaemia requiring 
the assistance of another person has 
occurred in the preceding 12 months 
Has full awareness of hypoglycaemia 
Regularly monitors blood glucose at least 
twice daily and at times relevant to 
driving, (no more than 2 hours before the 
start of the first journey and every 2 
hours while driving). More frequent 
testing may be required if for any reason 
there is a greater risk of hypoglycaemia.  
At the annual examination by an 
independent Consultant Diabetologist, 3 
months of blood glucose readings must 
be available 
Advised to use a modern blood glucose 
meter which has a memory chip 
Must demonstrate an understanding of 
the risks of hypoglycaemia 
Managed with tablets that carry a risk of 
hypoglycaemia (i.e. sulfonylureas or 
Managed with tablets that carry a risk of 
hypoglycaemia (i.e. sulfonylureas or 
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glinides) glinides) 
DVLA must be notified 
Must not have had more than one 
episode of hypoglycaemia requiring the 
assistance of another person within the 
preceding 12 months. It may be 
appropriate to monitor blood glucose 
regularly and at times relevant to driving 
to enable the detection of 
hypoglycaemia. Must be under regular 
medical review. 
DVLA must be notified 
No episode of hypoglycaemia requiring 
the assistance of another person has 
occurred in the preceding 12 months 
Has full awareness of hypoglycaemia 
Regularly monitors blood glucose at least 
twice daily and at times relevant to 
driving 
Must demonstrate an understanding of 
the risks of hypoglycaemia 
There are no other debarring 
complications of diabetes such as a 
visual field defect 
Managed by tablets other than those 
above or by non-insulin injectable 
medication 
Managed by tablets other than those 
above or by non-insulin injectable 
medication 
DVLA does not require notification 
unless develops relevant disabilities.  
DVLA must be notified. Drivers will be 
licenced unless they develop relevant 
disabilities. 
Managed by diet alone Managed by diet alone 
DVLA does not require notification 
unless develops relevant disabilities. 
DVLA does not require notification 
unless develops relevant disabilities. 
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Since this study was conducted the previous suggestion of measuring glucose levels 
before each journey and at regular intervals during long journeys has been changed 
to a current requirement of measuring glucose up to 2 hours before the first journey 
and to then retest at two hourly intervals (DVLA, 2014).  Reviewing the data with 
these changes in mind, even before long journeys (>2 hours) just over a third of 
drivers (34.7%) would never check.  The previously published paper had anticipated 
this change with the statement that it may also be unnecessary to measure blood 
glucose before every journey when consecutive short trips are made and that an 
argument could be made for recommending testing at reasonable intervals (e.g. every 
two hours) during periods when some driving is taking place (Graveling et al., 2004).   
8.47 Other surveys of people’s driving practices in relation to their diabetes 
After the current study was published (Graveling et al., 2004), a study conducted in 
Aberdeen examined both patients and healthcare professionals’ knowledge of 
regulations surrounding diabetes driving (Watson et al., 2007).  A high proportion of 
participants (95%) were aware of the obligation to report their insulin treated status 
to the DVLA and had done so (92%).  Only 15% always tested and 24% would never 
test before driving.  Sixty-two percent of healthcare professionals were aware that 
people with insulin treated diabetes should be advised to test before driving.  A more 
recent survey using a modified version of this current study’s questionnaire 
conducted in Birmingham found similar results with 38% reporting never testing 
before driving (Bodansky and Bodansky, 2009).  A rather poorly worded 
questionnaire based survey conducted in Liverpool reported that 65% would consider 
checking before each journey and 68% carried carbohydrate in the car (Jackson-
Koku et al., 2010). 
8.48 Study limitations 
Participants with insulin treated diabetes were approached during their routine 
diabetes clinic appointment.  The high completion rate (n=99%) means that a 
representative cross-section of the clinic population was interviewed.  There was no 
way of verifying all of their answers although the responses are consistent with 
Chapter 8 
 337 
previous and subsequent studies carried out both in the UK and abroad (Watson et 
al., 2007).  
A score using the Gold questionnaire of 3 or more was used to indicate impaired 
awareness of hypoglycaemia (Gold et al., 1994).  As previously discussed in chapter 
7 this is a non-validated cut-off, a score of 4 or more was used in the original 
validation study.  This will have over-estimated the proportion of drivers with 
impaired awareness of hypoglycaemia. 
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8.5 Chapter Summary 
The present survey has shown that most insulin-treated diabetic drivers understand 
what is meant by hypoglycaemia and the dangers it can pose in relation to driving. 
However, most drivers rely on the development of symptoms to detect 
hypoglycaemia, and rarely test blood glucose either before or during journeys.  
While the present survey reflects local practice, these results have now been 
replicated in other centres in the UK.   
Patient education should emphasise the importance of using glucose meters to detect 
hypoglycaemia, particularly for people at high risk of hypoglycaemia, and of treating 
hypoglycaemia effectively before driving is resumed.  Reinforcement is clearly 
necessary, and a discussion of driving practice should be included as part of the 
annual review procedure.  An advice sheet has been compiled for drivers with 
insulin-treated diabetes in our clinic, and was given to all participants after the 
interview.   
Following the publication of this study the DVLA updated is guidance to motorists 
with insulin treated-diabetes (DVLA, 2014).  The key changes are a recommendation 
that blood glucose testing strips are always carried and that blood glucose levels 
should be checked no more than 2 hours before the start of each journey and every 2 
hours while driving.  This means that for shorter journeys, it is no longer necessary to 
check before each journey.  The updated DVLA advice is summarised below (Inkster 
and Frier, 2013, DVLA, 2014): 
• You should always carry your glucose meter and blood glucose strips with 
you.  
• You should check your blood glucose no more than 2 hours before the start of 
the first journey and every two hours whilst you are driving. 
• If driving multiple short journeys, you do not necessarily need to test before 
each additional journey as long as you test every 2 hours while driving. More 
frequent testing may be required if for any reason there is a greater risk of 
hypoglycaemia for example after physical activity or altered meal routine.  
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• The intention is to ensure that blood glucose is always above 5.0mmol/l while 
driving.  In each case if your blood glucose is 5.0mmol/l or less, take a snack.  
If it is less than 4.0mmol/l or you feel hypoglycaemic, do not drive. 
• If hypoglycaemia develops while driving, stop the vehicle as soon as 
possible.  You should switch off the engine, remove the keys from the 
ignition and move from the driver’s seat. 
• You should not start driving until 45 minutes after blood glucose has returned 
to normal (confirmed by measuring blood glucose). It takes up to 45 minutes 
for the brain to recover fully. 
• Always keep an emergency supply of fast-acting carbohydrate such as 
glucose tablets or sweets within easy reach in the vehicle. 
• You should carry personal identification to show that you have diabetes in 
case of injury in a road traffic accident. 
• Particular care should be taken during changes of insulin regimens, changes 
of lifestyle, exercise, travel and pregnancy. 
• You must take regular meals, snacks and rest periods on long journeys. 
Always avoid alcohol. 
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Chapter 9:  Discussion and Conclusions 
9.1 Introduction 
For people with T1DM the DCCT and follow on EDIC study provided proof that 
intensive glycaemic control reduced the risk of complications; particularly 
microvascular complications but also macrovascular disease (DCCT Research 
Group, 1993, Nathan et al., 2005, DCCT/EDIC Group et al., 2009).  The downside of 
intensive glycaemic control is the substantially elevated risk of hypoglycaemia.  The 
impact of hypoglycaemia on the daily lives of affected individuals is often 
substantial and ranges from the embarrassment of suffering an episode in a public 
place to being admitted to hospital with a suspected hypoglycaemic seizure.  The 
first five chapters of this thesis describe the important effects of hypoglycaemia on 
various parts of the body and mind.  These five chapters therefore provide a 
summary of the background on which the experimental work in this thesis is based. 
This thesis presents three main studies: (1) the effect of acute hypoglycaemia on 
executive functions which are crucial for the performance of many everyday 
activities; (2) the prevalence of impaired awareness in a paediatric or adolescent 
population with T1DM with identification of symptoms sub-groups that best herald 
the onset of hypoglycaemia; (3) a questionnaire based survey of practices in people 
with insulin-treated diabetes with regard to testing and treating hypoglycaemia while 
driving. 
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9.2 Acute hypoglycaemia and executive cognitive functioning in adults with 
and without diabetes (chapter 6) 
The aim of this study was to examine the effect of acute hypoglycaemia on executive 
function in healthy adults with and without T1DM.  The current study showed that 
executive functions were profoundly affected by acute hypoglycaemia, with 
moderate to large effect sizes by Cohen’s d statistic.  This is not unexpected given 
that previous studies have shown that higher order cognitive functions are 
preferentially and often profoundly disrupted by hypoglycaemia.  
Previous research into some other areas of cognitive function (e.g. psychomotor 
function) has suggested that those with diabetes are less affected by hypoglycaemia 
than participants without diabetes (Geddes et al., 2008).  This was suggested as being 
a result of a lesser degree of counter-regulatory hormonal release in those with 
diabetes resulting in reduced amplitude and frequency of tremor.  An unexpected 
finding in the current study was that in a number of tests (sorting test, Stroop A and 
Stroop B) the participants with diabetes were affected by hypoglycaemia to a worse 
degree than those without diabetes.  This would suggest that cerebral adaptation does 
not occur; participants with diabetes would have been expected to have much greater 
experience of hypoglycaemia than participants without diabetes.  In the current study 
the participants without diabetes achieved higher NART scores (a test of pre-morbid 
crystallised intelligence).  Higher baseline intelligence is known to affect the scores 
achieved during the Stroop test, although the differences persisted when NART 
scores were included as a co-variate.  Other measures of intelligence could be 
utilised in future to build a more accurate picture of the pre-morbid ability of the test 
population.  Participants without diabetes might have a greater cognitive reserve.  
The idea of diabetes acting as a cognitive disruptor during hypoglycaemia is an 
interesting hypothesis and worthy of further research. 
Given the large effect size seen following moderate hypoglycaemia (2.5mmol/L) it 
would be interesting to determine whether a greater (e.g. 2.0mmol/L) or lesser degree 
(e.g. 3.0 mmol/L) of hypoglycaemia would alter the findings.  The latter experiment 
would have practical relevance in determining the impact of relatively mild 
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hypoglycaemia on higher order cognitive functions and therefore the impact on many 
daily activities (e.g. composing a shopping list). 
In the current study the quality rather than just speed of responses was poorer.  
Extrapolating these results would suggest that acute hypoglycaemia profoundly 
disrupts many activities of daily living.  Many of these tests assess multiple 
executive functions and it is therefore difficult to demonstrate specific effects on 
particular cognitive processes that comprise executive functioning.  Their 
overlapping nature would make it very difficult to design a test battery that examined 
the individual cognitive processes that comprise executive function.  Some of the 
composite scoring used by the D-KEFS (i.e. for the Stroop test) aims to break down 
some of the cognitive processes by subtracting scores for lower order cognitive 
functions to try and better estimate the impact of hypoglycaemia on individual areas 
of executive functioning although some overlap remains. 
Future research could combine executive function testing with functional imaging, 
although there are several practical difficulties that would need to be overcome.  The 
most obvious hurdle would be performing the cognitive tests while undergoing 
cerebral imaging which would difficult in the confines of an MRI scanner.  The areas 
of the brain involved in executive functioning are not as clearly defined as in other 
cognitive tasks that may make image analysis more difficult. 
In summary, further research into the specific cognitive processes involved in 
executive functioning is indicated although for the reasons outlined above, will be 
challenging.  The mechanism behind the performance difference during 
hypoglycaemia in those with and without T1DM is unclear. 
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9.3 Prevalence of impaired awareness of hypoglycaemia and identification of 
predictive symptoms in children and adolescents with type 1 diabetes (chapter 
7) 
The aim of the current study was to ascertain the prevalence of impaired awareness 
in a typical cohort of patients with T1DM attending a paediatric clinic.  Symptoms 
reported by the patients and clinical features observed by parents during 
hypoglycaemic episodes were also determined. Using the Clarke method the 
prevalence of IAH in the present study was just over 20%, similar to a previous study 
of an Australian paediatric population (Ly et al., 2009).    The mean duration of 
diabetes of the current study’s participants was shorter than a lot of studies in the 
adult population with T1DM.  Those with IAH had an increased risk of 
hypoglycaemia requiring third party assistance or hospital admission.  The increased 
morbidity observed in the IAH population increases the clinical utility of targeted 
screening for IAH, perhaps in children admitted with a hypoglycaemic event.  
Having identified a group at increased risk the healthcare team could then target this 
group with specific guidance and intervention to try and reduce the impact of IAH.  
Further research is urgently required to examine a longitudinal cohort of paediatric 
patients to determine how awareness status changes over time.  It could be 
hypothesised that younger children would have a higher prevalence of IAH that 
would reduce over time until they became teenagers, at which point an increased 
prevalence may then be observed due to behavioural factors. 
The cut off employed to define hypoglycaemia awareness considerably affects the 
prevalence of IAH, whether using the Gold or the Clarke method.  A potential 
weakness of the current study is that the impaired group used the non-validated cut 
off of ≥3, when the validated cut-off of ≥4 was used; the prevalence of IAH fell 
significantly.  The present study showed that in a paediatric population the Clarke 
method of assessing impaired awareness of hypoglycaemia was more accurate than 
the Gold method (irrespective of the cut-off used).  Whether using the participant or 
their parent’s answers, the Gold method tended to overestimate the prevalence of 
IAH.  This was in contrast to the adult population where good concordance between 
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these two methods has been demonstrated (Geddes et al., 2007).  The Gold method 
uses a single question and is therefore simpler to administer than the Clarke method.  
This makes it popular in research involving adults but on the basis of the current 
study’s findings, it cannot be recommended for use in children. An important point to 
note for further research is that almost all children aged over 9 years were able to 
provide sufficient answers to allow their awareness status to be calculated.   
Despite the key role that parents play in the management of their child’s diabetes, in 
line with other studies, identification of hypoglycaemic episodes by parents was 
particularly poor (Gonder-Frederick et al., 2008).  Parents of children with normal 
awareness detected just 4% of episodes, this increased slightly to 6% in parents of 
children with impaired awareness.  Targeted parental support in the identification of 
hypoglycaemia in their offspring may help improve this percentage.  Development of 
programmes that deliver blood glucose awareness training for parents of children 
with diabetes may be useful. 
Loss or diminution of symptoms was reported by 11% of all the study participants 
and less than a third of those with IAH; this is a lower proportion than would be 
reported by an adult population with IAH (Pramming et al., 1991).  The classical 
explanation for the development of IAH is that it arises as a result of reduced 
counter-regulatory responses seen with established T1DM; this is clearly not the 
explanation (or at the very least not the whole explanation) for the presence of IAH 
in children.   Given that there is no clear pathophysiological mechanism, further 
examination of the clinical features observed and reported during hypoglycaemic 
episodes affecting children is key to advancing our understanding of this condition 
and these are discussed in the next two paragraphs. 
Autonomic symptoms such as tremor are usually readily attributable to the onset of 
hypoglycaemia.  In contrast, behavioural symptoms are less specific and may herald 
the onset of any number of issues such as tiredness, frustration or jealousy of another 
sibling or person.  This may make it more difficult to promptly attribute these 
symptoms to the onset of hypoglycaemia.  It is noteworthy that the most commonly 
reported clinical features identified by parents were behavioural (Figure 7.6).  A 
Canadian study compared hypoglycaemic symptoms reported by adults with those 
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reported by children.  Using a comparative factor analysis, behavioural symptoms 
(i.e. tearful or aggressive) were more predominant in children than adults (Amin et 
al., 2014).  Perhaps the fact that behavioural symptoms are the most commonly 
reported symptoms during hypoglycaemia partly explains the poor parental 
recognition of hypoglycaemic episodes.   A recent consensus statement 
acknowledges the important of behavioural symptoms in the recognition of 
hypoglycaemia although doesn’t cite the present study (Ly et al., 2014). 
The symptoms reported during hypoglycaemia segregated into 3 sub-groups when 
using principal components analysis.  Behavioural symptoms were shown to be most 
useful in predicting awareness status.  While this has not been found to be case in 
adults, there are differences in the behaviour of adults with IAH in terms of 
adherence to suggested management strategies (Smith et al., 2009).  That there might 
be a behavioural component to the development of IAH raises the question of 
whether this is a subconscious or deliberate behaviour.  If IAH is a voluntary 
behaviour then this raises the possibility that an individual might choose to ignore the 
onset of hypoglycaemia.  Some children may do this to trigger parental guilt, some 
might do it in an attempt not to seem different from other children or some might 
“enjoy” or at least not dislike the sensation of hypoglycaemia.  Further research, 
perhaps using qualitative interviewing, of children and their parents with IAH is 
indicated.  
In summary, further research is indicated into better identification of those with IAH 
particularly how awareness status changes over time (i.e. the “natural history” of the 
condition).  Closer examination of symptoms, particularly behavioural symptoms is 
also indicated.  Having identified a group of children at increased risk, further 
research is required into intervention programmes for both the child and their parents 
with the aim of reducing the morbidity of this condition.  
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9.4 Hypoglycaemia and driving in people with insulin-treated diabetes:  self-
treatment and adherence to recommendations for avoidance (chapter 8) 
The aim of the current study was to examine participants’ management of their 
insulin treated diabetes in relation to driving.  While compliance with reporting their 
condition to the insurance company and DVLA was excellent, half of the participants 
reported one or more unsafe practices with regards to driving and diabetes (i.e. not 
checking a blood glucose level before driving).  It is disappointing that subsequent 
surveys have failed to show a significant reduction in the number of drivers adopting 
potentially unsafe practices despite many diabetes centres giving advice regarding 
diabetes and driving (Watson et al., 2007).   
Following the European Union legislation regarding diabetes and driving and the 
subsequent update of the DVLA guidance in 2012 regarding diabetes and driving 
there have been some key changes that affect car drivers with diabetes.  The 
requirement for testing before driving has been altered to checking blood glucose no 
more than 2 hours before driving and every 2 hours while driving.  It would be useful 
to repeat the present study following the change in advice to drivers with insulin 
treated diabetes from the DVLA.  This would allow an assessment of awareness and 
compliance with the change in guidance.  From clinical practice it would be 
suspected that compliance with the new guidance remains poor and that unsafe 
driving practices persist.   
The most contentious requirement has been that if drivers suffer more than one 
episode of hypoglycaemia in the preceding 12 months they most report themselves to 
the DVLA.  Anecdotally drivers with diabetes are becoming aware of this legislation; 
recent research in Denmark shows that following implementation of this legislation 
there has been a 55% reduction in self-reported rates of severe hypoglycaemia 
(Pedersen-Bjergaard et al., 2014).  It would be interesting to perform a similar study 
in the UK, along with ascertainment of the proportion of drivers with IAH who 
report themselves to the DVLA.  
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The effect of hypoglycaemia on driving performance has not been studied in the UK 
using a driving simulator.  British roads tend to be congested and British cars tend to 
have manual gearboxes rather than automatic.  The seminal driving simulator studies 
were carried out well over 10 years ago in the United States (Cox et al., 2000), an 
update of these studies utilising contemporary computer technology would be 
extremely useful.  Different road and weather conditions could be examined (i.e. 
driving through town or on the motorway, driving in snow or at night).  Based on the 
work showing that more complex cognitive functions are preferentially affected by 
acute hypoglycaemia it could be speculated that with increasingly levels of driving 
difficulty would result in a greater decrement in performance during acute 
hypoglycaemia. Many people with diabetes fail to appreciate the impact of 
hypoglycaemia on their driving performance and perhaps an update of the driving 
simulator studies might help convince some of them.    
Although the impact of insulin treated diabetes on accident risk is difficult to 
quantify there is no doubt that any episode of hypoglycaemia while driving will 
increase the risk of a road traffic accident.  The use of emerging technology such as 
meter downloads or CGM could be linked with driving data from the person’s car.  
While initially confined to the experimental setting, in the future cars may require a 
safe blood glucose level prior to starting the engine and at intervals during the 
journey. 
In summary, approximately half of a representative cohort of drivers with insulin 
treated diabetes reported unsafe driving practices.  Repeating the study following the 
introduction of new regulations in the United Kingdom would demonstrate whether 
there has been any improvement in safe driving practices. 
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9.5 Chapter summary 
Hypoglycaemia continues to be a major barrier to the management of insulin treated 
diabetes.  These three studies examine a different area of how hypoglycaemia affects 
daily life and the various strategies people employ to deal with it.  The cognitive 
function study (chapter 6) shows that acute hypoglycaemia affects both the speed and 
quality of thinking when asked to perform complex cognitive tasks.  The paediatric 
study (chapter 7) has determined the prevalence of IAH in a paediatric cohort and 
examined the symptom sub-groups that may be predictive of this.  The driving study 
(chapter 8) showed that drivers with insulin treated diabetes adopt a number of 
potentially dangerous practices when it comes to managing their condition while 
driving.  The work contained within this thesis has expanded our knowledge of how 
hypoglycaemia affects the lives of people with insulin treated diabetes. 
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Appendix 1: Baseline Paediatric Questionnaire 
Retrospective Questionnaire 
(to be completed at subject recruitment by the researcher) 
Year of diagnosis of Diabetes (approximately)  
Family history of type 1 diabetes? Yes  No 
If yes is it  parent  sibling  other 
Timing of insulin injections (please write in the name of the insulin and how many 
units you use): 
 Type of insulin Number of units 
Before breakfast 1)  
2)  
Before lunch 1)  
2)  
Before evening meal 1)  
2)  
Bedtime 1)  
2)  
Other medications (i.e. tablets etc.)  ………………………………………. 
“We are interested in the opinion of both yourself and your child.  If it is okay with 
you I would like to ask each question to your child first and then ask you the same 
question.”
Appendix 1 (Baseline questionnaire) 
 361 
1) (CHILD) Can you tell when your blood glucose is low? 
Never    !  Child unable to answer ! 
Occasionally  !     
Usually  !  
Always  !  
1a) (PARENT) Can you tell when your child’s blood glucose is low? 
 
Never    ! 
Occasionally  !     
Usually  !  
Always  ! 
2) (CHILD) Tick the category that best describes you (tick one only) 
I always have symptoms when my blood glucose is low   ! 
I sometimes have symptoms when my blood glucose is low   ! 
I do not have symptoms when my blood glucose is low   ! 
Child unable to answer       ! 
2a) (PARENT) Tick the category that best describes your child (tick one only) 
My child always has symptoms when his/her blood glucose is low  ! 
My child sometimes has symptoms when his/her blood glucose is low ! 
My child does not have symptoms when his/her blood glucose is low ! 
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3) (CHILD) Have you lost some of the symptoms that used to occur when your blood 
glucose was low? 
Yes   ! Which symptoms have been lost? (e.g. sweating) 
No   ! …………………………………………………. 
Child unable to answer! …………………………………………………. 
3a) (PARENT) Do you think that your child has lost some of the symptoms that used 
to occur when their blood glucose was low? 
Yes ! 
No ! 
4) (CHILD) How often in the past year have you had a severe hypoglycaemic 
episode? These are episodes where you were unconscious or had a fit and needed 
Glucagen® or intravenous glucose. 
Never !   4 times  !  9 times   ! 
1 time !   6 times  !  10 times  ! 
2 times !   7 times  !  11 times  ! 
3 times !   8 times  !  12 or more times ! 
Child unable to answer ! 
4a) (PARENT) How often in the past year has your child had a severe 
hypoglycaemic episode? These are episodes where you were unconscious or had a fit 
and needed Glucagen® or intravenous glucose. 
Never !   4 times  !  9 times   ! 
1 time !   6 times  !  10 times  ! 
2 times !   7 times  !  11 times  ! 
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3 times !   8 times  !  12 or more times ! 
5) (CHILD) In the past six months how often have you had a hypoglycaemia episode 
where you were unable to treat yourself.  You might have also felt confused, 
disorientated, or lethargic.  This includes episodes of severe hypoglycaemia. 
Never    !  Child unable to answer ! 
Once or twice   ! 
Every other month  ! 
Once a month   ! 
More than once a month ! 
5a) (PARENT) In the past six months how often has your child had a hypoglycaemia 
episode where they were unable to treat themselves.   This includes episodes of 
severe hypoglycaemia 
Never    !  
Once or twice   ! 
Every other month  ! 
Once a month   ! 
More than once a month ! 
6) (CHILD) How often in the past month have you had a blood glucose of less than 
3.9mmol/L with symptoms? 
Never    !    2 to3 times/week ! 
1-3 times   !    4 to 5 times/week ! 
1 time/week   !    Almost daily  ! 
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Child unable to answer ! 
6a) (PARENT) How often in the past month has your child had a blood glucose of 
less than 3.9mmol/L with symptoms? 
Never  !    2 to3 times/week ! 
1-3 times !    4 to 5 times/week ! 
1 time/week !    Almost daily  ! 
7) (CHILD) How often in the past month have you had a blood glucose of less than 
3.9mmol/L with no symptoms? 
Never    !    2 to3 times/week ! 
1-3 times   !    4 to 5 times/week ! 
1 time/week   !    Almost daily  ! 
Child unable to answer ! 
7a) (PARENT) How often in the past month has your child had a blood glucose of 
less than 3.9mmol/L with no symptoms? 
Never  !    2 to3 times/week ! 
1-3 times !    4 to 5 times/week ! 
1 time/week !    Almost daily  ! 
8) (CHILD) How low does your blood glucose go before you feel symptoms? 
3.3-3.8 mmol/L  !   2.2-2.7mmol/L  ! 
2.8-3.3 mmol/L     !   below 2.2mmol/L  ! 
Child unable to answer ! 
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8a) (PARENT) How low does your child’s blood glucose go before you feel that 
they develop symptoms? 
3.3-3.8 mmol/L !   2.2-2.7mmol/L  ! 
2.8-3.3 mmol/L    !   below 2.2mmol/L  ! 
9) (CHILD) Can you tell by your symptoms that your blood glucose is low? 
Never   !  Often    ! 
Rarely   !  Always   ! 
Sometimes  !  Child unable to answer !   
9) (PARENT) To what extent can you tell by your child’s symptoms that their blood 
glucose is low? 
Never  !  Often  ! 
Rarely  !  Always ! 
Sometimes !  
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10. (CHILD): Please score how much you experience the following symptoms 
during a hypo (circle a number for each symptom) 
Not present        Present a great deal 
   Alt wording 
Headache  sore head 1 2 3 4 5 6 7 
Irritable  bad tempered 1 2 3 4 5 6 7 
Unco-ordinated clumsy  1 2 3 4 5 6 7 
Weak   “floppy” 1 2 3 4 5 6 7 
Aggressive  getting angry 1 2 3 4 5 6 7 
Trembling  shaking 1 2 3 4 5 6 7 
Sleepiness  falling asleep 1 2 3 4 5 6 7 
Sweating    1 2 3 4 5 6 7 
Blurred vision  hazy sight 1 2 3 4 5 6 7 
Tummy pain  sore tummy  1 2 3 4 5 6 7 
Feeling sick    1 2 3 4 5 6 7 
Yawning    1 2 3 4 5 6 7 
Odd behaviour acting strangely1 2 3 4 5 6 7 
Argumentative picking a fight 1 2 3 4 5 6 7 
Tired   “sluggish” 1 2 3 4 5 6 7 
Feeling awful  “yukky” 1 2 3 4 5 6 7 
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Other symptoms (e.g. sore legs)?   Yes ! No ! 
Please specify & score as above 
_______________________  1 2 3 4 5 6 7 
_______________________  1 2 3 4 5 6 7 
_______________________  1 2 3 4 5 6 7 
Child unable to answer ! 
 
Appendix 1 (Baseline questionnaire) 
 368 
10a. (PARENT) Please score how much you feel your child experiences the 
following symptoms during a hypo (circle a number for each symptom)   
    Not present   Present a great deal  
Alt wording 
Tearful  crying  1 2 3 4 5 6 7 
Headache  sore head 1 2 3 4 5 6 7 
Irritable  bad tempered 1 2 3 4 5 6 7 
Uncoordinated clumsy  1 2 3 4 5 6 7 
Naughty    1 2 3 4 5 6 7 
Aggressive  getting angry 1 2 3 4 5 6 7 
Trembling  shaking 1 2 3 4 5 6 7 
Sleepiness  falling asleep 1 2 3 4 5 6 7 
Sweating    1 2 3 4 5 6 7 
Slurred speech  difficulty speaking1 2 3 4 5 6 7 
Warmness  feeling warm  1 2 3 4 5 6 7 
Restless  fidgety  1 2 3 4 5 6 7 
Daydreaming  not paying attention1 2 3 4 5 6 7 
Argumentative picking a fight 1 2 3 4 5 6 7 
Pounding heart ‘thumping’ in chest1 2 3 4 5 6 7 
Confused    1 2 3 4 5 6 7 
Tired   ‘sluggish’ 1 2 3 4 5 6 7 
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Other (e.g. pallor)?   Yes ! No ! 
Please specify & score as above 
______________   1 2 3 4 5 6 7 
______________   1 2 3 4 5 6 7 
______________   1 2 3 4 5 6 7 
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11. (CHILD) Do you know when your hypos are commencing?  Please circle a 
number: 
   Always aware     Never aware 
Awareness   1 2 3 4 5 6 7 
Child unable to answer ! 
11a. (PARENT) Do you know when your child’s hypos are commencing?  Please 
circle a number: 
   Always aware     Never aware 
Awareness   1 2 3 4 5 6 7 
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Appendix 2: Parental and child prospective hypoglycaemia questionnaire 
PARENT 
DATE……………… TIME…………………   
BLOOD GLUCOSE VALUE……………. 
Please score   
Not present    Present a great deal 
 
Tearful   1 2 3 4 5 6 7 
Headache   1 2 3 4 5 6 7 
Irritable   1 2 3 4 5 6 7 
Uncoordinated   1 2 3 4 5 6 7 
Naughty   1 2 3 4 5 6 7 
Aggressive   1 2 3 4 5 6 7 
Trembling   1 2 3 4 5 6 7 
Sleepiness   1 2 3 4 5 6 7 
Sweating   1 2 3 4 5 6 7 
Slurred speech   1 2 3 4 5 6 7 
Warmness   1 2 3 4 5 6 7 
Restless   1 2 3 4 5 6 7 
Daydreaming   1 2 3 4 5 6 7 
Argumentative   1 2 3 4 5 6 7 
Pounding heart  1 2 3 4 5 6 7 
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Confused   1 2 3 4 5 6 7 
Tired    1 2 3 4 5 6 7 
Other (1) ______________ 1 2 3 4 5 6 7 
Other (2) ______________ 1 2 3 4 5 6 7 
 
The reaction was recognised by (please circle one): 
Your child   Routine testing on meter   Someone else 
Additional information (Please circle yes or no): 
Was the hypo treated according to Sick Kids” Hypo guidelines?  Yes No 
Did you need to phone the “Emergency Helpline” at Sick Kids?  Yes No 
Did your child require an injection of Glucagen® (orange box)?  Yes No 
Did your child require to be taken to hospital?    Yes  No 
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CHILD 
DATE………………  TIME……………  
BLOOD GLUCOSE VALUE………… 
Please score the extent to which you experienced the following symptoms during the episode 
of hypoglycaemia (circle a number for each symptom) 
Not present    Present a great deal 
 
Headache   1 2 3 4 5 6 7 
Irritable   1 2 3 4 5 6 7 
Uncoordinated   1 2 3 4 5 6 7 
Weak    1 2 3 4 5 6 7 
Aggressive   1 2 3 4 5 6 7 
Trembling   1 2 3 4 5 6 7 
Sleepiness   1 2 3 4 5 6 7 
Sweating   1 2 3 4 5 6 7 
Blurred vision   1 2 3 4 5 6 7 
Tummy pain   1 2 3 4 5 6 7 
Feeling sick   1 2 3 4 5 6 7 
Yawning   1 2 3 4 5 6 7 
Odd behaviour  1 2 3 4 5 6 7 
Argumentative   1 2 3 4 5 6 7 
Tired    1 2 3 4 5 6 7 
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Feeling awful   1 2 3 4 5 6 7 
Other (1) ______________ 1 2 3 4 5 6 7 
Other (2) ______________ 1 2 3 4 5 6 7 
The reaction was recognised by (please circle one): 
You   Routine testing on meter   Someone else 
Additional information (Please tick yes or no): 
Was the hypo treated according to Sick Kids” Hypo guidelines?   Yes No 
Did you need to phone the “Emergency Helpline” at Sick Kids?   Yes No 
Did you require an injection of Glucagen® (orange box)?   Yes No 
Did you need to be taken to hospital?      Yes  No 
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Appendix 3:  Diabetes and driving questionnaire 
Please remember that all information given in this questionnaire is kept confidential 
Patient number:  _____ 
Date of interview:  _____ 
Patient Demographics 
1)  Sex  Male Female  (please circle) 
2)  Age  ___   years 
3) Occupation manual, semi-skilled, skilled, professional, retired, 
unemployed 
 Specify  _________________ 
Diabetes 
4) Date of diagnosis of diabetes   ______  
5) Type of diabetes (to be completed by the researcher) Type 1 __ Type 2 __ 
6) Date of commencing insulin at diagnosis ___ other date (type 2) ___ 
7) HbA1c at this/last clinic visit  ___ %  
Insulin Treatment Regimen 
8)  
 Time of day   Insulin type  Dose (units) 
 Before breakfast     
 before lunch     
 before evening meal     
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 bedtime     
 Oral therapy (tablets)?  Specify ______________________ 
Home Blood Glucose Testing 
9) Do you measure your blood glucose?  (tick description that usually 
applies) 
 No, never      ___ 
 Only if I think it is too high or too low  ___ 
 Less than once a week   ___ 
 At least once a week    ___ 
 At least three times a week   ___ 
 At least once a day    ___ 
 Three or more times a day   ___ 
Hypoglycaemic History 
10) Have you ever experienced hypoglycaemia (low blood glucose)? Yes __    
No __ 
11) If YES, approximately how often do you have a mild hypo?  A mild hypo is 
one that can be treated by yourself.  [Question should assess patient’s subjective 
view of hypoglycaemic onset but quote 4 mmol/L if asked for a blood glucose level]   
 Less than 1 per year    ___ 
 Less than 1 per month (1-3 per year) ___ 
 At least 1 per month   ___ 
 2 or more per month   ___ 
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 At least 1 per week   ___ 
 3 or more per week    ___ 
12) To what level does your blood glucose fall before you have symptoms of 
mild hypoglycaemia? 
Doesn’t measure blood sugar during episodes of hypoglycaemia  __ 
above 4.0 mmol/L  __ 4.0-3.6 mmol/L  __ 3.5-3.1 mmol/L  __ 
3.0-2.6 mmol/L  __ 2.5-2.0 mmol/L __ below 2.0 mmol/L __ 
13) If yes to Q11, how many severe hypos have you had in the last year (a severe 
hypo is one in which you have felt that you needed assistance from another person) 
 None: ___ One: ___ Two-five: ___ more than 5: ___ 
14) Do you know when a hypo is starting?  (please circle) 
 always  1 2 3 4 5 6 7 never 
15) At what time of day do you usually have hypos? (please tick) 
 Before breakfast __ Before lunch   __ Before evening meal  __ 
 At bed-time     __ Through the night __ Any time  __ 
16) Do you check your blood glucose while experiencing a hypo?  (please 
circle) 
 always  1 2 3 4 5 6 7 never 
Driving 
17) Do you have a current driving licence? (please tick) 
 Provisional __  Ordinary __  C1 __ 
18) How long have you held a driving licence? 
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 Less than a year __ 1-5 years __  5+ years __ 
19) Is there a period restriction on your licence?  Yes __  No __ 
 If yes:  1 year __ 2 years __ 3 years __ 
20) How many miles do you usually drive in a year?  
 Less than 5,000 __ 5,000-9,999 ___ 10,000-20,000 __  
 More than 20,000 __ 
21) Do you travel to work by car? 
 Yes __     No __    Retired __   Unemployed __ 
 If YES, 
 Every day  __  At least twice a week  __ 
 Once a week  __  Less than once a week __  
22) Do you have to drive as part of your job, other than commuting to and from 
work?  (please choose the statement that most closely matches your usual driving 
habits) 
 Yes __  No __   Retired __  Unemployed __ 
 If YES,  Everyday   __ At least twice a week __ 
 Once a week  __ Less than once a week __  
23) Is driving essential for your job?  Yes __  No __  N/A __ 
Blood Glucose Monitoring While Driving 
24) Do you carry your blood glucose testing kit with you while driving? (please 
circle) 
 Always Only on long journeys (>2 hours)  Sometimes  Never  
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25) Do you test your blood glucose level before driving? (please tick statement 
that most closely applies to your testing habits 
 No, never       ___ 
 Yes, but only if I think it may be too high or too low ___ 
 Yes, but less than 1 in 10 journeys   ___  
 Yes, about 1 journey in 5    ___ 
 Yes, at least every other journey (1 in 2)  ___ 
 Yes, every journey     ___ 
26) If you were about to set off on a car journey lasting more than two hours 
would you test your blood glucose before you drive? 
 No, never       ___ 
 Yes, but only if I think it might be too high or too low ___ 
 Yes, but less than 1 in 10 journeys   ___  
 Yes, about 1 journey in 5    ___ 
 Yes, at least every other journey   ___ 
 Yes, for every journey    ___ 
27) If you were about to set off on a car journey lasting between half an hour and 
two hours would you test your blood glucose before you drive? 
 No, never       ___ 
 Yes, but only if I think I might be too high or too low ___ 
 Yes, but less than 1 in 10 journeys   ___  
 Yes, about 1 journey in 5    ___ 
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 Yes, at least every other journey   ___ 
 Yes, for every journey    ___ 
28) If you were about to set out on a car journey lasting less than half an hour 
would you test your blood glucose before you drive? 
 No, never       ___ 
 Yes, but only if I think it might be too high or too low ___ 
 Yes, but less than 1 in 10 journeys   ___  
 Yes, about 1 journey in 5    ___ 
 Yes, at least every other journey   ___ 
 Yes, for every journey    ___ 
29) When driving do you ever test your blood glucose level during a journey? 
Always Only on long journeys (>2 hours)  Sometimes   Never 
30) If yes to Q29, for how long would you drive before testing?   _ hrs or__ miles 
31) If yes to Q29, which statement is most applicable? 
 always test 1 2 3 4 5 6 7 never test 
Driving and hypoglycaemia 
32) Have you ever experienced hypoglycaemia while driving? Yes __ No __ 
33) Have you experienced hypoglycaemia in the last year? Yes __  No 
__ 
34) How many mild hypos have you had in the last year while driving? (A mild 
hypo is one that could be treated by yourself without medical assistance)  
 0 __ 1-2  __ 3-5  __ more than 5 __ 
Appendix 3: Diabetes and driving questionnaire 
 381 
35) How many severe hypos have you had in the last year while driving, a severe 
hypo is when assistance is required from another person? 
 0 __ 1-2  __ 3-5  __ more than 5 __ 
36) Has an episode of hypoglycaemia while driving resulted in an accident? 
(Includes any accident when they were hypoglycaemic whether they thought they 
were responsible or not) 
 No hypos while driving __ Accident in the last year __ 
 Accident at any time  __ Episode(s) did not result in an accident __  
37) If YES to question 36, did the accident result in: 
 Damage to vehicle  __   Damage to person(s) __ (other than 
minor cuts & bruises) 
38) Did you measure your blood glucose when you had a mild hypo?  
 No hypos while driving __ Always __ Sometimes __  Never __ 
39) Did you measure your blood glucose when you had a severe hypo? 
 No hypos while driving __ Always __ Sometimes __  Never __ 
Action taken if hypoglycaemia is suspected while driving  
40) Do you carry some type of carbohydrate in the car for the treatment of a 
hypo? 
Always   Only on long journeys (>2 hours)  Sometimes    Never 
41) If yes, what type of carbohydrate? (please tick) 
 Glucose tablets   __ 
 Biscuits   __ 
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 Chocolate bar   __ 
 Confectionery (sweets)  __ 
 Soft drink or Energy drink __ 
 Other (please specify)  ____________  
42) If you thought you were becoming hypoglycaemic while driving would 
you…?  
Carry on driving __ 
Continue driving but with increased care __ 
Stop driving, eat some food or have a sugary drink, then carry on driving __ 
Stop driving, eat some food or have a glucose drink and then rest for at least 
half an hour before driving again  __ 
43) Assuming you are carrying your blood glucose testing kit, would you 
measure your blood glucose after treating the hypo? (please circle) 
 Always Only if severe   Sometimes   Never 
44) If yes to Q43, how long after treating the hypo would you wait before 
measuring blood glucose? (please circle)  
 Wouldn’t measure Immediately 5-10 mins 11-20 mins 
 21-30 mins 31-40 mins >40 mins 
45) How long would you wait after treating the hypo before starting driving 
again? (please circle) 
 Wouldn’t stop Immediately 5-10 mins 11-20 mins 21-30 mins 
 31-40 mins >40 mins 
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46) Do you reduce your insulin dose to allow for the increased energy required 
for driving, especially over a long distance? (please tick) 
 Always Only if on long journeys Sometimes   Never 
47) If yes, by how much? 
 5% __  10% __ 20% __ >20% __ 
Knowledge 
48) Below which blood glucose level would you consider it unsafe to drive?  
___ mmol/L 
49) Have you ever received detailed advice about driving and diabetes?  Yes __   
No __ 
50) If yes, from what source? (please tick all that apply) 
 Diabetic clinic doctor  ___ Family/Friends  ___ 
 Diabetic clinic nurse/dietician ___ Diabetes literature  ___ 
 GP    ___ Newspaper/magazine  ___ 
 GP practice nurse  ___ Internet   ___ 
 Other medical professional ___ DVLA    ___ 
51) Are you required by law to inform the DVLA that you have insulin-treated 
diabetes? 
 Yes __  No __  Not sure __ 
52) Have you informed the DVLA that you have insulin-treated diabetes? 
 Yes__   No __ 
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53) Are you required by law to inform you motor insurance company that you 
have insulin-treated diabetes? 
 Yes __  No __  Not sure __ 
54) Have you informed your motor insurance company that you have insulin-
treated diabetes? Yes__   No __ 
 If no to Q49, ask where they received the advice concerning the answer to 
Q51-54 [because several patients reported that they been given no advice, but did in 
fact know the correct answers, and subsequently agreed that they had been informed 
by the clinic] 
55) From what source? (please tick all that apply) 
Diabetic clinic doctor  ___ Family/Friends   ___ 
Diabetic clinic nurse/dietician ___ Diabetes literature   ___ 
GP    ___ Newspaper/magazine   ___ 
GP practice nurse  ___ Internet    ___ 
Other medical professional ___ DVLA     ___ 
Unknown source    ___ 
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Articles based on work described in this thesis are reproduced here, with permission 
of the copyright holder in each case. 
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